,hasResults,protocolSection.identificationModule.nctId,protocolSection.identificationModule.orgStudyIdInfo.id,protocolSection.identificationModule.secondaryIdInfos,protocolSection.identificationModule.organization.fullName,protocolSection.identificationModule.organization.class,protocolSection.identificationModule.briefTitle,protocolSection.identificationModule.officialTitle,protocolSection.statusModule.statusVerifiedDate,protocolSection.statusModule.overallStatus,protocolSection.statusModule.expandedAccessInfo.hasExpandedAccess,protocolSection.statusModule.startDateStruct.date,protocolSection.statusModule.startDateStruct.type,protocolSection.statusModule.primaryCompletionDateStruct.date,protocolSection.statusModule.primaryCompletionDateStruct.type,protocolSection.statusModule.completionDateStruct.date,protocolSection.statusModule.completionDateStruct.type,protocolSection.statusModule.studyFirstSubmitDate,protocolSection.statusModule.studyFirstSubmitQcDate,protocolSection.statusModule.studyFirstPostDateStruct.date,protocolSection.statusModule.studyFirstPostDateStruct.type,protocolSection.statusModule.resultsFirstSubmitDate,protocolSection.statusModule.resultsFirstSubmitQcDate,protocolSection.statusModule.resultsFirstPostDateStruct.date,protocolSection.statusModule.resultsFirstPostDateStruct.type,protocolSection.statusModule.lastUpdateSubmitDate,protocolSection.statusModule.lastUpdatePostDateStruct.date,protocolSection.statusModule.lastUpdatePostDateStruct.type,protocolSection.sponsorCollaboratorsModule.responsibleParty.type,protocolSection.sponsorCollaboratorsModule.leadSponsor.name,protocolSection.sponsorCollaboratorsModule.leadSponsor.class,protocolSection.sponsorCollaboratorsModule.collaborators,protocolSection.oversightModule.oversightHasDmc,protocolSection.oversightModule.isFdaRegulatedDrug,protocolSection.oversightModule.isFdaRegulatedDevice,protocolSection.descriptionModule.briefSummary,protocolSection.descriptionModule.detailedDescription,protocolSection.conditionsModule.conditions,protocolSection.conditionsModule.keywords,protocolSection.designModule.studyType,protocolSection.designModule.phases,protocolSection.designModule.designInfo.allocation,protocolSection.designModule.designInfo.interventionModel,protocolSection.designModule.designInfo.primaryPurpose,protocolSection.designModule.designInfo.maskingInfo.masking,protocolSection.designModule.designInfo.maskingInfo.whoMasked,protocolSection.designModule.enrollmentInfo.count,protocolSection.designModule.enrollmentInfo.type,protocolSection.armsInterventionsModule.armGroups,protocolSection.armsInterventionsModule.interventions,protocolSection.outcomesModule.primaryOutcomes,protocolSection.outcomesModule.secondaryOutcomes,protocolSection.eligibilityModule.eligibilityCriteria,protocolSection.eligibilityModule.healthyVolunteers,protocolSection.eligibilityModule.sex,protocolSection.eligibilityModule.minimumAge,protocolSection.eligibilityModule.stdAges,protocolSection.contactsLocationsModule.overallOfficials,protocolSection.contactsLocationsModule.locations,protocolSection.referencesModule.references,protocolSection.referencesModule.seeAlsoLinks,protocolSection.ipdSharingStatementModule.ipdSharing,protocolSection.ipdSharingStatementModule.description,protocolSection.ipdSharingStatementModule.url,resultsSection.participantFlowModule.groups,resultsSection.participantFlowModule.periods,resultsSection.baselineCharacteristicsModule.populationDescription,resultsSection.baselineCharacteristicsModule.groups,resultsSection.baselineCharacteristicsModule.denoms,resultsSection.baselineCharacteristicsModule.measures,resultsSection.outcomeMeasuresModule.outcomeMeasures,resultsSection.adverseEventsModule.frequencyThreshold,resultsSection.adverseEventsModule.timeFrame,resultsSection.adverseEventsModule.description,resultsSection.adverseEventsModule.eventGroups,resultsSection.adverseEventsModule.seriousEvents,resultsSection.adverseEventsModule.otherEvents,resultsSection.moreInfoModule.certainAgreement.piSponsorEmployee,resultsSection.moreInfoModule.certainAgreement.restrictionType,resultsSection.moreInfoModule.certainAgreement.restrictiveAgreement,resultsSection.moreInfoModule.certainAgreement.otherDetails,resultsSection.moreInfoModule.pointOfContact.title,resultsSection.moreInfoModule.pointOfContact.organization,resultsSection.moreInfoModule.pointOfContact.email,resultsSection.moreInfoModule.pointOfContact.phone,documentSection.largeDocumentModule.largeDocs,derivedSection.miscInfoModule.versionHolder,derivedSection.conditionBrowseModule.meshes,derivedSection.conditionBrowseModule.ancestors,derivedSection.conditionBrowseModule.browseLeaves,derivedSection.conditionBrowseModule.browseBranches,derivedSection.interventionBrowseModule.meshes,derivedSection.interventionBrowseModule.ancestors,derivedSection.interventionBrowseModule.browseLeaves,derivedSection.interventionBrowseModule.browseBranches
0,True,NCT02709486,A4091057,"[{'id': '2013-004508-21', 'type': 'EUDRACT_NUMBER'}, {'id': 'OA 6-MONTH EU STUDY', 'type': 'OTHER', 'domain': 'Alias Study Number'}]",Pfizer,INDUSTRY,Study of the Analgesic Efficacy and Safety of Subcutaneous Tanezumab in Subjects With Osteoarthritis of the Hip or Knee.,"A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF THE SUBCUTANEOUS ADMINISTRATION OF TANEZUMAB IN SUBJECTS WITH OSTEOARTHRITIS OF THE HIP OR KNEE",2019-06,COMPLETED,False,2016-03-02,ACTUAL,2018-06-08,ACTUAL,2018-11-14,ACTUAL,2016-02-26,2016-03-10,2016-03-16,ESTIMATED,2019-06-06,2019-06-06,2019-06-26,ACTUAL,2019-06-06,2019-06-26,ACTUAL,SPONSOR,Pfizer,INDUSTRY,"[{'name': 'Eli Lilly and Company', 'class': 'INDUSTRY'}]",True,True,False,"Tanezumab is a monoclonal antibody that binds to and inhibits the actions of nerve growth factor (NGF). The Nerve Growth Factor Inhibitor (NGFI) class may offer an important breakthrough in the treatment of chronic pain and is under clinical investigation for the treatment of pain associated with osteoarthritis or other chronic pain conditions.

The primary objective of this study is to demonstrate superior efficacy of tanezumab 5 mg and 2.5 mg administered subcutaneously (SC) every 8 weeks versus placebo at Week 24 in subjects with osteoarthritis of the knee or hip. The 2.5 mg dose was shown to provide efficacy benefits with a favorable safety profile when administered intravenously in previous Phase 3 clinical trials. The 5 mg dose is expected to provide added efficacy benefit over the 2.5 mg dose based on data from previous studies.","This is a randomized, double blind, placebo controlled, parallel group multicenter Phase 3 study of the efficacy and safety of tanezumab when administered by SC injection for 24 weeks compared to placebo in subjects with osteoarthritis of the knee or hip. A total of approximately 810 subjects will be randomized to 1 of 3 treatment groups in a 1:1:1 ratio (ie, 270/group). The randomization will be stratified by index joint (hip or knee), and most severe Kellgren-Lawrence grade (of any knee or hip joint) at study entry (grade 2, 3 or 4). Subjects will receive up to three SC doses of one of the following treatments at an 8-week interval between each injection:

1. tanezumab 2.5 mg;
2. tanezumab 5 mg;
3. Placebo to match tanezumab. The study is designed with a total (post-randomization) duration of 48 weeks and will consist of three periods: Screening (up to 37 days), Double-blind Treatment (24 weeks) and Safety Follow-up (24 weeks). The Screening Period (beginning up to 37 days prior to Randomization) includes a Washout Period (lasting a minimum of 2 days for all prohibited pain medications), if required, and an Initial Pain Assessment Period (the 7 days prior to Randomization/Baseline).

Week 24 is the landmark analysis in this study. Subjects who do not complete the Double-blind Treatment period will enter and complete the 24-week Early-termination follow-up period.","['Osteoarthritis, Hip', 'Osteoarthritis, Knee']","['Osteoarthritis, pain, tanezumab.']",INTERVENTIONAL,['PHASE3'],RANDOMIZED,PARALLEL,TREATMENT,DOUBLE,"['PARTICIPANT', 'INVESTIGATOR']",849,ACTUAL,"[{'label': 'Low dose', 'type': 'EXPERIMENTAL', 'description': 'Investigational product', 'interventionNames': ['Drug: Tanezumab']}, {'label': 'High dose', 'type': 'EXPERIMENTAL', 'description': 'Investigational product', 'interventionNames': ['Drug: Tanezumab']}, {'label': 'Placebo', 'type': 'PLACEBO_COMPARATOR', 'description': 'Investigational product', 'interventionNames': ['Drug: Placebo']}]","[{'type': 'DRUG', 'name': 'Tanezumab', 'description': '2.5 mg', 'armGroupLabels': ['Low dose']}, {'type': 'DRUG', 'name': 'Tanezumab', 'description': '5 mg', 'armGroupLabels': ['High dose']}, {'type': 'DRUG', 'name': 'Placebo', 'description': 'Placebo', 'armGroupLabels': ['Placebo']}]","[{'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24', 'description': ""WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function."", 'timeFrame': 'Baseline, Week 24'}, {'measure': ""Change From Baseline in the Patient's Global Assessment (PGA) of Osteoarthritis at Week 24"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.', 'timeFrame': 'Baseline, Week 24'}]","[{'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 2, 4, 8, 12 and 16', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 16'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 32', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Week 32'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 2, 4, 8, 12 and 16', 'description': ""WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function."", 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 16'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 32', 'description': ""WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function."", 'timeFrame': 'Baseline, Week 32'}, {'measure': ""Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 16"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities).', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 16'}, {'measure': ""Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis at Week 32"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition.', 'timeFrame': 'Baseline, Week 32'}, {'measure': 'Percentage of Participants Meeting Outcomes Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index', 'description': 'Participants were considered as OMERACT-OARSI responders: if the change (improvement) from baseline to week of interest was greater than or equal to (\\>=) 50 percent and \\>= 2 units in either WOMAC pain subscale or physical function subscale score; if change (improvement) from baseline to week of interest was \\>=20 percent and \\>=1 unit in at least 2 of the following: 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 \\[no pain\\] to 10 \\[extreme pain\\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \\[minimum difficulty\\] to 10 \\[extreme difficulty\\], higher score = worse physical function) and PGA of OA (score: 1 \\[very good\\] to 5 \\[very poor\\], higher score = worse condition). Missing data was imputed using mixed baseline/last observation carried forward (BOCF/LOCF).', 'timeFrame': 'Weeks 2, 4, 8, 12, 16, 24 and 32'}, {'measure': 'Percentage of Participants With Cumulative Percent Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 16 and 24', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a NRS. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Percentage of participants with cumulative reduction (as percent) (greater than 0% ; \\>= 10, 20, 30, 40, 50, 60, 70, 80 and 90%; = 100 %) in WOMAC pain subscale from Baseline to Weeks 16 and 24 were reported, participants (%) are reported more than once in categories specified. Missing data was imputed using mixed BOCF/LOCF.', 'timeFrame': 'Baseline, Weeks 16 and 24'}, {'measure': 'Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response', 'description': 'Percentage of participants with reduction in WOMAC pain intensity of at least (\\>=) 30%, 50%, 70% and 90% at Weeks 2, 4, 8, 12, 16, 24 and 32 compared to baseline were classified as responders to WOMAC pain subscale and are reported here. WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a NRS. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Missing data was imputed using mixed BOCF/LOCF.', 'timeFrame': 'Week 2, 4, 8, 12, 16, 24 and 32'}, {'measure': 'Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response', 'description': ""Percentage of participants with reduction in WOMAC physical function of at least (\\>=)30%,50%,70% and 90% at weeks 2,4,8,12,16,24 and 32 compared to baseline were classified as responders to WOMAC physical function subscale. WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function:Participant's ability to move around and perform usual activities of daily living. WOMAC physical function subscale17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee/hip) during past 48 hours, calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical subscale on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Missing data was imputed using mixed BOCF/LOCF."", 'timeFrame': 'Weeks 2, 4, 8, 12, 16, 24 and 32'}, {'measure': 'Percentage of Participants With Cumulative Percent Change From Baseline Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 16 and 24', 'description': ""Percentage of participants with cumulative reduction (as percent) (greater than 0 %; \\>= 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 % and 90%; =100 %) in WOMAC physical function subscale from Baseline to Weeks 16 and 24 were reported. WOMAC:Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function: participant's ability to move around and perform usual activities of daily living. WOMAC physical function subscale:17-item questionnaire to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours, calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC Pain subscale on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), higher scores indicate extreme difficulty/worse physical function. Missing data was imputed using mixed BOCF/LOCF."", 'timeFrame': 'Baseline, Weeks 16 and 24'}, {'measure': ""Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where, 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition. Percentage of participants with improvement of at least 2 points from Baseline in PGA of OA were reported. Missing data was imputed using mixed BOCF/LOCF.', 'timeFrame': 'Weeks 2, 4, 8, 12, 16, 24 and 32'}, {'measure': 'Change From Baseline for Average Pain Score in the Index Joint at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24', 'description': 'Participants assessed their average pain in the index hip/knee in the past 24 hours using a scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Data represents averages of the values reported during the 8-week interval up to and including the given week. Change from baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score.', 'timeFrame': 'Baseline, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24'}, {'measure': 'Change From Baseline for Average Pain Score in the Index Joint at Weeks 28 and 32', 'description': 'Participants assessed their average pain in the index hip/knee in the past 24 hours using a scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Data represents averages of the values reported during the 8-week interval up to and including the given week. Change from baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score.', 'timeFrame': 'Baseline, Weeks 28 and 32'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on a NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness.', 'timeFrame': 'Baseline, Week 32'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA of index joint (knee or hip). WOMAC pain subscale assess amount of pain experienced (score: 0 \\[no pain\\] to 10 \\[extreme pain\\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \\[no difficulty\\] to 10 \\[extreme difficulty\\], higher score = worse physical function) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 \\[no stiffness\\] to 10 \\[extreme stiffness\\], higher score = higher stiffness). WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, where higher scores indicated worse response.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA of index joint (knee or hip). WOMAC pain subscale assess amount of pain experienced (score: 0 \\[no pain\\] to 10 \\[extreme pain\\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \\[no difficulty\\] to 10 \\[extreme difficulty\\], higher score = worse physical function) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 \\[no stiffness\\] to 10 \\[extreme stiffness\\], higher score = higher stiffness). WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, where higher scores indicated worse response.', 'timeFrame': 'Baseline, Week 32'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Walking on a Flat Surface) at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when walking on a flat surface?"". Participants responded about the amount of pain they experienced when walking on a flat surface by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Walking on a Flat Surface) at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when walking on a flat surface?"". Participants responded about the amount of pain they experienced when walking on a flat surface by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Week 32'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Going Up or Downstairs) at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when going up or down the stairs?"" Participants responded about the amount of pain they experienced when going up or down stairs by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Going Up or Downstairs) at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when going up or down the stairs?"" Participants responded about the amount of pain they experienced when going up or down stairs by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'timeFrame': 'Baseline, Week 32'}, {'measure': 'Work Productivity and Activity Impairment Questionnaire for Osteoarthritis (WPAI:OA) Scores at Baseline', 'description': 'WPAI is 6-question participant rated questionnaire to determine the impact of OA on absenteeism, presenteeism, work productivity, and daily activity impairment for a period of 7 days prior to a visit. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism), overall work impairment (work productivity) and activity impairment (daily activity impairment). These sub-scores are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'Baseline'}, {'measure': 'Change From Baseline in Work Productivity and Activity Impairment Questionnaire for Osteoarthritis (WPAI:OA) Impairment Scores at Weeks 8, 16 and 24', 'description': 'WPAI is 6-question participant rated questionnaire to determine the impact of OA on absenteeism, presenteeism, work productivity, and daily activity impairment for a period of 7 days prior to a visit. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism), overall work impairment (work productivity) and activity impairment (daily activity impairment). These sub-scores are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.', 'timeFrame': 'Baseline, Weeks 8, 16 and 24'}, {'measure': 'European Quality of Life- 5 Dimension-5 Levels (EQ-5D-5L) Dimensions Score', 'description': 'EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The health utility score for a participant with no problems in all 5 items is 1 for all countries (except for Zimbabwe where it is 0.9), and is reduced where a participant reports greater levels of problems across the five dimensions.', 'timeFrame': 'Baseline, Weeks 8, 16 and 24'}, {'measure': 'European Quality of Life- 5 Dimension-5 Levels (EQ-5D-5L) Overall Health Utility Score/ Index Value', 'description': 'EQ-5D-5L: standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional VAS. EQ-5D health state profile comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Responses from the five domains were used to calculate a single utility index (the Overall health utility score) where values are less than equal to (\\<=) 1. The Overall health utility score for a participant with no problems in all 5 items is 1 for all countries (except for Zimbabwe where it is 0.9), and is reduced where a participant reports greater levels of problems across the five dimensions.', 'timeFrame': 'Baseline, Weeks 8, 16 and 24'}, {'measure': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Reported Treatment Impact Assessment-Overall, How Satisfied Are You With The Drug That You Received in This Study?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. For participant satisfaction, participants responded using interactive response technology (IRT) on a 5 point likert scale from 1-5, where 1=extremely dissatisfied, 2=dissatisfied, 3=neither satisfied nor dissatisfied, 4=satisfied and 5=extremely satisfied. Higher scores indicated greater satisfaction.', 'timeFrame': 'Weeks 16 and 24'}, {'measure': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Global Preference Assessment- What is The Current or Most Recent Treatment You Were Receiving For Osteoarthritis Pain Before Enrolling?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. To assess previous treatment, participants responded for, 1=injectable prescription medicines, 2=prescription medicines taken by mouth, 3=surgery, 4=prescription medicines and surgery and 5=no treatment.', 'timeFrame': 'Weeks 16 and 24'}, {'measure': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Global Preference Assessment- Overall, do You Prefer The Drug That You Received in This Study to Previous Treatment?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. To assess preference to continue using the investigational product, participants responded using interactive response technology (IRT) on a 5 point likert scale from 1-5, where, 1= yes, I definitely prefer the drug that I am receiving now, 2= I have a slight preference for the drug that I am receiving now, 3= I have no preference either way, 4= I have a slight preference for my previous treatment, 5= No, I definitely prefer my previous treatment. Higher scores indicate lesser preference to use the investigational product.', 'timeFrame': 'Weeks 16 and 24'}, {'measure': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Willingness to Use Drug Again Assessment- Willing to Use The Same Drug That You Have Received in This Study For Your Osteoarthritis Pain?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. To assess Patient willingness to use drug again, participants responded using interactive response technology (IRT) on a 5 point likert scale from 1-5, where, 1= yes, I would definitely want to use the same drug again, 2= I might want to use the same drug again, 3= I am not sure, 4= I might not want to use the same drug again, 5= no, I definitely would not want to use the same drug again. Higher scores indicate lesser willingness to use the investigational product.', 'timeFrame': 'Weeks 16 and 24'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Visits of Services Directly Related to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Visits of services directly related to osteoarthritis evaluated were: visits to primary care physician, neurologist, rheumatologist, physician assistant or nurse practitioner, pain specialist, orthopedist, physical therapist, chiropractor, alternative medicine or therapy, podiatrist, nutritionist/dietitian, radiologist, home healthcare services and other practitioner.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Participants Who Visited the Emergency Room Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of participants who visited the emergency room due to osteoarthritis.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Visits to the Emergency Room Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of visits to the emergency room due to OA.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Participants Hospitalized Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of participants who were hospitalized due to OA.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Nights Stayed in the Hospital Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of nights stayed in the hospital due to OA.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Participants Who Used Any Aids/Devices for Doing Things', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of participants who used any aids/devices for doing things. Aids such as walking aid, wheelchair, device or utensil for dress/bathe/eat and any other aids/devices.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Number of Participants Who Quit Job Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage (during 3 months prior to baseline) at baseline, Week 32 and Week 48. Domain evaluated was number of participants who quit job due to OA.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Health Care Resource Utilization (HCRU): Duration Since Quitting Job Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage (during 3 months prior to baseline) at baseline, Week 32 and Week 48. Domain evaluated was duration since quitting job due to OA.', 'timeFrame': 'Baseline, Weeks 32 and 48'}, {'measure': 'Number of Participants Who Withdrew Due to Lack of Efficacy', 'description': 'Number of participants who withdrew from treatment due to lack of efficacy have been reported here.', 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Time to Discontinuation Due to Lack of Efficacy', 'description': 'Time to discontinuation due to lack of efficacy was defined as the time interval from the date of first study drug administration up to the date of discontinuation of participant from treatment due to lack of efficacy.', 'timeFrame': 'Baseline up to Week 24'}, {'measure': 'Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12, 16 and 24', 'description': 'In case of inadequate pain relief, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week could be taken as rescue medication between day 1 and week 24. Number of participants with any use of rescue medication during the particular study week were summarized.', 'timeFrame': 'Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Number of Participants Who Took Rescue Medication During Week 32', 'description': 'In case of inadequate pain relief, after Week 24, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week could be taken as rescue medication and use was reported weekly via diary. Number of participants with any use of rescue medication during the 4 weeks up to and including the particular study week were summarized.', 'timeFrame': 'Week 32'}, {'measure': 'Number of Days of Rescue Medication Used at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'In case of inadequate pain relief during the treatment period, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week a could be taken as rescue medication. Number of days the participants used the rescue medication during the particular study weeks were summarized.', 'timeFrame': 'Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Number of Days of Rescue Medication Used at Week 32', 'description': 'In case of inadequate pain relief, after Week 24, acetaminophen/paracetamol up to 4000 mg per day up to 7 days in a week could be taken as rescue medication and use was reported weekly via diary. Number of days per week the participants used the rescue medication during the 4 weeks up to and including the particular study week were summarized.', 'timeFrame': 'Week 32'}, {'measure': 'Amount of Rescue Medication Used at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'In case of inadequate pain relief, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week could be taken as rescue medication. The total dosage of acetaminophen in milligrams used during the specified week were summarized.', 'timeFrame': 'Weeks 2, 4, 8, 12, 16 and 24'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to End of Study', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to week 48 that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) up to End of Study', 'description': 'Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to week 48 that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities With Regard to Normal Baseline', 'description': 'Primary Abnormality criteria: HGB, hematocrit, RBC count \\<0.8\\* lower limit of normal(LLN); Ery. mean corpuscular volume/hemoglobin/ HGB concentration, RBCs distribution width \\<0.9\\*LLN, \\>1.1\\*upper limit of normal(ULN); platelets \\<0.5\\*LLN,\\>1.75\\*ULN; WBC count\\<0.6\\*LLN, \\>1.5\\*ULN; Lymphocytes,Leukocytes,Neutrophils \\<0.8\\*LLN, \\>1.2\\*ULN; Basophils,Eosinophils,Monocytes\\>1.2\\*ULN; Prothrombin time/Intl. normalized ratio\\>1.1\\*ULN; total bilirubin\\>1.5\\*ULN; aspartate aminotransferase,alanine aminotransferase,gamma GT,LDH,alkaline phosphatase \\>3.0\\*ULN; total protein; albumin\\<0.8\\*LLN, \\>1.2\\*ULN; blood urea nitrogen,creatinine,Cholesterol,triglycerides \\>1.3\\*ULN; Urate\\>1.2\\*ULN; sodium\\<0.95\\*LLN,\\>1.05\\*ULN; potassium,chloride,calcium,magnesium,bicarbonate \\<0.9\\*LLN, \\>1.1\\*ULN; phosphate\\<0.8\\*LLN, \\>1.2\\*ULN; glucose\\<0.6\\*LLN, \\>1.5\\*ULN; HGB A1C \\>1.3\\*ULN; creatine kinase\\>2.0\\*ULN, specific gravity\\<1.003, \\>1.030; pH\\<4.5, \\>8; Urine Glucose, protein,HGB,bilirubin \\>=1; Ketones\\>=1;Urine erythrocytes,Leukocytes\\>=20.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities With Regard to Abnormal Baseline', 'description': 'Primary Abnormality criteria: hemoglobin; hematocrit; RBC count \\< 0.8\\*LLN; Ery. mean corpuscular volume/ hemoglobin/ HGB concentration, erythrocytes distribution width \\<0.9\\*LLN, \\>1.1\\*ULN; platelets \\<0.5\\*LLN,\\>1.75\\*upper limit of normal (ULN); white blood cell count\\<0.6\\*LLN, \\>1.5\\*ULN; Lymphocytes, Leukocytes, Neutrophils \\<0.8\\*LLN, \\>1.2\\*ULN; Basophils, Eosinophils, Monocytes \\>1.2\\*ULN; total bilirubin\\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, gamma GT,LDH, alkaline phosphatase \\>3.0\\*ULN; total protein; albumin\\<0.8\\*LLN, \\>1.2\\*ULN; blood urea nitrogen, creatinine, Cholesterol, triglycerides \\>1.3\\*ULN; Urate \\>1.2\\*ULN; sodium \\<0.95\\*LLN,\\>1.05\\*ULN; potassium, chloride, calcium, magnesium, bicarbonate \\<0.9\\*LLN, \\>1.1\\*ULN; phosphate \\<0.8\\*LLN, \\>1.2\\*ULN; glucose \\<0.6\\*LLN, \\>1.5\\*ULN; Hemoglobin A1C \\>1.3\\*ULN; creatine kinase \\>2.0\\*ULN; Nitrite \\>=1.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Change From Baseline in Blood Pressure (BP) at Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'description': 'Measurement of BP included sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP).', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16, 24, 32 and 48'}, {'measure': 'Change From Baseline in Heart Rate at Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'description': 'Heart rate was measured at sitting position.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12,16, 24, 32 and 48'}, {'measure': 'Change From Baseline in Electrocardiogram (ECG) Parameters at Weeks 24 and 48', 'description': 'A 12-lead ECG was recorded after participants had rested for at least 5 minutes in the supine position in a quiet environment. All standard intervals (PR, QRS, QT, QTcF, QTcB, QTcF, RR intervals) were collected.', 'timeFrame': 'Baseline, Weeks 24 and 48'}, {'measure': 'Change From Baseline in Heart Rate (as Assessed by ECG) at Weeks 24 and 48', 'description': 'Heart rate was measured at sitting position.', 'timeFrame': 'Baseline, Weeks 24 and 48'}, {'measure': 'Percentage of Participants With Adjudicated Joint Safety Outcomes', 'description': 'Incidence of participants with any of the joint safety adjudication outcomes of primary osteonecrosis, rapidly progressive OA (type 1 and type 2), subchondral insufficiency fracture (or SPONK), or pathological fracture.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Percentage of Participants With Total Joint Replacements', 'description': 'Percentage of participants who underwent at least one total knee, hip or shoulder joint replacement surgery.', 'timeFrame': 'Baseline up to Week 48'}, {'measure': 'Number of Participants With Confirmed Orthostatic Hypotension', 'description': 'Orthostatic hypotension was defined as postural change (supine to standing) that met the following criteria: For systolic BP \\<=150 mmHg (mean supine): Reduction in systolic BP\\>=20 mmHg or reduction in diastolic BP\\>=10 mmHg at the 1 and/or 3 minute standing BP measurements. For systolic BP \\>150 mmHg (mean supine): Reduction in systolic BP\\>=30 mmHg or reduction in diastolic BP\\>=15 mmHg at the 1 and/or 3 minute standing BP measurements. If the 1 minute or 3 minute standing BP in a sequence met the orthostatic hypotension criteria, then that sequence was considered positive. If 2 of 2 or 2 of 3 sequences were positive, then orthostatic hypotension was considered confirmed.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16, 24, 32 and 48'}, {'measure': 'Change From Baseline in Survey of Autonomic Symptom (SAS) Scores at Week 24', 'description': 'The SAS is a 12 item (11 for females) questionnaire, from which the total number of symptoms (0-12 for males and 0-11 for females) is calculated. Each positive symptom is rated from 1 (not at all) to 5 (a lot). The total impact score was the sum of all symptom rating scores, with 0 assigned where the participant did not have the particular symptom. The range for the total impact score is 0-60 for males and 0-55 for females, higher scores indicating higher impact.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'description': 'NIS is a standardized instrument used to evaluate participant for signs of peripheral neuropathy. NIS is the sum of scores of 37 items, from both the left and right side, where 24 items scored from 0 (normal) to 4 (paralysis), higher score indicated higher abnormality/impairment and 13 items scored from 0 (normal), 1 (decreased) and 2 (absent), higher score indicated higher impairment. NIS possible overall score ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased impairment.', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16, 24, 32 and 48'}, {'measure': 'Number of Participants With Anti Tanezumab Antibodies', 'description': 'Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using a semi quantitative enzyme linked immunosorbent assay (ELISA). Participants listed as having anti-tanezumab antibodies had ADA titer level \\>=3.32. Less than 3.32 was considered below the limit of quantitation.', 'timeFrame': 'Baseline, Weeks 8,16, 24, 32 and 48'}]","Inclusion Criteria:

* A diagnosis of osteoarthritis of the index hip or knee based on American College of Rheumatology criteria with Kellgren Lawrence x-ray Grade of at least 2 as diagnosed by the Central Reader
* A history of insufficient pain relief from acetaminophen along with a history of insufficient pain relief from, inability to tolerate or contraindication to taking NSAIDs, and tramadol or opioid treatments.
* WOMAC Pain subscale score of at least 5 in the index hip or knee at Screening.
* Be willing to discontinue all non study pain medications for osteoarthritis and not use prohibited pain medications throughout the duration of the study.
* Female subjects of childbearing potential must agree to comply with protocol specified contraceptive requirements.

Exclusion Criteria:

* Subjects exceeding protocol defined BMI or body weight limits.
* History of other diseases specified in the protocol (e.g. inflammatory joint diseases, crystalline diseases such as gout or pseudogout) that may involve the index joint and that could interfere with efficacy assessments.
* Radiographic evidence of protocol specified bone or joint conditions in any screening radiograph as determined by the central radiology reviewer.
* A history of osteonecrosis or osteoporotic fracture.
* History of significant trauma or surgery to a knee, hip or shoulder within the previous year.
* Planned surgical procedure during the duration of the study.
* Presence of conditions (e.g. fibromyalgia, radiculopathy) associated with moderate to severe pain that may confound assessments or self evaluation of osteoarthritis pain.
* Signs or symptoms of carpal tunnel syndrome in the year prior to Screening.
* Considered unfit for surgery based upon American Society of Anesthesiologists physical classification system for surgery grading, or subjects who would not be willing to undergo joint replacement surgery if required.
* History of intolerance or hypersensitivity to acetaminophen or any of its excipients or existence of a medical condition or use of concomitant medication for which the use of acetaminophen is contraindicated.
* Use of prohibited medications without the appropriate washout period prior to Screening or Initial Pain Assessment Period.
* History of cancer within 5 years of Screening, except for cutaneous basal cell or squamous cell cancer resolved by excision.
* Subjects with signs and symptoms of clinically significant cardiac disease as described in the protocol.
* Diagnosis of a transient ischemic attack in the 6 months prior to Screening, diagnosis of stroke with residual deficits that would preclude completion of required study activities.
* History, diagnosis, or signs and symptoms of clinically significant neurological disease such as but not limited to peripheral or autonomic neuropathy.
* History, diagnosis, signs or symptoms of any clinically significant psychiatric disorder.
* History of known alcohol, analgesic or drug abuse within 2 years of Screening.
* Previous exposure to exogenous NGF or to an anti-NGF antibody.
* History of allergic or anaphylactic reaction to a therapeutic or diagnostic monoclonal antibody or IgG fusion protein.
* Poorly controlled hypertension as defined in the protocol or taking an antihypertensive that has not been stable for at least 1 month prior to Screening.
* Evidence of protocol defined orthostatic hypotension at Screening.
* Disqualifying score on the Survey of Autonomic Symptoms questionnaire at Screening.
* Screening AST, ALT, serum creatinine or HbA1c values that exceed protocol defined limits.
* Presence of drugs of abuse in screening urine toxicology panel.
* Positive hepatitis B, hepatitis C or HIV test results indicative of current infection.
* Participation in other investigational drug studies within protocol defined time limits.
* Pregnant, breastfeeding or female subjects of childbearing potential who are unwilling or unable to follow protocol required contraceptive requirements.
* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that in the judgment of the investigator, would make the subject inappropriate for entry into this study.",False,ALL,18 Years,"['ADULT', 'OLDER_ADULT']","[{'name': 'Pfizer CT.gov Call Center', 'affiliation': 'Pfizer', 'role': 'STUDY_DIRECTOR'}]","[{'facility': 'Nuhr Medical Center', 'city': 'Senftenberg', 'zip': '3541', 'country': 'Austria', 'geoPoint': {'lat': 48.43333, 'lon': 15.55}}, {'facility': 'Rheuma Zentrum Favoriten', 'city': 'Wien', 'zip': '1100', 'country': 'Austria', 'geoPoint': {'lat': 48.20849, 'lon': 16.37208}}, {'facility': 'Medical Center BLAGOEVGRAD 2009, EOOD', 'city': 'Blagoevgrad', 'zip': '2700', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.01667, 'lon': 23.1}}, {'facility': 'DCC St. Pantaleimon OOD', 'city': 'Pleven', 'zip': '5800', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.41667, 'lon': 24.61667}}, {'facility': 'Medical Center "" Health for all"" EOOD', 'city': 'Plovdiv', 'zip': '4000', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.15, 'lon': 24.75}}, {'facility': 'UMHAT Kaspela', 'city': 'Plovdiv', 'zip': '4002', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.15, 'lon': 24.75}}, {'facility': '""Medical Center Teodora"" EOOD', 'city': 'Ruse', 'zip': '7012', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.85639, 'lon': 25.97083}}, {'facility': 'Multiprofile Hospital for Active Treatment-Silistra AD', 'city': 'Silistra', 'zip': '7500', 'country': 'Bulgaria', 'geoPoint': {'lat': 44.11667, 'lon': 27.26667}}, {'facility': '""Medical Center- Smolyan"" OOD', 'city': 'Smolyan', 'zip': '4700', 'country': 'Bulgaria', 'geoPoint': {'lat': 41.58528, 'lon': 24.69194}}, {'facility': 'NMTH \'Tsar Boris III"". Clinic of Internal Diseases', 'city': 'Sofia', 'zip': '1233', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Multiprofile hospital for active treatment - ""Lyulin"" EAD', 'city': 'Sofia', 'zip': '1336', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Diagnostic Consultative Center XIV- Sofia EOOD', 'city': 'Sofia', 'zip': '1408', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'Medical Center-Avicena EOOD', 'city': 'Sofia', 'zip': '1408', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'UMHAT Sveti Ivan Rilski - EAD', 'city': 'Sofia', 'zip': '1612', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'UMHAT ""Sofiamed"" OOD, Block 2', 'city': 'Sofia', 'zip': '1750', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': '""Medical Center - Dr. Hayvazov"" EOOD', 'city': 'Sofia', 'zip': '1784', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'facility': 'UMHAT ""Prof. Dr. Stoyan Kirkovich"" AD', 'city': 'Stara Zagora', 'zip': '6000', 'country': 'Bulgaria', 'geoPoint': {'lat': 42.43278, 'lon': 25.64194}}, {'facility': 'Multiprofile Hospital for active treatment ""SVETA PETKA"" AD', 'city': 'Vidin', 'zip': '3700', 'country': 'Bulgaria', 'geoPoint': {'lat': 43.99, 'lon': 22.8725}}, {'facility': 'Dextra Oy/Pihlajalinna Ite Kuopio', 'city': 'Kuopio', 'zip': '70100', 'country': 'Finland', 'geoPoint': {'lat': 62.89238, 'lon': 27.67703}}, {'facility': 'Oulu Deaconess Institute', 'city': 'Oulu', 'zip': '90100', 'country': 'Finland', 'geoPoint': {'lat': 65.01236, 'lon': 25.46816}}, {'facility': 'Hpital Edouard Herriot', 'city': 'Lyon', 'zip': '69003', 'country': 'France', 'geoPoint': {'lat': 45.74848, 'lon': 4.84669}}, {'facility': 'Unite Clinique Therapeutique des Maladies Osteoarticulaires', 'city': 'Montpellier Cedex 5', 'zip': '34295', 'country': 'France', 'geoPoint': {'lat': 43.61092, 'lon': 3.87723}}, {'facility': 'CHR Orleans La Source', 'city': 'Orleans', 'zip': '45067', 'country': 'France', 'geoPoint': {'lat': 47.90289, 'lon': 1.90389}}, {'facility': 'Hopital Lariboisiere', 'city': 'Paris cedex 10', 'zip': '75475', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Hopital Saint-Antoine', 'city': 'Paris cedex 12', 'zip': '75571', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Hpital Cochin', 'city': 'Paris cedex 14', 'zip': '75659', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Hopital Cochin', 'city': 'Paris cedex 14', 'zip': '75679', 'country': 'France', 'geoPoint': {'lat': 48.85341, 'lon': 2.3488}}, {'facility': 'Praxis Dr. Kronung', 'city': 'Offenbach', 'state': 'Hesse', 'zip': '63073', 'country': 'Germany', 'geoPoint': {'lat': 50.10061, 'lon': 8.76647}}, {'facility': 'Rheumapraxis', 'city': 'Aachen', 'zip': '52064', 'country': 'Germany', 'geoPoint': {'lat': 50.77664, 'lon': 6.08342}}, {'facility': 'Rheumazentrum Prof. Dr. med Gunther Neeck', 'city': 'Bad Doberan', 'zip': '18209', 'country': 'Germany', 'geoPoint': {'lat': 54.10712, 'lon': 11.90051}}, {'facility': 'Kerckhoff Klinik GmbH', 'city': 'Bad Nauheim', 'zip': '61231', 'country': 'Germany', 'geoPoint': {'lat': 50.36463, 'lon': 8.73859}}, {'facility': 'Charite Universitaetsmedizin Berlin', 'city': 'Berlin', 'zip': '10117', 'country': 'Germany', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'facility': 'CIRI GmbH', 'city': 'Frankfurt am Main', 'zip': '60590', 'country': 'Germany', 'geoPoint': {'lat': 50.11552, 'lon': 8.68417}}, {'facility': 'Bekes Megyei Kzponti Korhaz Dr Rethy Pal Tagkorhaz, Reumatologia Szakrendeles', 'city': 'Bekescsaba', 'zip': '5600', 'country': 'Hungary', 'geoPoint': {'lat': 46.68333, 'lon': 21.1}}, {'facility': 'Clinexpert Egeszsegugyi Szolgaltato es Kereskedelmi Kft.', 'city': 'Budapest', 'zip': '1033', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Obudai Egeszsegugyi Centrum Kft', 'city': 'Budapest', 'zip': '1036', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Qualiclinic Kft.', 'city': 'Budapest', 'zip': '1036', 'country': 'Hungary', 'geoPoint': {'lat': 47.49801, 'lon': 19.03991}}, {'facility': 'Jutrix Kft', 'city': 'Kecskemt', 'zip': '6000', 'country': 'Hungary', 'geoPoint': {'lat': 46.90618, 'lon': 19.69128}}, {'facility': 'Tolna Megyei Balassa Janos Korhaz, Ortopediai osztaly', 'city': 'Szekszard', 'zip': '7100', 'country': 'Hungary', 'geoPoint': {'lat': 46.35014, 'lon': 18.70905}}, {'facility': 'Farmacia AOUC Settore Sperimentazione Farmaci', 'city': 'Firenze', 'state': 'FI', 'zip': '50134', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'facility': 'Istituto Clinico Humanitas Unita Operativa di Medicina Generale e Reumatologia -', 'city': 'Rozzano', 'state': 'Milan', 'zip': '20089', 'country': 'Italy', 'geoPoint': {'lat': 45.38193, 'lon': 9.1559}}, {'facility': 'Azienda Ospedaliera-Universitaria S.Orsola-Malpighi', 'city': 'Bologna', 'zip': '40138', 'country': 'Italy', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'facility': 'Farmacia Clinica Puggioli', 'city': 'Bologna', 'zip': '40138', 'country': 'Italy', 'geoPoint': {'lat': 44.49381, 'lon': 11.33875}}, {'facility': 'AZ OSPEDALIERO - UNIVERSITARIA CAREGGI-SOD Reumatologia - Dip. Medicina Sperimentale e Clinica', 'city': 'Firenze', 'zip': '50134', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'facility': 'Dipartmento di diagnostica per immagini', 'city': 'Firenze', 'zip': '50134', 'country': 'Italy', 'geoPoint': {'lat': 43.77925, 'lon': 11.24626}}, {'facility': 'AOU Maggiore della Carita di Novara - S.C. Medicina Fisica e Riabilitativa', 'city': 'Novara', 'zip': '28100', 'country': 'Italy', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'facility': 'Dipartimento Immagini Radiologia', 'city': 'Novara', 'zip': '28100', 'country': 'Italy', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'facility': 'Farmacia Ospedaliera', 'city': 'Novara', 'zip': '28100', 'country': 'Italy', 'geoPoint': {'lat': 45.44694, 'lon': 8.62118}}, {'facility': 'Azienda Ospedaliero-Universitaria E Policlinico Umberto I', 'city': 'Rome', 'zip': '00161', 'country': 'Italy', 'geoPoint': {'lat': 41.89193, 'lon': 12.51133}}, {'facility': 'Azienda Ospedaliera Universitaria Senese - UOC Reumatologia,', 'city': 'Siena', 'zip': '53100', 'country': 'Italy', 'geoPoint': {'lat': 43.31822, 'lon': 11.33064}}, {'facility': 'U.O.C. Farmacia - Gestione medicinali per la sperimentazione clinica', 'city': 'Siena', 'zip': '53100', 'country': 'Italy', 'geoPoint': {'lat': 43.31822, 'lon': 11.33064}}, {'facility': 'Ospedale Civile Maggiore Borgo Trento', 'city': 'Verona', 'zip': '37126', 'country': 'Italy', 'geoPoint': {'lat': 45.4299, 'lon': 10.98444}}, {'facility': 'Sato Orthopedic Clinic', 'city': 'Ichikawa', 'state': 'Chiba', 'zip': '272-0021', 'country': 'Japan', 'geoPoint': {'lat': 40.58333, 'lon': 141.45}}, {'facility': 'Kamagaya General Hospital', 'city': 'Kamagaya', 'state': 'Chiba', 'zip': '273-0121', 'country': 'Japan', 'geoPoint': {'lat': 35.76971, 'lon': 140.00238}}, {'facility': 'Fukuoka Mirai Hospital', 'city': 'Higashi-ku,Fukuoka', 'state': 'Fukuoka', 'zip': '813-0017', 'country': 'Japan'}, {'facility': 'Shinkokura Hospital', 'city': 'Kitakyushu', 'state': 'Fukuoka', 'zip': '803-8505', 'country': 'Japan', 'geoPoint': {'lat': 33.85181, 'lon': 130.85034}}, {'facility': 'Obase Hospital', 'city': 'Miyako-gun', 'state': 'Fukuoka', 'zip': '800-0344', 'country': 'Japan', 'geoPoint': {'lat': 39.64691, 'lon': 141.94057}}, {'facility': 'Takagi Hospital', 'city': 'Okawa', 'state': 'Fukuoka', 'zip': '831-0016', 'country': 'Japan', 'geoPoint': {'lat': 33.20565, 'lon': 130.37521}}, {'facility': 'Himeno Hospital', 'city': 'Yamegun', 'state': 'Fukuoka', 'zip': '834-0115', 'country': 'Japan'}, {'facility': 'Takahashi Orthopedics Clinic', 'city': 'Chitose', 'state': 'Hokkaido', 'zip': '066-0062', 'country': 'Japan', 'geoPoint': {'lat': 42.81944, 'lon': 141.65222}}, {'facility': 'Hakodate Central General Hospital', 'city': 'Hakodate', 'state': 'Hokkaido', 'zip': '040-8585', 'country': 'Japan', 'geoPoint': {'lat': 41.77583, 'lon': 140.73667}}, {'facility': 'Hakodate Ohmura Orthopedic Hospital', 'city': 'Hakodate', 'state': 'Hokkaido', 'zip': '041-0802', 'country': 'Japan', 'geoPoint': {'lat': 41.77583, 'lon': 140.73667}}, {'facility': 'Obihiro Orthopaedic Hospital', 'city': 'Obihiro', 'state': 'Hokkaido', 'zip': '080-0802', 'country': 'Japan', 'geoPoint': {'lat': 42.91722, 'lon': 143.20444}}, {'facility': 'Okubo Hospital', 'city': 'Akashi', 'state': 'Hyogo', 'zip': '674-0051', 'country': 'Japan', 'geoPoint': {'lat': 34.65522, 'lon': 135.00687}}, {'facility': 'Kobe Kaisei Hospital', 'city': 'Kobe', 'state': 'Hyogo', 'zip': '657-0068', 'country': 'Japan', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'facility': 'Kobe Konan Yamate clinic', 'city': 'Kobe', 'state': 'Hyogo', 'zip': '658-0011', 'country': 'Japan', 'geoPoint': {'lat': 34.6913, 'lon': 135.183}}, {'facility': 'National Hospital Organization Sagamihara National Hospital', 'city': 'Sagamihara', 'state': 'Kanagawa', 'zip': '252-0392', 'country': 'Japan', 'geoPoint': {'lat': 35.54899, 'lon': 139.26064}}, {'facility': 'Medical Corporation Association Sankikai, Yokohama Shinmidori General Hospital', 'city': 'Yokohama', 'state': 'Kanagawa', 'zip': '226-0025', 'country': 'Japan', 'geoPoint': {'lat': 35.43333, 'lon': 139.65}}, {'facility': 'Marunouchi Hospital', 'city': 'Matsumoto', 'state': 'Nagano', 'zip': '390-8601', 'country': 'Japan', 'geoPoint': {'lat': 36.23333, 'lon': 137.96667}}, {'facility': 'National Hospital Organization Nagasaki Medical Center', 'city': 'Omura', 'state': 'Nagasaki', 'zip': '856-8562', 'country': 'Japan', 'geoPoint': {'lat': 32.92139, 'lon': 129.95389}}, {'facility': 'Sobajima Clinic/Orthopedics', 'city': 'Higashiosaka', 'state': 'Osaka', 'zip': '577-0011', 'country': 'Japan', 'geoPoint': {'lat': 34.66667, 'lon': 135.58333}}, {'facility': 'National Hospital Organization Osaka Minami Medical Center', 'city': 'Kawachinagano', 'state': 'Osaka', 'zip': '586-8521', 'country': 'Japan'}, {'facility': 'Hamamatsu Medical Center', 'city': 'Hamamatsu', 'state': 'Shizuoka', 'zip': '432-8580', 'country': 'Japan', 'geoPoint': {'lat': 34.7, 'lon': 137.73333}}, {'facility': 'National Hospital Organization Utsunomiya national Hospital', 'city': 'Utsunomiya', 'state': 'Tochigi', 'zip': '329-1193', 'country': 'Japan', 'geoPoint': {'lat': 36.56667, 'lon': 139.88333}}, {'facility': 'Sonodakai Joint Replacement Center Hospital', 'city': 'Adachi-ku', 'state': 'Tokyo', 'zip': '121-0064', 'country': 'Japan'}, {'facility': 'Kitasato University Kitasato Institute Hospital', 'city': 'Minato-ku', 'state': 'Tokyo', 'zip': '108-8642', 'country': 'Japan', 'geoPoint': {'lat': 34.2152, 'lon': 135.1501}}, {'facility': 'Ohimachi Orthopaedic Clinic', 'city': 'Shinagawa-ku', 'state': 'Tokyo', 'zip': '140-0014', 'country': 'Japan', 'geoPoint': {'lat': 33.63627, 'lon': 133.00572}}, {'facility': 'Akita City Hospital', 'city': 'Akita', 'zip': '010-0933', 'country': 'Japan', 'geoPoint': {'lat': 39.71667, 'lon': 140.10826}}, {'facility': 'Kyushu Central Hospital', 'city': 'Fukuoka', 'zip': '815-8588', 'country': 'Japan', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'facility': 'Hiroshima Clinic', 'city': 'Hiroshima', 'zip': '733-0032', 'country': 'Japan', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'facility': 'Jujo Takeda Rehabilitation Hospital', 'city': 'Kyoto', 'zip': '601-8325', 'country': 'Japan', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'facility': 'Nagayoshi General Hospital', 'city': 'Osaka', 'zip': '547-0016', 'country': 'Japan', 'geoPoint': {'lat': 34.69374, 'lon': 135.50218}}, {'facility': 'NZOZ OSTEO-MEDIC s.c. A. Racewicz, J. Supronik', 'city': 'Bialystok', 'zip': '15-351', 'country': 'Poland', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'facility': 'ClinicMed Daniluk, Nowak Spoka Jawna', 'city': 'Bialystok', 'zip': '15-879', 'country': 'Poland', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'facility': 'Centrum Kliniczno - Badawcze J. Brzezicki, B. Gornikiewicz - Brzezicka Lekarze Spolka Partnerska', 'city': 'Elblag', 'zip': '82-300', 'country': 'Poland', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'facility': 'Centrum Medyczne Pratia Gdynia', 'city': 'Gdynia', 'zip': '81-338', 'country': 'Poland', 'geoPoint': {'lat': 54.51889, 'lon': 18.53188}}, {'facility': 'Centrum Medyczne Pratia Krakow', 'city': 'Krakow', 'zip': '30-002', 'country': 'Poland', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'facility': 'Malopolskie Centrum Medyczne S.C', 'city': 'Krakow', 'zip': '30-510', 'country': 'Poland', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'facility': 'Centrum Terapii Wspolczesnej J.M Jasnorzewska', 'city': 'Lodz', 'zip': '90-242', 'country': 'Poland', 'geoPoint': {'lat': 51.75, 'lon': 19.46667}}, {'facility': 'MTZ Clinical Research Sp. z o.o.', 'city': 'Warszawa', 'zip': '02-106', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'REUMATIKA - Centrum Reumatologii NZOZ', 'city': 'Warszawa', 'zip': '02-691', 'country': 'Poland', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'facility': 'Hospital Conde de Bertiandos', 'city': 'Ponte De Lima', 'state': 'Viana DO Castelo', 'zip': '4990-041', 'country': 'Portugal', 'geoPoint': {'lat': 41.76719, 'lon': -8.58393}}, {'facility': 'Centro Hospitalar Lisboa Ocidental, E.P.E., Hospital Egas Moniz', 'city': 'Lisboa', 'zip': '1349-019', 'country': 'Portugal', 'geoPoint': {'lat': 38.71667, 'lon': -9.13333}}, {'facility': 'Hospital Egas Moniz', 'city': 'Lisboa', 'zip': '1349-019', 'country': 'Portugal', 'geoPoint': {'lat': 38.71667, 'lon': -9.13333}}, {'facility': 'SC Duo Medical SRL', 'city': 'Bucuresti', 'state': 'Sector 1', 'zip': '010584', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Centrul Medical SANA S.R.L.', 'city': 'Bucuresti', 'state': 'Sector 1', 'zip': '011025', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Spitalul Judetean de Urgenta Bacau', 'city': 'Bacau', 'zip': '600114', 'country': 'Romania', 'geoPoint': {'lat': 46.56718, 'lon': 26.91384}}, {'facility': 'Spitalul Clinic ""Sf. Maria""', 'city': 'Bucuresti', 'zip': '011172', 'country': 'Romania', 'geoPoint': {'lat': 44.42802, 'lon': 26.09665}}, {'facility': 'Spitalul Clinic Judetean de Urgenta Sf. Apostol Andrei Constanta', 'city': 'Constanta', 'zip': '900591', 'country': 'Romania', 'geoPoint': {'lat': 44.18073, 'lon': 28.63432}}, {'facility': 'Spitalul Clinic Judetean de Urgenta Sibiu', 'city': 'Sibiu', 'zip': '550245', 'country': 'Romania', 'geoPoint': {'lat': 45.8, 'lon': 24.15}}, {'facility': 'AB-BA ambulancia s.r.o.', 'city': 'Bratislava', 'zip': '851 07', 'country': 'Slovakia', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'facility': 'ROMJAN s.r.o.', 'city': 'Bratislava', 'zip': '85101', 'country': 'Slovakia', 'geoPoint': {'lat': 48.14816, 'lon': 17.10674}}, {'facility': 'Kompan, s.r.o', 'city': 'Dolny Kubn', 'zip': '02601', 'country': 'Slovakia', 'geoPoint': {'lat': 49.20983, 'lon': 19.30341}}, {'facility': 'ALGMED s.r.o.', 'city': 'Kosice', 'zip': '040 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.71395, 'lon': 21.25808}}, {'facility': 'Reum. hapi s.r.o.', 'city': 'Nove Mesto nad Vahom', 'zip': '915 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.75763, 'lon': 17.8309}}, {'facility': 'Medipa s.r.o.', 'city': 'Piestany', 'zip': '921 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.59479, 'lon': 17.82591}}, {'facility': 'MUDr. Viliam Cibik, PhD, s.r.o.', 'city': 'Pruske', 'zip': '018 52', 'country': 'Slovakia', 'geoPoint': {'lat': 49.02636, 'lon': 18.21257}}, {'facility': 'Reumex s.r.o', 'city': 'Rimavska Sobota', 'zip': '979 01', 'country': 'Slovakia', 'geoPoint': {'lat': 48.38284, 'lon': 20.02239}}, {'facility': 'Hospital La Esperanza', 'city': 'Santiago de Compostela', 'state': 'A Coruna', 'zip': '15705', 'country': 'Spain', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'facility': 'Corporacio Sanitaria Parc Tauli de Sabadell', 'city': 'Sabadell', 'state': 'Barcelona', 'zip': '08208', 'country': 'Spain', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'facility': 'Corporaci Sanitaria Parc Taul de Sabadell', 'city': 'Sabadell', 'state': 'Barcelona', 'zip': '08208', 'country': 'Spain', 'geoPoint': {'lat': 41.54329, 'lon': 2.10942}}, {'facility': 'Hospital Universitario Marqus de Valdecilla', 'city': 'Santander', 'state': 'Cantabria', 'zip': '39008', 'country': 'Spain', 'geoPoint': {'lat': 43.46472, 'lon': -3.80444}}, {'facility': 'Hospital Universitario de Getafe', 'city': 'Getafe', 'state': 'Madrid', 'zip': '28905', 'country': 'Spain', 'geoPoint': {'lat': 40.30571, 'lon': -3.73295}}, {'facility': 'Complejo Hospital Universitario A Coruna (CHUAC)', 'city': 'A Coruna', 'zip': '15006', 'country': 'Spain', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'facility': 'Hospital La Esperanza', 'city': 'A Corua', 'zip': '15705', 'country': 'Spain', 'geoPoint': {'lat': 43.37135, 'lon': -8.396}}, {'facility': 'Instituto de Ciencias Medicas', 'city': 'Alicante', 'zip': '03004', 'country': 'Spain', 'geoPoint': {'lat': 38.34517, 'lon': -0.48149}}, {'facility': 'Instituto de Ciencias Mdicas', 'city': 'Alicante', 'zip': '03004', 'country': 'Spain', 'geoPoint': {'lat': 38.34517, 'lon': -0.48149}}, {'facility': 'Hospital del Mar', 'city': 'Barcelona', 'zip': '08003', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital CIMA Sanitas', 'city': 'Barcelona', 'zip': '08034', 'country': 'Spain', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'facility': 'Hospital Universitario Reina Sofia.', 'city': 'Cordoba', 'zip': '14004', 'country': 'Spain', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'facility': 'Hospital Universitario Reina Sofia', 'city': 'Cordoba', 'zip': '14004', 'country': 'Spain', 'geoPoint': {'lat': 37.89155, 'lon': -4.77275}}, {'facility': 'Hospital Universitario de Getafe', 'city': 'Getafe, Madrid', 'zip': '28905', 'country': 'Spain'}, {'facility': 'Hospital General Universitario de Guadalajara', 'city': 'Guadalajara', 'zip': '19002', 'country': 'Spain', 'geoPoint': {'lat': 40.62862, 'lon': -3.16185}}, {'facility': 'Hospital Universitario La Princesa Farmacia - Ensayos Clinicos', 'city': 'Madrid', 'zip': '28006', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario La Princesa', 'city': 'Madrid', 'zip': '28006', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario La Paz Servicio de Farmacia', 'city': 'Madrid', 'zip': '28046', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Universitario La Paz', 'city': 'Madrid', 'zip': '28046', 'country': 'Spain', 'geoPoint': {'lat': 40.4165, 'lon': -3.70256}}, {'facility': 'Hospital Regional Universitario de Malaga. Farmacia del Hospital Civil', 'city': 'Malaga', 'zip': '29009', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Hospital Regional Universitario de Malaga', 'city': 'Malaga', 'zip': '29009', 'country': 'Spain', 'geoPoint': {'lat': 36.72016, 'lon': -4.42034}}, {'facility': 'Hospital Infanta Luisa', 'city': 'Sevilla', 'zip': '41010', 'country': 'Spain', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'facility': 'Ladulaas Kliniska Studier', 'city': 'Boras', 'zip': 'SE-50630', 'country': 'Sweden', 'geoPoint': {'lat': 57.72101, 'lon': 12.9401}}, {'facility': 'CTC (Clinical Trial Center), Sahlgrenska University Hospital', 'city': 'Gothenburg', 'zip': '413 45', 'country': 'Sweden', 'geoPoint': {'lat': 57.70716, 'lon': 11.96679}}, {'facility': 'ProbarE i Lund AB', 'city': 'Lund', 'zip': '222 22', 'country': 'Sweden', 'geoPoint': {'lat': 55.70584, 'lon': 13.19321}}, {'facility': 'PharmaSite', 'city': 'Malmo', 'zip': '211 52', 'country': 'Sweden', 'geoPoint': {'lat': 55.60587, 'lon': 13.00073}}, {'facility': 'Avdelningen for kliniska provningar, S-huset', 'city': 'Orebro', 'zip': '703 62', 'country': 'Sweden', 'geoPoint': {'lat': 59.27412, 'lon': 15.2066}}, {'facility': 'ProbarE', 'city': 'Stockholm', 'zip': '11137', 'country': 'Sweden', 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}, {'facility': 'Karolinska Trial Alliance, Fas 1', 'city': 'Stockholm', 'zip': '141 86', 'country': 'Sweden', 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}, {'facility': 'Karolinska Trial Alliance, KTA.', 'city': 'Stockholm', 'zip': '141 86', 'country': 'Sweden', 'geoPoint': {'lat': 59.33258, 'lon': 18.0649}}, {'facility': 'The Alverton Practice', 'city': 'Penzance', 'state': 'Cornwall', 'zip': 'TR18 4JH', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.11861, 'lon': -5.53715}}, {'facility': 'Brannel Surgery', 'city': 'St. Austell', 'state': 'Cornwall', 'zip': 'PL26 7RL', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.3425, 'lon': -4.77442}}, {'facility': 'Knowle House Surgery', 'city': 'Plymouth', 'state': 'Devon', 'zip': 'PL5 3JB', 'country': 'United Kingdom', 'geoPoint': {'lat': 50.37153, 'lon': -4.14305}}, {'facility': 'Western General Hospital', 'city': 'Edinburgh', 'state': 'Midlothian', 'zip': 'EH4 2XU', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.95206, 'lon': -3.19648}}, {'facility': 'Clinical Trials, Bradford on Avon Health Centre', 'city': 'Bradford on Avon', 'zip': 'BA13 1DQ', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.34772, 'lon': -2.25065}}, {'facility': 'Health Centre, Bradford on Avon & Melksham Health Partnership', 'city': 'Bradford on Avon', 'zip': 'BA15 1DQ', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.34772, 'lon': -2.25065}}, {'facility': 'Oxford University Hospitals NHS Foundation Trust', 'city': 'Headington, Oxford', 'zip': 'OX3 7LD', 'country': 'United Kingdom'}, {'facility': ""St George's University Hospitals NHS Foundation Trust"", 'city': 'London', 'zip': 'SW17 0QT', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}, {'facility': 'Northumbria Healthcare NHS Foundation Trust', 'city': 'North Shields', 'zip': 'NE29 8NH', 'country': 'United Kingdom', 'geoPoint': {'lat': 55.01646, 'lon': -1.44925}}, {'facility': 'Nuffield Department of Orthopaedics', 'city': 'Oxford', 'zip': 'OX3 7HE', 'country': 'United Kingdom', 'geoPoint': {'lat': 51.75222, 'lon': -1.25596}}]","[{'pmid': '36301512', 'type': 'DERIVED', 'citation': 'Atkinson J, Edwards RA, Bonfanti G, Barroso J, Schnitzer TJ. A Two-Step, Trajectory-Focused, Analytics Approach to Attempt Prediction of Analgesic Response in Patients with Moderate-to-Severe Osteoarthritis. Adv Ther. 2023 Jan;40(1):252-264. doi: 10.1007/s12325-022-02336-6. Epub 2022 Oct 27.'}, {'pmid': '35980115', 'type': 'DERIVED', 'citation': 'Mease P, Kuritzky L, Wright WL, Mallick-Searle T, Fountaine R, Yang R, Sadrarhami M, Faison W, Johnston E, Viktrup L. Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trials. Curr Med Res Opin. 2022 Nov;38(11):1909-1922. doi: 10.1080/03007995.2022.2113689. Epub 2022 Aug 28.'}, {'pmid': '35960482', 'type': 'DERIVED', 'citation': 'Schnitzer TJ, Bonfanti G, Atkinson J, Donevan S, Viktrup L, Barroso J, Whalen E, Edwards RA. Characterizing 16-Week Responder Profiles Using Group-Based Trajectory Modeling in Over 4300 Clinical Trial Participants Receiving Pharmaceutical Treatment for Moderate to Severe Osteoarthritis. Adv Ther. 2022 Oct;39(10):4742-4756. doi: 10.1007/s12325-022-02290-3. Epub 2022 Aug 12.'}, {'pmid': '35232805', 'type': 'DERIVED', 'citation': 'Conaghan PG, Dworkin RH, Schnitzer TJ, Berenbaum F, Bushmakin AG, Cappelleri JC, Viktrup L, Abraham L. WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or Knee. J Rheumatol. 2022 Jun;49(6):615-621. doi: 10.3899/jrheum.210543. Epub 2022 Mar 1.'}, {'pmid': '35105318', 'type': 'DERIVED', 'citation': 'Conaghan PG, Abraham L, Viktrup L, Cislo P. Impact of tanezumab on health status, non-work activities and work productivity in adults with moderate-to-severe osteoarthritis. BMC Musculoskelet Disord. 2022 Feb 1;23(1):106. doi: 10.1186/s12891-022-05029-x.'}, {'pmid': '34626502', 'type': 'DERIVED', 'citation': 'Berenbaum F, Schnitzer T, Kivitz A, Viktrup L, Johnston E, Yang R, Whalen E, Tive L, Semel D. Gender, age, disease severity, body mass index and diabetes may not affect response to subcutaneous tanezumab in patients with osteoarthritis after 16 weeks of treatment. A subgroup analysis of placebo-controlled trials. Int J Clin Pract. 2021 Dec;75(12):e14975. doi: 10.1111/ijcp.14975. Epub 2021 Oct 21.'}, {'pmid': '33973384', 'type': 'DERIVED', 'citation': 'Berenbaum F, Schnitzer TJ, Kivitz AJ, Viktrup L, Hickman A, Pixton G, Brown MT, Davignon I, West CR. General Safety and Tolerability of Subcutaneous Tanezumab for Osteoarthritis: A Pooled Analysis of Three Randomized, Placebo-Controlled Trials. Arthritis Care Res (Hoboken). 2022 Jun;74(6):918-928. doi: 10.1002/acr.24637. Epub 2022 Mar 25.'}, {'pmid': '33728717', 'type': 'DERIVED', 'citation': 'Berenbaum F, Langford R, Perrot S, Miki K, Blanco FJ, Yamabe T, Isogawa N, Junor R, Carey W, Viktrup L, West CR, Brown MT, Verburg KM. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained? Eur J Pain. 2021 Aug;25(7):1525-1539. doi: 10.1002/ejp.1764. Epub 2021 May 3.'}, {'pmid': '32234715', 'type': 'DERIVED', 'citation': 'Berenbaum F, Blanco FJ, Guermazi A, Miki K, Yamabe T, Viktrup L, Junor R, Carey W, Brown MT, West CR, Verburg KM. Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period. Ann Rheum Dis. 2020 Jun;79(6):800-810. doi: 10.1136/annrheumdis-2019-216296. Epub 2020 Mar 31.'}]","[{'label': 'To obtain contact information for a study center near you, click here.', 'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091057'}, {'label': 'To obtain contact information for a study center near you, click here.', 'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4091057&StudyName=A+Phase+3+Randomized%2C+Double-blind%2C+Placebo-controlled%2C+Multicenter+Study+Of+The+Analgesic+Efficacy+And+Safety+Of+The+Subcutaneous+Administration+Of+Tanezumab+In+Subjects+With+Osteoarthritis+Of+The+Hip+Or+Knee'}]",YES,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests,"[{'id': 'FG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'FG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'FG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}]","[{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '282'}, {'groupId': 'FG001', 'numSubjects': '283'}, {'groupId': 'FG002', 'numSubjects': '284'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '238'}, {'groupId': 'FG001', 'numSubjects': '249'}, {'groupId': 'FG002', 'numSubjects': '239'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '44'}, {'groupId': 'FG001', 'numSubjects': '34'}, {'groupId': 'FG002', 'numSubjects': '45'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Insufficient clinical response', 'reasons': [{'groupId': 'FG000', 'numSubjects': '7'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Lost to Follow-up', 'reasons': [{'groupId': 'FG000', 'numSubjects': '3'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '32'}, {'groupId': 'FG001', 'numSubjects': '22'}, {'groupId': 'FG002', 'numSubjects': '32'}]}]}]",The safety population was defined as all participants treated with tanezumab or placebo subcutaneously.,"[{'id': 'BG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'BG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'BG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}]","[{'units': 'Participants', 'counts': [{'groupId': 'BG000', 'value': '282'}, {'groupId': 'BG001', 'value': '283'}, {'groupId': 'BG002', 'value': '284'}, {'groupId': 'BG003', 'value': '849'}]}]","[{'title': 'Age, Continuous', 'paramType': 'MEAN', 'dispersionType': 'STANDARD_DEVIATION', 'unitOfMeasure': 'years', 'classes': [{'categories': [{'measurements': [{'groupId': 'BG000', 'value': '64.24', 'spread': '9.58'}, {'groupId': 'BG001', 'value': '65.17', 'spread': '8.39'}, {'groupId': 'BG002', 'value': '65.23', 'spread': '10.16'}, {'groupId': 'BG003', 'value': '64.88', 'spread': '9.41'}]}]}]}, {'title': 'Sex: Female, Male', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'groupId': 'BG000', 'value': '196'}, {'groupId': 'BG001', 'value': '198'}, {'groupId': 'BG002', 'value': '193'}, {'groupId': 'BG003', 'value': '587'}]}, {'title': 'Male', 'measurements': [{'groupId': 'BG000', 'value': '86'}, {'groupId': 'BG001', 'value': '85'}, {'groupId': 'BG002', 'value': '91'}, {'groupId': 'BG003', 'value': '262'}]}]}]}, {'title': 'Ethnicity (NIH/OMB)', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '19'}, {'groupId': 'BG001', 'value': '19'}, {'groupId': 'BG002', 'value': '10'}, {'groupId': 'BG003', 'value': '48'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'groupId': 'BG000', 'value': '263'}, {'groupId': 'BG001', 'value': '264'}, {'groupId': 'BG002', 'value': '274'}, {'groupId': 'BG003', 'value': '801'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}]}]}, {'title': 'Race/Ethnicity, Customized', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'classes': [{'categories': [{'title': 'White', 'measurements': [{'groupId': 'BG000', 'value': '247'}, {'groupId': 'BG001', 'value': '245'}, {'groupId': 'BG002', 'value': '248'}, {'groupId': 'BG003', 'value': '740'}]}, {'title': 'Black or African American', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}, {'title': 'Asian', 'measurements': [{'groupId': 'BG000', 'value': '34'}, {'groupId': 'BG001', 'value': '38'}, {'groupId': 'BG002', 'value': '34'}, {'groupId': 'BG003', 'value': '106'}]}, {'title': 'Other', 'measurements': [{'groupId': 'BG000', 'value': '1'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '2'}, {'groupId': 'BG003', 'value': '3'}]}, {'title': 'Unknown', 'measurements': [{'groupId': 'BG000', 'value': '0'}, {'groupId': 'BG001', 'value': '0'}, {'groupId': 'BG002', 'value': '0'}, {'groupId': 'BG003', 'value': '0'}]}]}]}]","[{'type': 'PRIMARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 24', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with osteoarthritis (OA). The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': 'The intent to treat (ITT) population included all randomized participants who received at least one dose of subcutaneous (SC) study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.24', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.70', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.85', 'spread': '0.17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. Analysis of covariance (ANCOVA) model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Step-down testing procedure within each of the primary outcome measures was applied to maintain Type I error. Tanezumab 5 mg versus placebo was tested first and if found significant, then the testing was continued for Tanezumab 2.5 mg versus placebo. Tanezumab treatment group was declared as superior to placebo if the corresponding treatment contrast was significant over all 3 primary outcome measures.', 'pValue': '0.0088', 'pValueComment': 'Threshold for significance at 0.05 level.', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.46', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.81', 'ciUpperLimit': '-0.12', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A step-down testing procedure within each of the primary outcome measures was applied to maintain Type I error. Tanezumab 5 mg versus placebo was tested first and if found significant, then the testing was continued for Tanezumab 2.5 mg versus placebo. A tanezumab treatment group was declared as superior to placebo if the corresponding treatment contrast was significant over all 3 primary outcome measures.', 'pValue': '0.0006', 'pValueComment': 'Threshold for significance at 0.05 level.', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.97', 'ciUpperLimit': '-0.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}]}, {'type': 'PRIMARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 24', 'description': ""WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function."", 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.11', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.70', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.82', 'spread': '0.17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Step-down testing procedure within each of the primary outcome measures was applied to maintain Type I error. Tanezumab 5 mg versus placebo was tested first and if found significant, then the testing was continued for Tanezumab 2.5 mg versus placebo. Tanezumab treatment group was declared as superior to placebo if the corresponding treatment contrast was significant over all 3 primary outcome measures.', 'pValue': '0.0008', 'pValueComment': 'Threshold for significance at 0.05 level.', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.59', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.93', 'ciUpperLimit': '-0.24', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'Step-down testing procedure within each of the primary outcome measures was applied to maintain Type I error. Tanezumab 5 mg versus placebo was tested first and if found significant, then the testing was continued for Tanezumab 2.5 mg versus placebo. Tanezumab treatment group was declared as superior to placebo if the corresponding treatment contrast was significant over all 3 primary outcome measures.', 'pValue': '<.0001', 'pValueComment': 'Threshold for significance at 0.05 level.', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.71', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.05', 'ciUpperLimit': '-0.36', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}]}, {'type': 'PRIMARY', 'title': ""Change From Baseline in the Patient's Global Assessment (PGA) of Osteoarthritis at Week 24"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5= very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worsening of condition.', 'populationDescription': 'The intent to treat population was defined as all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.72', 'spread': '0.06'}, {'groupId': 'OG001', 'value': '-0.82', 'spread': '0.06'}, {'groupId': 'OG002', 'value': '-0.90', 'spread': '0.06'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A step-down testing procedure within each of the primary outcome measures was applied to maintain Type I error. Tanezumab 5 mg versus placebo was tested first and if found significant, then the testing was continued for Tanezumab 2.5 mg versus placebo. A tanezumab treatment group was declared as superior to placebo if the corresponding treatment contrast was significant over all 3 primary outcome measures.', 'pValue': '0.1092', 'pValueComment': 'Threshold for significance at 0.05 level.', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.11', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.24', 'ciUpperLimit': '0.02', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.07'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets included treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'nonInferiorityComment': 'A step-down testing procedure within each of the primary outcome measures was applied to maintain Type I error. Tanezumab 5 mg versus placebo was tested first and if found significant, then the testing was continued for Tanezumab 2.5 mg versus placebo. A tanezumab treatment group was declared as superior to placebo if the corresponding treatment contrast was significant over all 3 primary outcome measures.', 'pValue': '0.0051', 'pValueComment': 'Threshold for significance at 0.05 level.', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.19', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.32', 'ciUpperLimit': '-0.06', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.07'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 2, 4, 8, 12 and 16', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 16', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.35', 'spread': '0.14'}, {'groupId': 'OG001', 'value': '-2.02', 'spread': '0.14'}, {'groupId': 'OG002', 'value': '-1.69', 'spread': '0.14'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.78', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.57', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.56', 'spread': '0.15'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.84', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.47', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.61', 'spread': '0.15'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.19', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.91', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.96', 'spread': '0.16'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.10', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.69', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.69', 'spread': '0.17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.94', 'ciUpperLimit': '-0.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0149', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.34', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.61', 'ciUpperLimit': '-0.07', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.08', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.78', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.07', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.92', 'ciUpperLimit': '-0.32', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.07', 'ciUpperLimit': '-0.47', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.05', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.09', 'ciUpperLimit': '-0.44', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0005', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.59', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.93', 'ciUpperLimit': '-0.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0004', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.60', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.93', 'ciUpperLimit': '-0.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Week 32', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to osteoarthritis of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a numerical rating scale (NRS). Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.59', 'spread': '0.94'}, {'groupId': 'OG001', 'value': '6.70', 'spread': '0.94'}, {'groupId': 'OG002', 'value': '6.60', 'spread': '0.89'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.70', 'spread': '2.06'}, {'groupId': 'OG001', 'value': '-2.29', 'spread': '1.95'}, {'groupId': 'OG002', 'value': '-2.26', 'spread': '2.24'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 2, 4, 8, 12 and 16', 'description': ""WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function."", 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 16', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.26', 'spread': '0.14'}, {'groupId': 'OG001', 'value': '-1.95', 'spread': '0.14'}, {'groupId': 'OG002', 'value': '-1.69', 'spread': '0.14'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.71', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.52', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.50', 'spread': '0.15'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.76', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.38', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.52', 'spread': '0.15'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.04', 'spread': '2.16'}, {'groupId': 'OG001', 'value': '-2.83', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.87', 'spread': '0.16'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.02', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.68', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.69', 'spread': '0.16'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.69', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.95', 'ciUpperLimit': '-0.42', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0014', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.43', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.70', 'ciUpperLimit': '-0.17', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.09', 'ciUpperLimit': '-0.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.08', 'ciUpperLimit': '-0.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.63', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.93', 'ciUpperLimit': '-0.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.76', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.06', 'ciUpperLimit': '-0.47', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.11', 'ciUpperLimit': '-0.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.82', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.15', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '-0.34', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC physical function subscale and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.68', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '-0.35', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Week 32', 'description': ""WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function refers to participant's ability to move around and perform usual activities of daily living. The WOMAC physical function subscale is a 17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours. It was calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical function subscale score on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function."", 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.59', 'spread': '0.94'}, {'groupId': 'OG001', 'value': '6.70', 'spread': '0.94'}, {'groupId': 'OG002', 'value': '6.60', 'spread': '0.89'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.70', 'spread': '2.06'}, {'groupId': 'OG001', 'value': '-2.29', 'spread': '1.95'}, {'groupId': 'OG002', 'value': '-2.26', 'spread': '2.24'}]}]}]}, {'type': 'SECONDARY', 'title': ""Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis at Weeks 2, 4, 8, 12 and 16"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities).', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12 and 16', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.50', 'spread': '0.05'}, {'groupId': 'OG001', 'value': '-0.73', 'spread': '0.05'}, {'groupId': 'OG002', 'value': '-0.67', 'spread': '0.05'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.60', 'spread': '0.05'}, {'groupId': 'OG001', 'value': '-0.85', 'spread': '0.05'}, {'groupId': 'OG002', 'value': '-0.93', 'spread': '0.05'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.62', 'spread': '0.05'}, {'groupId': 'OG001', 'value': '-0.79', 'spread': '0.05'}, {'groupId': 'OG002', 'value': '-0.88', 'spread': '0.05'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.71', 'spread': '0.06'}, {'groupId': 'OG001', 'value': '-0.99', 'spread': '0.06'}, {'groupId': 'OG002', 'value': '-1.03', 'spread': '0.06'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.64', 'spread': '0.06'}, {'groupId': 'OG001', 'value': '-0.78', 'spread': '0.06'}, {'groupId': 'OG002', 'value': '-0.90', 'spread': '0.06'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.23', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.33', 'ciUpperLimit': '-0.12', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.05'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0022', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.17', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.27', 'ciUpperLimit': '-0.06', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.05'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.24', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.35', 'ciUpperLimit': '-0.14', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.05'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.32', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.43', 'ciUpperLimit': '-0.22', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.05'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0029', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.17', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.28', 'ciUpperLimit': '-0.06', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.06'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.26', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.37', 'ciUpperLimit': '-0.15', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.06'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.29', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.40', 'ciUpperLimit': '-0.17', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.06'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.32', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.43', 'ciUpperLimit': '-0.20', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.06'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0352', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.13', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.26', 'ciUpperLimit': '-0.01', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.06'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline PGA of osteoarthritis and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.25', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.37', 'ciUpperLimit': '-0.13', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.06'}]}, {'type': 'SECONDARY', 'title': ""Change From Baseline in Patient's Global Assessment (PGA) of Osteoarthritis at Week 32"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip (index joint) affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.55', 'spread': '0.62'}, {'groupId': 'OG001', 'value': '3.61', 'spread': '0.62'}, {'groupId': 'OG002', 'value': '3.56', 'spread': '0.63'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.84', 'spread': '0.87'}, {'groupId': 'OG001', 'value': '-0.64', 'spread': '0.88'}, {'groupId': 'OG002', 'value': '-0.63', 'spread': '0.91'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Meeting Outcomes Measures in Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index', 'description': 'Participants were considered as OMERACT-OARSI responders: if the change (improvement) from baseline to week of interest was greater than or equal to (\\>=) 50 percent and \\>= 2 units in either WOMAC pain subscale or physical function subscale score; if change (improvement) from baseline to week of interest was \\>=20 percent and \\>=1 unit in at least 2 of the following: 1) WOMAC pain subscale score, 2) WOMAC physical function subscale score, 3) PGA of osteoarthritis. WOMAC pain subscale assess amount of pain experienced (score: 0 \\[no pain\\] to 10 \\[extreme pain\\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \\[minimum difficulty\\] to 10 \\[extreme difficulty\\], higher score = worse physical function) and PGA of OA (score: 1 \\[very good\\] to 5 \\[very poor\\], higher score = worse condition). Missing data was imputed using mixed baseline/last observation carried forward (BOCF/LOCF).', 'populationDescription': ""ITT population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here 'Overall number of participants analyzed' = participants who were evaluable for this outcome measure and 'Number analyzed' = participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 2, 4, 8, 12, 16, 24 and 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '44.1'}, {'groupId': 'OG001', 'value': '63.1'}, {'groupId': 'OG002', 'value': '54.9'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '53.0'}, {'groupId': 'OG001', 'value': '74.8'}, {'groupId': 'OG002', 'value': '71.8'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '61.9'}, {'groupId': 'OG001', 'value': '75.5'}, {'groupId': 'OG002', 'value': '75.4'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '68.7'}, {'groupId': 'OG001', 'value': '80.9'}, {'groupId': 'OG002', 'value': '81.0'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '64.4'}, {'groupId': 'OG001', 'value': '78.7'}, {'groupId': 'OG002', 'value': '76.1'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '65.1'}, {'groupId': 'OG001', 'value': '76.2'}, {'groupId': 'OG002', 'value': '77.1'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '74.0'}, {'groupId': 'OG001', 'value': '66.4'}, {'groupId': 'OG002', 'value': '63.0'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Odds ratio and 95 percent (%) confidence interval (CI) estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.23', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.59', 'ciUpperLimit': '3.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0085', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.56', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.12', 'ciUpperLimit': '2.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.71', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.89', 'ciUpperLimit': '3.88'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.31', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.62', 'ciUpperLimit': '3.28'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0005', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.91', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.33', 'ciUpperLimit': '2.75'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0005', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.90', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.32', 'ciUpperLimit': '2.73'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0009', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.94', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.31', 'ciUpperLimit': '2.86'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0008', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.95', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.32', 'ciUpperLimit': '2.89'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0002', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.06', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.41', 'ciUpperLimit': '3.01'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0022', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.78', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.23', 'ciUpperLimit': '2.57'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0032', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.21', 'ciUpperLimit': '2.54'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0013', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.85', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.27', 'ciUpperLimit': '2.69'}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Cumulative Percent Change From Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at Weeks 16 and 24', 'description': 'WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a NRS. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Percentage of participants with cumulative reduction (as percent) (greater than 0% ; \\>= 10, 20, 30, 40, 50, 60, 70, 80 and 90%; = 100 %) in WOMAC pain subscale from Baseline to Weeks 16 and 24 were reported, participants (%) are reported more than once in categories specified. Missing data was imputed using mixed BOCF/LOCF.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Overall number of participants analyzed' = Participants evaluable for this outcome measure."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of Participants', 'timeFrame': 'Baseline, Weeks 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 16: >0%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '81.9'}, {'groupId': 'OG001', 'value': '91.8'}, {'groupId': 'OG002', 'value': '89.4'}]}]}, {'title': 'Week 16: >=10%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '77.6'}, {'groupId': 'OG001', 'value': '87.6'}, {'groupId': 'OG002', 'value': '82.0'}]}]}, {'title': 'Week 16: >=20%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '66.9'}, {'groupId': 'OG001', 'value': '79.4'}, {'groupId': 'OG002', 'value': '76.1'}]}]}, {'title': 'Week 16: >=30%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '56.2'}, {'groupId': 'OG001', 'value': '68.1'}, {'groupId': 'OG002', 'value': '68.7'}]}]}, {'title': 'Week 16: >=40%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '45.2'}, {'groupId': 'OG001', 'value': '57.8'}, {'groupId': 'OG002', 'value': '59.9'}]}]}, {'title': 'Week 16: >=50%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '35.9'}, {'groupId': 'OG001', 'value': '49.6'}, {'groupId': 'OG002', 'value': '47.5'}]}]}, {'title': 'Week 16: >=60%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '27.0'}, {'groupId': 'OG001', 'value': '34.4'}, {'groupId': 'OG002', 'value': '36.6'}]}]}, {'title': 'Week 16: >=70%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17.1'}, {'groupId': 'OG001', 'value': '22.3'}, {'groupId': 'OG002', 'value': '24.3'}]}]}, {'title': 'Week 16: >=80%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.0'}, {'groupId': 'OG001', 'value': '14.5'}, {'groupId': 'OG002', 'value': '14.4'}]}]}, {'title': 'Week 16: >=90%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.2'}, {'groupId': 'OG001', 'value': '7.4'}, {'groupId': 'OG002', 'value': '4.9'}]}]}, {'title': 'Week 16: =100%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.1'}, {'groupId': 'OG001', 'value': '1.8'}, {'groupId': 'OG002', 'value': '3.2'}]}]}, {'title': 'Week 24: >0%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '80.1'}, {'groupId': 'OG001', 'value': '89.7'}, {'groupId': 'OG002', 'value': '88.4'}]}]}, {'title': 'Week 24: >=10%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '70.8'}, {'groupId': 'OG001', 'value': '83.0'}, {'groupId': 'OG002', 'value': '83.5'}]}]}, {'title': 'Week 24: >=20%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '65.8'}, {'groupId': 'OG001', 'value': '76.2'}, {'groupId': 'OG002', 'value': '76.8'}]}]}, {'title': 'Week 24: >=30%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '56.6'}, {'groupId': 'OG001', 'value': '65.6'}, {'groupId': 'OG002', 'value': '68.7'}]}]}, {'title': 'Week 24: >=40%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '44.8'}, {'groupId': 'OG001', 'value': '55.0'}, {'groupId': 'OG002', 'value': '59.2'}]}]}, {'title': 'Week 24: >=50%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33.8'}, {'groupId': 'OG001', 'value': '45.4'}, {'groupId': 'OG002', 'value': '47.9'}]}]}, {'title': 'Week 24: >=60%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '24.9'}, {'groupId': 'OG001', 'value': '33.3'}, {'groupId': 'OG002', 'value': '36.6'}]}]}, {'title': 'Week 24: >=70%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17.8'}, {'groupId': 'OG001', 'value': '21.3'}, {'groupId': 'OG002', 'value': '23.2'}]}]}, {'title': 'Week 24: >=80%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11.4'}, {'groupId': 'OG001', 'value': '12.1'}, {'groupId': 'OG002', 'value': '14.1'}]}]}, {'title': 'Week 24: >=90%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.2'}, {'groupId': 'OG001', 'value': '5.3'}, {'groupId': 'OG002', 'value': '6.0'}]}]}, {'title': 'Week 24: =100%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.1'}, {'groupId': 'OG001', 'value': '0.7'}, {'groupId': 'OG002', 'value': '2.8'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Reduction >=30 Percent (%), >=50%, >=70% and >=90% Response', 'description': 'Percentage of participants with reduction in WOMAC pain intensity of at least (\\>=) 30%, 50%, 70% and 90% at Weeks 2, 4, 8, 12, 16, 24 and 32 compared to baseline were classified as responders to WOMAC pain subscale and are reported here. WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. The WOMAC pain subscale is a 5-item questionnaire used to assess the amount of pain experienced due to OA of index joint (knee or hip) during past 48 hours. It was calculated as the mean of scores from 5 individual questions scored on a NRS. Scores for each question and WOMAC Pain subscale score on NRS ranged from 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain. Missing data was imputed using mixed BOCF/LOCF.', 'populationDescription': ""ITT population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here 'Overall number of participants analyzed' = participants who were evaluable for this outcome measure and 'Number analyzed' = participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Week 2, 4, 8, 12, 16, 24 and 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33.5'}, {'groupId': 'OG001', 'value': '46.8'}, {'groupId': 'OG002', 'value': '42.6'}]}]}, {'title': 'Week 2: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '16.7'}, {'groupId': 'OG001', 'value': '27.7'}, {'groupId': 'OG002', 'value': '18.3'}]}]}, {'title': 'Week 2: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.0'}, {'groupId': 'OG001', 'value': '10.3'}, {'groupId': 'OG002', 'value': '6.7'}]}]}, {'title': 'Week 2: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.1'}, {'groupId': 'OG001', 'value': '2.5'}, {'groupId': 'OG002', 'value': '1.4'}]}]}, {'title': 'Week 4: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '45.2'}, {'groupId': 'OG001', 'value': '61.3'}, {'groupId': 'OG002', 'value': '58.8'}]}]}, {'title': 'Week 4: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '22.8'}, {'groupId': 'OG001', 'value': '33.0'}, {'groupId': 'OG002', 'value': '37.7'}]}]}, {'title': 'Week 4: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.5'}, {'groupId': 'OG001', 'value': '13.1'}, {'groupId': 'OG002', 'value': '15.8'}]}]}, {'title': 'Week 4: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.4'}, {'groupId': 'OG001', 'value': '3.9'}, {'groupId': 'OG002', 'value': '4.9'}]}]}, {'title': 'Week 8: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '50.5'}, {'groupId': 'OG001', 'value': '64.2'}, {'groupId': 'OG002', 'value': '61.6'}]}]}, {'title': 'Week 8: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '26.0'}, {'groupId': 'OG001', 'value': '37.2'}, {'groupId': 'OG002', 'value': '44.4'}]}]}, {'title': 'Week 8: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.7'}, {'groupId': 'OG001', 'value': '15.2'}, {'groupId': 'OG002', 'value': '22.2'}]}]}, {'title': 'Week 8: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.1'}, {'groupId': 'OG001', 'value': '4.3'}, {'groupId': 'OG002', 'value': '5.6'}]}]}, {'title': 'Week 12: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '58.4'}, {'groupId': 'OG001', 'value': '71.6'}, {'groupId': 'OG002', 'value': '71.1'}]}]}, {'title': 'Week 12: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33.8'}, {'groupId': 'OG001', 'value': '46.8'}, {'groupId': 'OG002', 'value': '50.7'}]}]}, {'title': 'Week 12: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '15.7'}, {'groupId': 'OG001', 'value': '24.1'}, {'groupId': 'OG002', 'value': '23.2'}]}]}, {'title': 'Week 12: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.8'}, {'groupId': 'OG001', 'value': '8.5'}, {'groupId': 'OG002', 'value': '7.0'}]}]}, {'title': 'Week 16: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '56.2'}, {'groupId': 'OG001', 'value': '68.1'}, {'groupId': 'OG002', 'value': '68.7'}]}]}, {'title': 'Week 16: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '35.9'}, {'groupId': 'OG001', 'value': '49.6'}, {'groupId': 'OG002', 'value': '47.5'}]}]}, {'title': 'Week 16: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17.1'}, {'groupId': 'OG001', 'value': '22.3'}, {'groupId': 'OG002', 'value': '24.3'}]}]}, {'title': 'Week 16: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.2'}, {'groupId': 'OG001', 'value': '7.4'}, {'groupId': 'OG002', 'value': '4.9'}]}]}, {'title': 'Week 24: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '56.6'}, {'groupId': 'OG001', 'value': '65.6'}, {'groupId': 'OG002', 'value': '68.7'}]}]}, {'title': 'Week 24: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '33.8'}, {'groupId': 'OG001', 'value': '45.4'}, {'groupId': 'OG002', 'value': '47.9'}]}]}, {'title': 'Week 24: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17.8'}, {'groupId': 'OG001', 'value': '21.3'}, {'groupId': 'OG002', 'value': '23.2'}]}]}, {'title': 'Week 24: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.2'}, {'groupId': 'OG001', 'value': '5.3'}, {'groupId': 'OG002', 'value': '6.0'}]}]}, {'title': 'Week 32: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '65.4'}, {'groupId': 'OG001', 'value': '54.7'}, {'groupId': 'OG002', 'value': '57.3'}]}]}, {'title': 'Week 32: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '43.7'}, {'groupId': 'OG001', 'value': '32.8'}, {'groupId': 'OG002', 'value': '32.9'}]}]}, {'title': 'Week 32: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21.2'}, {'groupId': 'OG001', 'value': '12.1'}, {'groupId': 'OG002', 'value': '15.4'}]}]}, {'title': 'Week 32: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.8'}, {'groupId': 'OG001', 'value': '1.6'}, {'groupId': 'OG002', 'value': '4.9'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.83', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.30', 'ciUpperLimit': '2.59'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0160', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.53', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.08', 'ciUpperLimit': '2.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0008', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.03', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.34', 'ciUpperLimit': '3.07'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.5118', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.16', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.75', 'ciUpperLimit': '1.80'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0093', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.45', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.25', 'ciUpperLimit': '4.81'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3017', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.46', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.71', 'ciUpperLimit': '3.01'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2160', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.40', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.60', 'ciUpperLimit': '9.58'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.7174', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.33', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.29', 'ciUpperLimit': '6.08'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.04', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.45', 'ciUpperLimit': '2.87'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.29', 'ciUpperLimit': '2.54'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0024', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.23', 'ciUpperLimit': '2.65'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.17', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.49', 'ciUpperLimit': '3.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0373', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.04', 'ciUpperLimit': '3.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0046', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.17', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.27', 'ciUpperLimit': '3.72'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0683', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.95', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.92', 'ciUpperLimit': '9.47'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0214', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '11.66'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.83', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.30', 'ciUpperLimit': '2.58'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0048', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.63', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.16', 'ciUpperLimit': '2.28'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0012', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.84', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.27', 'ciUpperLimit': '2.65'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.41', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.68', 'ciUpperLimit': '3.47'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0537', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.99', 'ciUpperLimit': '2.74'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.55', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.58', 'ciUpperLimit': '4.13'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1155', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.26', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.82', 'ciUpperLimit': '6.27'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0271', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.00', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.13', 'ciUpperLimit': '7.96'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0007', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.85', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.30', 'ciUpperLimit': '2.63'}, {'groupIds': ['OG000'], 'groupDescription': 'Week 12, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0011', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.26', 'ciUpperLimit': '2.56'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0009', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.27', 'ciUpperLimit': '2.52'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.07', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.47', 'ciUpperLimit': '2.91'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0064', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.18', 'ciUpperLimit': '2.78'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0180', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.68', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.09', 'ciUpperLimit': '2.58'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '5.61', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '2.09', 'ciUpperLimit': '15.08'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0034', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '4.46', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.64', 'ciUpperLimit': '12.13'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0022', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '2.44'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0014', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.25', 'ciUpperLimit': '2.50'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0003', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.87', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.33', 'ciUpperLimit': '2.64'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0030', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.68', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.19', 'ciUpperLimit': '2.36'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0754', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.47', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.96', 'ciUpperLimit': '2.24'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0253', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.61', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.06', 'ciUpperLimit': '2.44'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0098', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.98', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.30', 'ciUpperLimit': '6.83'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2230', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.72', 'ciUpperLimit': '4.13'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0201', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.50', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.07', 'ciUpperLimit': '2.12'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=30%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0021', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.73', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '2.44'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0022', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '2.43'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=50%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0004', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.87', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.32', 'ciUpperLimit': '2.64'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2031', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.32', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.86', 'ciUpperLimit': '2.01'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=70%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0867', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.44', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.95', 'ciUpperLimit': '2.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1746', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.77', 'ciUpperLimit': '4.22'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=90%: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1039', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.99', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.87', 'ciUpperLimit': '4.57'}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants Achieving Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale Reduction >=30%, >=50%, >=70% and >=90% Response', 'description': ""Percentage of participants with reduction in WOMAC physical function of at least (\\>=)30%,50%,70% and 90% at weeks 2,4,8,12,16,24 and 32 compared to baseline were classified as responders to WOMAC physical function subscale. WOMAC: Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function:Participant's ability to move around and perform usual activities of daily living. WOMAC physical function subscale17-item questionnaire used to assess the degree of difficulty experienced due to OA in index joint (knee/hip) during past 48 hours, calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC physical subscale on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), where higher scores indicated extreme difficulty/worse physical function. Missing data was imputed using mixed BOCF/LOCF."", 'populationDescription': ""ITT population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here 'Overall number of participants analyzed' = participants who were evaluable for this outcome measure and 'Number analyzed' = participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 2, 4, 8, 12, 16, 24 and 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '30.2'}, {'groupId': 'OG001', 'value': '44.3'}, {'groupId': 'OG002', 'value': '38.7'}]}]}, {'title': 'Week 2: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.6'}, {'groupId': 'OG001', 'value': '19.1'}, {'groupId': 'OG002', 'value': '18.3'}]}]}, {'title': 'Week 2: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.9'}, {'groupId': 'OG001', 'value': '9.2'}, {'groupId': 'OG002', 'value': '5.3'}]}]}, {'title': 'Week 2: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.1'}, {'groupId': 'OG001', 'value': '2.5'}, {'groupId': 'OG002', 'value': '1.8'}]}]}, {'title': 'Week 4: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '36.3'}, {'groupId': 'OG001', 'value': '55.0'}, {'groupId': 'OG002', 'value': '53.9'}]}]}, {'title': 'Week 4: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '18.1'}, {'groupId': 'OG001', 'value': '28.0'}, {'groupId': 'OG002', 'value': '32.4'}]}]}, {'title': 'Week 4: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.4'}, {'groupId': 'OG001', 'value': '11.7'}, {'groupId': 'OG002', 'value': '12.0'}]}]}, {'title': 'Week 4: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.1'}, {'groupId': 'OG001', 'value': '2.8'}, {'groupId': 'OG002', 'value': '4.6'}]}]}, {'title': 'Week 8: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '45.6'}, {'groupId': 'OG001', 'value': '57.4'}, {'groupId': 'OG002', 'value': '59.2'}]}]}, {'title': 'Week 8: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '22.8'}, {'groupId': 'OG001', 'value': '33.7'}, {'groupId': 'OG002', 'value': '37.3'}]}]}, {'title': 'Week 8: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.5'}, {'groupId': 'OG001', 'value': '16.0'}, {'groupId': 'OG002', 'value': '15.5'}]}]}, {'title': 'Week 8: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.4'}, {'groupId': 'OG001', 'value': '5.0'}, {'groupId': 'OG002', 'value': '4.9'}]}]}, {'title': 'Week 12: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.2'}, {'groupId': 'OG001', 'value': '67.4'}, {'groupId': 'OG002', 'value': '69.4'}]}]}, {'title': 'Week 12: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '27.8'}, {'groupId': 'OG001', 'value': '43.6'}, {'groupId': 'OG002', 'value': '43.7'}]}]}, {'title': 'Week 12: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '12.8'}, {'groupId': 'OG001', 'value': '19.9'}, {'groupId': 'OG002', 'value': '21.1'}]}]}, {'title': 'Week 12: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.7'}, {'groupId': 'OG001', 'value': '6.7'}, {'groupId': 'OG002', 'value': '5.6'}]}]}, {'title': 'Week 16: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '53.0'}, {'groupId': 'OG001', 'value': '65.2'}, {'groupId': 'OG002', 'value': '66.2'}]}]}, {'title': 'Week 16: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32.0'}, {'groupId': 'OG001', 'value': '42.9'}, {'groupId': 'OG002', 'value': '44.0'}]}]}, {'title': 'Week 16: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.2'}, {'groupId': 'OG001', 'value': '21.3'}, {'groupId': 'OG002', 'value': '18.3'}]}]}, {'title': 'Week 16: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.5'}, {'groupId': 'OG001', 'value': '6.0'}, {'groupId': 'OG002', 'value': '6.0'}]}]}, {'title': 'Week 24: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.2'}, {'groupId': 'OG001', 'value': '64.9'}, {'groupId': 'OG002', 'value': '68.7'}]}]}, {'title': 'Week 24: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32.4'}, {'groupId': 'OG001', 'value': '41.5'}, {'groupId': 'OG002', 'value': '44.7'}]}]}, {'title': 'Week 24: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.6'}, {'groupId': 'OG001', 'value': '19.1'}, {'groupId': 'OG002', 'value': '17.3'}]}]}, {'title': 'Week 24: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.8'}, {'groupId': 'OG001', 'value': '5.3'}, {'groupId': 'OG002', 'value': '5.3'}]}]}, {'title': 'Week 32: At least 30% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '60.2'}, {'groupId': 'OG001', 'value': '51.4'}, {'groupId': 'OG002', 'value': '53.7'}]}]}, {'title': 'Week 32: At least 50% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '40.3'}, {'groupId': 'OG001', 'value': '31.2'}, {'groupId': 'OG002', 'value': '30.5'}]}]}, {'title': 'Week 32: At least 70% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '16.9'}, {'groupId': 'OG001', 'value': '11.7'}, {'groupId': 'OG002', 'value': '11.4'}]}]}, {'title': 'Week 32: At least 90% reduction', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.5'}, {'groupId': 'OG001', 'value': '2.0'}, {'groupId': 'OG002', 'value': '3.3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0003', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.89', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.33', 'ciUpperLimit': '2.68'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0286', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.48', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.04', 'ciUpperLimit': '2.10'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1031', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.45', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.93', 'ciUpperLimit': '2.27'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2033', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.34', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.85', 'ciUpperLimit': '2.10'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0064', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.34', 'ciUpperLimit': '5.86'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3706', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.44', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.65', 'ciUpperLimit': '3.23'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2121', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.39', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.61', 'ciUpperLimit': '9.41'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.4859', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.39', 'ciUpperLimit': '7.11'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.25', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.60', 'ciUpperLimit': '3.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.10', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.50', 'ciUpperLimit': '2.96'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0020', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.91', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.27', 'ciUpperLimit': '2.87'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.28', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.53', 'ciUpperLimit': '3.40'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0107', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.23', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.21', 'ciUpperLimit': '4.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0126', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.18', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.18', 'ciUpperLimit': '4.02'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1516', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.70', 'ciUpperLimit': '10.26'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0210', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '4.49', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.25', 'ciUpperLimit': '16.05'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0034', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.18', 'ciUpperLimit': '2.31'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0010', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.26', 'ciUpperLimit': '2.45'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0014', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.86', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.27', 'ciUpperLimit': '2.71'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.13', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.46', 'ciUpperLimit': '3.10'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0007', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.61', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.49', 'ciUpperLimit': '4.55'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0018', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.43', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.39', 'ciUpperLimit': '4.24'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0150', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '4.10', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.31', 'ciUpperLimit': '12.79'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0211', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '11.78'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.01', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.43', 'ciUpperLimit': '2.84'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.19', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.55', 'ciUpperLimit': '3.10'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.10', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.47', 'ciUpperLimit': '3.00'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.08', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.46', 'ciUpperLimit': '2.96'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0180', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.10', 'ciUpperLimit': '2.76'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0072', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.86', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.18', 'ciUpperLimit': '2.94'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0015', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '10.84', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '2.49', 'ciUpperLimit': '47.22'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0044', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '8.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.96', 'ciUpperLimit': '37.96'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0018', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '2.43'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0011', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.26', 'ciUpperLimit': '2.50'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0035', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.68', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.19', 'ciUpperLimit': '2.38'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0022', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.22', 'ciUpperLimit': '2.43'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0155', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.11', 'ciUpperLimit': '2.72'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1549', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.39', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.88', 'ciUpperLimit': '2.20'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0212', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.94', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.18', 'ciUpperLimit': '7.37'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0373', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.64', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.06', 'ciUpperLimit': '6.57'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.83', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.29', 'ciUpperLimit': '2.57'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=30%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.13', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.51', 'ciUpperLimit': '3.02'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0152', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.54', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.09', 'ciUpperLimit': '2.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=50%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0018', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.73', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.23', 'ciUpperLimit': '2.45'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0970', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.47', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.93', 'ciUpperLimit': '2.31'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=70%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3435', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.25', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.79', 'ciUpperLimit': '1.98'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0236', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.30', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.17', 'ciUpperLimit': '9.27'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24, \\>=90%: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC physical function subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0296', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.14', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.12', 'ciUpperLimit': '8.81'}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Cumulative Percent Change From Baseline Reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at Weeks 16 and 24', 'description': ""Percentage of participants with cumulative reduction (as percent) (greater than 0 %; \\>= 10 %, 20 %, 30 %, 40 %, 50 %, 60 %, 70 %, 80 % and 90%; =100 %) in WOMAC physical function subscale from Baseline to Weeks 16 and 24 were reported. WOMAC:Self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Physical function: participant's ability to move around and perform usual activities of daily living. WOMAC physical function subscale:17-item questionnaire to assess the degree of difficulty experienced due to OA in index joint (knee or hip) during past 48 hours, calculated as mean of the scores from 17 individual questions scored on a NRS. Scores for each question and WOMAC Pain subscale on NRS ranged from 0 (no difficulty) to 10 (extreme difficulty), higher scores indicate extreme difficulty/worse physical function. Missing data was imputed using mixed BOCF/LOCF."", 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Overall number of participants analyzed' = Participants evaluable for this outcome measure."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Baseline, Weeks 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 16: >=0%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '84.7'}, {'groupId': 'OG001', 'value': '93.6'}, {'groupId': 'OG002', 'value': '93.0'}]}]}, {'title': 'Week 16: >=10%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '75.1'}, {'groupId': 'OG001', 'value': '87.2'}, {'groupId': 'OG002', 'value': '83.8'}]}]}, {'title': 'Week 16: >=20%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '61.6'}, {'groupId': 'OG001', 'value': '73.8'}, {'groupId': 'OG002', 'value': '73.9'}]}]}, {'title': 'Week 16: >=30%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '53.0'}, {'groupId': 'OG001', 'value': '65.2'}, {'groupId': 'OG002', 'value': '66.2'}]}]}, {'title': 'Week 16: >=40%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '44.1'}, {'groupId': 'OG001', 'value': '55.3'}, {'groupId': 'OG002', 'value': '56.0'}]}]}, {'title': 'Week 16: >=50%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32.0'}, {'groupId': 'OG001', 'value': '42.9'}, {'groupId': 'OG002', 'value': '44.0'}]}]}, {'title': 'Week 16: >=60%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '20.3'}, {'groupId': 'OG001', 'value': '30.1'}, {'groupId': 'OG002', 'value': '30.3'}]}]}, {'title': 'Week 16: >=70%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.2'}, {'groupId': 'OG001', 'value': '21.3'}, {'groupId': 'OG002', 'value': '18.3'}]}]}, {'title': 'Week 16: >=80%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.1'}, {'groupId': 'OG001', 'value': '12.4'}, {'groupId': 'OG002', 'value': '11.3'}]}]}, {'title': 'Week 16: >=90%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.5'}, {'groupId': 'OG001', 'value': '6.0'}, {'groupId': 'OG002', 'value': '6.0'}]}]}, {'title': 'Week 16: =100%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.7'}, {'groupId': 'OG001', 'value': '0.7'}, {'groupId': 'OG002', 'value': '1.8'}]}]}, {'title': 'Week 24: >=0%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '79.7'}, {'groupId': 'OG001', 'value': '89.0'}, {'groupId': 'OG002', 'value': '90.1'}]}]}, {'title': 'Week 24: >=10%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '70.1'}, {'groupId': 'OG001', 'value': '85.8'}, {'groupId': 'OG002', 'value': '84.2'}]}]}, {'title': 'Week 24: >=20%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '61.6'}, {'groupId': 'OG001', 'value': '74.8'}, {'groupId': 'OG002', 'value': '78.2'}]}]}, {'title': 'Week 24: >=30%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '51.2'}, {'groupId': 'OG001', 'value': '64.9'}, {'groupId': 'OG002', 'value': '68.7'}]}]}, {'title': 'Week 24: >=40%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '41.3'}, {'groupId': 'OG001', 'value': '51.1'}, {'groupId': 'OG002', 'value': '57.0'}]}]}, {'title': 'Week 24: >=50%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32.4'}, {'groupId': 'OG001', 'value': '41.5'}, {'groupId': 'OG002', 'value': '44.7'}]}]}, {'title': 'Week 24: >=60%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '21.0'}, {'groupId': 'OG001', 'value': '30.9'}, {'groupId': 'OG002', 'value': '30.6'}]}]}, {'title': 'Week 24: >=70%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.6'}, {'groupId': 'OG001', 'value': '19.1'}, {'groupId': 'OG002', 'value': '17.3'}]}]}, {'title': 'Week 24: >=80%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.4'}, {'groupId': 'OG001', 'value': '10.6'}, {'groupId': 'OG002', 'value': '10.2'}]}]}, {'title': 'Week 24: >=90%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.8'}, {'groupId': 'OG001', 'value': '5.3'}, {'groupId': 'OG002', 'value': '5.3'}]}]}, {'title': 'Week 24: =100%', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0.4'}, {'groupId': 'OG002', 'value': '1.8'}]}]}]}, {'type': 'SECONDARY', 'title': ""Percentage of Participants Achieving Improvement of >=2 Points in Patient's Global Assessment (PGA) of Osteoarthritis"", 'description': 'PGA of OA was assessed by asking a question from participants: ""Considering all the ways your osteoarthritis in your knee or hip affects you, how are you doing today?"" Participants responded on a scale ranging from 1-5, where, 1=very good (no symptom and no limitation of normal activities), 2= good (mild symptoms and no limitation of normal activities), 3= fair (moderate symptoms and limitation of some normal activities), 4= poor (severe symptoms and inability to carry out most normal activities), and 5 = very poor (very severe symptoms and inability to carry out all normal activities). Higher scores indicated worse condition. Percentage of participants with improvement of at least 2 points from Baseline in PGA of OA were reported. Missing data was imputed using mixed BOCF/LOCF.', 'populationDescription': ""ITT population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here 'Overall number of participants analyzed' = participants who were evaluable for this outcome measure and 'Number analyzed' = participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Weeks 2, 4, 8, 12, 16, 24 and 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.5'}, {'groupId': 'OG001', 'value': '15.6'}, {'groupId': 'OG002', 'value': '12.0'}]}]}, {'title': 'Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.5'}, {'groupId': 'OG001', 'value': '17.7'}, {'groupId': 'OG002', 'value': '19.0'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '12.8'}, {'groupId': 'OG001', 'value': '21.3'}, {'groupId': 'OG002', 'value': '21.8'}]}]}, {'title': 'Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.6'}, {'groupId': 'OG001', 'value': '26.2'}, {'groupId': 'OG002', 'value': '28.5'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '14.6'}, {'groupId': 'OG001', 'value': '22.7'}, {'groupId': 'OG002', 'value': '27.1'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '17.4'}, {'groupId': 'OG001', 'value': '24.1'}, {'groupId': 'OG002', 'value': '25.7'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '19.9'}, {'groupId': 'OG001', 'value': '14.2'}, {'groupId': 'OG002', 'value': '15.4'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0132', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.14', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.17', 'ciUpperLimit': '3.90'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1274', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.87', 'ciUpperLimit': '3.02'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0016', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.44', 'ciUpperLimit': '4.76'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.34', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.84', 'ciUpperLimit': '6.03'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0089', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.04', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.20', 'ciUpperLimit': '3.49'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0012', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.41', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.42', 'ciUpperLimit': '4.10'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.40', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.45', 'ciUpperLimit': '3.98'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '3.16', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.92', 'ciUpperLimit': '5.21'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0203', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.83', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.10', 'ciUpperLimit': '3.06'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '2.94', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.77', 'ciUpperLimit': '4.86'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0775', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.56', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.95', 'ciUpperLimit': '2.55'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Odds ratio and 95% CI estimated from logistic regression model. Logistic regression model included baseline patient global assessment of osteoarthritis scale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0064', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.97', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '1.21', 'ciUpperLimit': '3.21'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline for Average Pain Score in the Index Joint at Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24', 'description': 'Participants assessed their average pain in the index hip/knee in the past 24 hours using a scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Data represents averages of the values reported during the 8-week interval up to and including the given week. Change from baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 1, 2, 3, 4, 6, 8, 10, 12, 16, 20 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 1', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.57', 'spread': '0.11'}, {'groupId': 'OG001', 'value': '-1.06', 'spread': '0.11'}, {'groupId': 'OG002', 'value': '-0.93', 'spread': '0.11'}]}]}, {'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.98', 'spread': '0.14'}, {'groupId': 'OG001', 'value': '-1.72', 'spread': '0.14'}, {'groupId': 'OG002', 'value': '-1.49', 'spread': '0.14'}]}]}, {'title': 'Change at Week 3', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.19', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-1.97', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-1.67', 'spread': '0.15'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.37', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.28', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.13', 'spread': '0.15'}]}]}, {'title': 'Change at Week 6', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.48', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '-2.38', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.43', 'spread': '0.16'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.57', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '-2.19', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.39', 'spread': '0.16'}]}]}, {'title': 'Change at Week 10', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.79', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.51', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.56', 'spread': '0.17'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.84', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.57', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.64', 'spread': '0.17'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.98', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.50', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.61', 'spread': '0.17'}]}]}, {'title': 'Change at Week 20', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.17', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.87', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '-2.86', 'spread': '0.18'}]}]}, {'title': 'Change at Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.21', 'spread': '0.19'}, {'groupId': 'OG001', 'value': '-2.60', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '-2.73', 'spread': '0.18'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 1: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.49', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.70', 'ciUpperLimit': '-0.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 1: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0009', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.36', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.58', 'ciUpperLimit': '-0.15', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '-0.48', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.13'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.51', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.77', 'ciUpperLimit': '-0.25', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.13'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 3: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.78', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.06', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 3: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.49', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.77', 'ciUpperLimit': '-0.21', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.91', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.20', 'ciUpperLimit': '-0.62', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.06', 'ciUpperLimit': '-0.47', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 6: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.90', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.20', 'ciUpperLimit': '-0.59', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 6: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.95', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.25', 'ciUpperLimit': '-0.64', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.61', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.93', 'ciUpperLimit': '-0.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.13', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 10: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.05', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 10: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.10', 'ciUpperLimit': '-0.44', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.73', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.06', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.13', 'ciUpperLimit': '-0.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0040', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.52', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.87', 'ciUpperLimit': '-0.16', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0005', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.63', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.98', 'ciUpperLimit': '-0.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 20: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0002', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.70', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.06', 'ciUpperLimit': '-0.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 20: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0002', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.68', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.05', 'ciUpperLimit': '-0.32', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0506', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.39', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.78', 'ciUpperLimit': '0.00', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.20'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0086', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.52', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.91', 'ciUpperLimit': '-0.13', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.20'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline for Average Pain Score in the Index Joint at Weeks 28 and 32', 'description': 'Participants assessed their average pain in the index hip/knee in the past 24 hours using a scale ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicated higher pain. Data represents averages of the values reported during the 8-week interval up to and including the given week. Change from baseline was calculated using the difference between each post-baseline weekly mean and the baseline mean score.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 28 and 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '278'}, {'groupId': 'OG001', 'value': '280'}, {'groupId': 'OG002', 'value': '280'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.79', 'spread': '1.56'}, {'groupId': 'OG001', 'value': '7.03', 'spread': '1.38'}, {'groupId': 'OG002', 'value': '6.90', 'spread': '1.43'}]}]}, {'title': 'Change at Week 28', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '239'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '254'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.26', 'spread': '2.27'}, {'groupId': 'OG001', 'value': '-2.63', 'spread': '2.32'}, {'groupId': 'OG002', 'value': '-2.58', 'spread': '2.33'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '226'}, {'groupId': 'OG001', 'value': '250'}, {'groupId': 'OG002', 'value': '245'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.19', 'spread': '2.40'}, {'groupId': 'OG001', 'value': '-2.07', 'spread': '2.33'}, {'groupId': 'OG002', 'value': '-2.13', 'spread': '2.40'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.25', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.03', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-1.90', 'spread': '0.15'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.90', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '-2.62', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.74', 'spread': '0.16'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.82', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.41', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.81', 'spread': '0.17'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.10', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.90', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.95', 'spread': '0.17'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.00', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.65', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '-2.77', 'spread': '0.18'}]}]}, {'title': 'Change at Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.97', 'spread': '0.19'}, {'groupId': 'OG001', 'value': '-2.59', 'spread': '0.19'}, {'groupId': 'OG002', 'value': '-2.84', 'spread': '0.19'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.07', 'ciUpperLimit': '-0.48', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.64', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.94', 'ciUpperLimit': '-0.35', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.03', 'ciUpperLimit': '-0.41', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.84', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.15', 'ciUpperLimit': '-0.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0004', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.58', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.91', 'ciUpperLimit': '-0.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.99', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.31', 'ciUpperLimit': '-0.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.14', 'ciUpperLimit': '-0.46', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.84', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.18', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0002', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.00', 'ciUpperLimit': '-0.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.12', 'ciUpperLimit': '-0.43', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline pain in the index joint as covariate, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0013', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.99', 'ciUpperLimit': '-0.24', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC stiffness subscales and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.87', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.25', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Stiffness Subscale at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA. Stiffness was defined as a sensation of decreased ease of movement in the index joint (knee or hip). The WOMAC stiffness subscale is a 2-item questionnaire used to assess the amount of stiffness experienced due to OA in the index joint (knee or hip) during the past 48 hours. It was calculated as the mean of scores from 2 individual questions scored on a NRS. Scores for each question and WOMAC stiffness subscale score on NRS ranged from 0 (no stiffness) to 10 (extreme stiffness), where higher scores indicated higher stiffness.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.46', 'spread': '1.43'}, {'groupId': 'OG001', 'value': '6.44', 'spread': '1.59'}, {'groupId': 'OG002', 'value': '6.44', 'spread': '1.53'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.57', 'spread': '2.22'}, {'groupId': 'OG001', 'value': '-2.34', 'spread': '2.18'}, {'groupId': 'OG002', 'value': '-2.31', 'spread': '2.51'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA of index joint (knee or hip). WOMAC pain subscale assess amount of pain experienced (score: 0 \\[no pain\\] to 10 \\[extreme pain\\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \\[no difficulty\\] to 10 \\[extreme difficulty\\], higher score = worse physical function) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 \\[no stiffness\\] to 10 \\[extreme stiffness\\], higher score = higher stiffness). WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, where higher scores indicated worse response.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.28', 'spread': '0.13'}, {'groupId': 'OG001', 'value': '-1.99', 'spread': '0.13'}, {'groupId': 'OG002', 'value': '-1.75', 'spread': '0.13'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.80', 'spread': '0.14'}, {'groupId': 'OG001', 'value': '-2.57', 'spread': '0.14'}, {'groupId': 'OG002', 'value': '-2.60', 'spread': '0.14'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.81', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.42', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.65', 'spread': '0.15'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.11', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '-2.89', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.92', 'spread': '0.16'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.04', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.67', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.71', 'spread': '0.16'}]}]}, {'title': 'Change at Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.11', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.66', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.83', 'spread': '0.17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.71', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.96', 'ciUpperLimit': '-0.45', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.13'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0004', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.47', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.73', 'ciUpperLimit': '-0.21', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.13'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.04', 'ciUpperLimit': '-0.49', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.08', 'ciUpperLimit': '-0.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.14'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.61', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.90', 'ciUpperLimit': '-0.32', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.84', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.13', 'ciUpperLimit': '-0.56', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.78', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.09', 'ciUpperLimit': '-0.47', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.12', 'ciUpperLimit': '-0.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.63', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.95', 'ciUpperLimit': '-0.35', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.99', 'ciUpperLimit': '-0.35', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0015', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.55', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.89', 'ciUpperLimit': '-0.21', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC average scores and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.73', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.07', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Average Score at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA of index joint (knee or hip). WOMAC pain subscale assess amount of pain experienced (score: 0 \\[no pain\\] to 10 \\[extreme pain\\], higher score = more pain), WOMAC physical function subscale assess degree of difficulty experienced (score: 0 \\[no difficulty\\] to 10 \\[extreme difficulty\\], higher score = worse physical function) and WOMAC stiffness subscale assess the amount of stiffness experienced (score: 0 \\[no stiffness\\] to 10 \\[extreme stiffness\\], higher score = higher stiffness). WOMAC average score was the mean of WOMAC pain, physical function and stiffness subscale scores and ranges from 0 to 10, where higher scores indicated worse response.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.57', 'spread': '0.90'}, {'groupId': 'OG001', 'value': '6.63', 'spread': '0.96'}, {'groupId': 'OG002', 'value': '6.60', 'spread': '0.91'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.61', 'spread': '1.96'}, {'groupId': 'OG001', 'value': '-2.28', 'spread': '1.87'}, {'groupId': 'OG002', 'value': '-2.27', 'spread': '2.12'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Walking on a Flat Surface) at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when walking on a flat surface?"". Participants responded about the amount of pain they experienced when walking on a flat surface by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.27', 'spread': '0.14'}, {'groupId': 'OG001', 'value': '-1.94', 'spread': '0.14'}, {'groupId': 'OG002', 'value': '-1.64', 'spread': '0.14'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.69', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.51', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.54', 'spread': '0.15'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.77', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '-2.36', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.49', 'spread': '0.15'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.17', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.91', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '-2.97', 'spread': '0.16'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.06', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.68', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.66', 'spread': '0.17'}]}]}, {'title': 'Change at Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.21', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.61', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.80', 'spread': '0.17'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.96', 'ciUpperLimit': '-0.38', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0139', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.37', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.67', 'ciUpperLimit': '-0.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.82', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.13', 'ciUpperLimit': '-0.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.86', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.16', 'ciUpperLimit': '-0.55', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0003', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.59', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.91', 'ciUpperLimit': '-0.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.04', 'ciUpperLimit': '-0.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.08', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.79', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.14', 'ciUpperLimit': '-0.44', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0006', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.98', 'ciUpperLimit': '-0.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0009', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.60', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.96', 'ciUpperLimit': '-0.25', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0377', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.40', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.78', 'ciUpperLimit': '-0.02', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when walking on a flat surface and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0019', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.59', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.96', 'ciUpperLimit': '-0.22', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Walking on a Flat Surface) at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when walking on a flat surface?"". Participants responded about the amount of pain they experienced when walking on a flat surface by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.73', 'spread': '1.25'}, {'groupId': 'OG001', 'value': '6.77', 'spread': '1.27'}, {'groupId': 'OG002', 'value': '6.79', 'spread': '1.19'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.46', 'spread': '2.24'}, {'groupId': 'OG001', 'value': '-2.01', 'spread': '2.10'}, {'groupId': 'OG002', 'value': '-1.99', 'spread': '2.49'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Going Up or Downstairs) at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when going up or down the stairs?"" Participants responded about the amount of pain they experienced when going up or down stairs by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.39', 'spread': '0.15'}, {'groupId': 'OG001', 'value': '-2.08', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-1.96', 'spread': '0.15'}]}]}, {'title': 'Change at Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.76', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '-2.73', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '-2.72', 'spread': '0.15'}]}]}, {'title': 'Change at Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.72', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '-2.49', 'spread': '0.17'}, {'groupId': 'OG002', 'value': '-2.74', 'spread': '0.17'}]}]}, {'title': 'Change at Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.17', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.92', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '-3.05', 'spread': '0.18'}]}]}, {'title': 'Change at Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.06', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '-2.72', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '-2.83', 'spread': '0.18'}]}]}, {'title': 'Change at Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.32', 'spread': '0.19'}, {'groupId': 'OG001', 'value': '-2.76', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '-3.04', 'spread': '0.18'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.69', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.99', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0002', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.57', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.87', 'ciUpperLimit': '-0.27', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.97', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.29', 'ciUpperLimit': '-0.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.96', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.28', 'ciUpperLimit': '-0.65', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.76', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.11', 'ciUpperLimit': '-0.42', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-1.01', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.35', 'ciUpperLimit': '-0.67', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.11', 'ciUpperLimit': '-0.39', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.87', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.23', 'ciUpperLimit': '-0.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0005', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.66', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.03', 'ciUpperLimit': '-0.29', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.13', 'ciUpperLimit': '-0.40', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.19'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0246', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.44', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-0.82', 'ciUpperLimit': '-0.06', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.20'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Multiple imputation method was applied for missing data, with imputation dependent on reason for missing data. ANCOVA model for imputed datasets includes treatment, randomization stratification variables (index joint and highest Kellgren-Lawrence grade) as fixed effects, baseline WOMAC pain when going up or down stairs and baseline diary average pain as covariates, and study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0003', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.71', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-1.10', 'ciUpperLimit': '-0.33', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.20'}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Item (Pain When Going Up or Downstairs) at Week 32', 'description': 'WOMAC: self-administered, disease-specific questionnaire which assesses clinically important, participant-relevant symptoms for pain, stiffness and physical function in participants with OA in index joint (knee or hip). Participants answered a question: ""How much pain have you had when going up or down the stairs?"" Participants responded about the amount of pain they experienced when going up or down stairs by using a NRS of 0 (no pain) to 10 (extreme pain), where higher scores indicated higher pain.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7.65', 'spread': '1.13'}, {'groupId': 'OG001', 'value': '7.79', 'spread': '1.06'}, {'groupId': 'OG002', 'value': '7.66', 'spread': '1.18'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '246'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.72', 'spread': '2.32'}, {'groupId': 'OG001', 'value': '-2.23', 'spread': '2.09'}, {'groupId': 'OG002', 'value': '-2.15', 'spread': '2.41'}]}]}]}, {'type': 'SECONDARY', 'title': 'Work Productivity and Activity Impairment Questionnaire for Osteoarthritis (WPAI:OA) Scores at Baseline', 'description': 'WPAI is 6-question participant rated questionnaire to determine the impact of OA on absenteeism, presenteeism, work productivity, and daily activity impairment for a period of 7 days prior to a visit. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism), overall work impairment (work productivity) and activity impairment (daily activity impairment). These sub-scores are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Percent Work Time Missed', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '81'}, {'groupId': 'OG001', 'value': '76'}, {'groupId': 'OG002', 'value': '72'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '9.7', 'spread': '23.46'}, {'groupId': 'OG001', 'value': '5.6', 'spread': '18.33'}, {'groupId': 'OG002', 'value': '6.9', 'spread': '21.33'}]}]}, {'title': 'Percent Impairment While Working', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '78'}, {'groupId': 'OG001', 'value': '74'}, {'groupId': 'OG002', 'value': '69'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '56.5', 'spread': '22.26'}, {'groupId': 'OG001', 'value': '58.9', 'spread': '21.81'}, {'groupId': 'OG002', 'value': '57.4', 'spread': '18.44'}]}]}, {'title': 'Percent Overall Work Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '78'}, {'groupId': 'OG001', 'value': '74'}, {'groupId': 'OG002', 'value': '69'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '59.3', 'spread': '21.32'}, {'groupId': 'OG001', 'value': '60.2', 'spread': '21.20'}, {'groupId': 'OG002', 'value': '58.3', 'spread': '18.89'}]}]}, {'title': 'Percent Activity Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '66.6', 'spread': '13.35'}, {'groupId': 'OG001', 'value': '67.7', 'spread': '15.53'}, {'groupId': 'OG002', 'value': '67.5', 'spread': '13.26'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Work Productivity and Activity Impairment Questionnaire for Osteoarthritis (WPAI:OA) Impairment Scores at Weeks 8, 16 and 24', 'description': 'WPAI is 6-question participant rated questionnaire to determine the impact of OA on absenteeism, presenteeism, work productivity, and daily activity impairment for a period of 7 days prior to a visit. It yields 4 sub-scores: work time missed (absenteeism), impairment while working (presenteeism), overall work impairment (work productivity) and activity impairment (daily activity impairment). These sub-scores are expressed as an impairment percentage (range from 0 to 100), with higher numbers indicating greater impairment and less productivity.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 8, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Change at Week 8: Percent Work Time Missed', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '65'}, {'groupId': 'OG001', 'value': '62'}, {'groupId': 'OG002', 'value': '60'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.04', 'spread': '2.12'}, {'groupId': 'OG001', 'value': '1.24', 'spread': '2.12'}, {'groupId': 'OG002', 'value': '-2.05', 'spread': '2.11'}]}]}, {'title': 'Change at Week 8:Percent Impairment While Working', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '64'}, {'groupId': 'OG001', 'value': '60'}, {'groupId': 'OG002', 'value': '57'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-13.57', 'spread': '3.11'}, {'groupId': 'OG001', 'value': '-20.26', 'spread': '3.10'}, {'groupId': 'OG002', 'value': '-26.26', 'spread': '3.12'}]}]}, {'title': 'Change at Week 8: Percent Overall Work Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '64'}, {'groupId': 'OG001', 'value': '60'}, {'groupId': 'OG002', 'value': '57'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-13.78', 'spread': '3.20'}, {'groupId': 'OG001', 'value': '-20.53', 'spread': '3.18'}, {'groupId': 'OG002', 'value': '-26.26', 'spread': '3.22'}]}]}, {'title': 'Change at Week 8: Percent Activity Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '268'}, {'groupId': 'OG001', 'value': '272'}, {'groupId': 'OG002', 'value': '281'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-15.66', 'spread': '1.55'}, {'groupId': 'OG001', 'value': '-21.84', 'spread': '1.54'}, {'groupId': 'OG002', 'value': '-24.79', 'spread': '1.53'}]}]}, {'title': 'Change at Week 16: Percent Work Time Missed', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '64'}, {'groupId': 'OG001', 'value': '59'}, {'groupId': 'OG002', 'value': '51'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.36', 'spread': '2.24'}, {'groupId': 'OG001', 'value': '1.74', 'spread': '2.29'}, {'groupId': 'OG002', 'value': '-2.16', 'spread': '2.36'}]}]}, {'title': 'Change at Week 16:Percent Impairment While Working', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '61'}, {'groupId': 'OG001', 'value': '58'}, {'groupId': 'OG002', 'value': '50'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-15.92', 'spread': '3.28'}, {'groupId': 'OG001', 'value': '-26.23', 'spread': '3.33'}, {'groupId': 'OG002', 'value': '-26.48', 'spread': '3.42'}]}]}, {'title': 'Change at Week 16: Percent Overall Work Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '61'}, {'groupId': 'OG001', 'value': '58'}, {'groupId': 'OG002', 'value': '50'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-16.38', 'spread': '3.33'}, {'groupId': 'OG001', 'value': '-25.79', 'spread': '3.37'}, {'groupId': 'OG002', 'value': '-26.42', 'spread': '3.47'}]}]}, {'title': 'Change at Week 16: Percent Activity Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '254'}, {'groupId': 'OG001', 'value': '261'}, {'groupId': 'OG002', 'value': '270'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-19.15', 'spread': '1.77'}, {'groupId': 'OG001', 'value': '-25.16', 'spread': '1.77'}, {'groupId': 'OG002', 'value': '-26.13', 'spread': '1.74'}]}]}, {'title': 'Change at Week 24: Percent Work Time Missed', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '50'}, {'groupId': 'OG001', 'value': '57'}, {'groupId': 'OG002', 'value': '51'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '4.09', 'spread': '3.27'}, {'groupId': 'OG001', 'value': '2.77', 'spread': '3.18'}, {'groupId': 'OG002', 'value': '1.16', 'spread': '3.27'}]}]}, {'title': 'Change at Week 24:Percent Impairment While Working', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '47'}, {'groupId': 'OG001', 'value': '55'}, {'groupId': 'OG002', 'value': '48'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-15.03', 'spread': '3.86'}, {'groupId': 'OG001', 'value': '-19.31', 'spread': '3.50'}, {'groupId': 'OG002', 'value': '-17.77', 'spread': '3.74'}]}]}, {'title': 'Change at Week 24: Percent Overall Work Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '47'}, {'groupId': 'OG001', 'value': '55'}, {'groupId': 'OG002', 'value': '48'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-15.17', 'spread': '3.92'}, {'groupId': 'OG001', 'value': '-19.03', 'spread': '3.56'}, {'groupId': 'OG002', 'value': '-17.29', 'spread': '3.82'}]}]}, {'title': 'Change at Week 24: Percent Activity Impairment', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '254'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-21.49', 'spread': '1.84'}, {'groupId': 'OG001', 'value': '-24.57', 'spread': '1.79'}, {'groupId': 'OG002', 'value': '-26.44', 'spread': '1.79'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Percent Work Time Missed: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.6427', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '1.20', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-3.90', 'ciUpperLimit': '6.29', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.57'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Percent Work Time Missed: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.4208', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-2.09', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-7.22', 'ciUpperLimit': '3.04', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.59'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Percent Work Time Missed: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.8204', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-6.03', 'ciUpperLimit': '4.79', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.73'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Percent Work Time Missed: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1157', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-4.52', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-10.16', 'ciUpperLimit': '1.13', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.85'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Percent Work Time Missed: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.5845', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-1.32', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-6.12', 'ciUpperLimit': '3.47', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.41'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Percent Work Time Missed: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2514', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-2.93', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-7.97', 'ciUpperLimit': '2.11', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '2.54'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Percent Impairment While Working: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0717', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-6.68', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-13.97', 'ciUpperLimit': '0.60', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.67'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Percent Impairment While Working: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0010', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-12.69', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-20.11', 'ciUpperLimit': '-5.26', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.74'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Percent Impairment While Working: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0079', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-10.31', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-17.85', 'ciUpperLimit': '-2.77', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.80'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Percent Impairment While Working: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0096', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-10.56', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-18.49', 'ciUpperLimit': '-2.63', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.00'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Percent Impairment While Working: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3302', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-4.28', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-12.97', 'ciUpperLimit': '4.41', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.37'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Percent Impairment While Working: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.5483', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-2.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-11.78', 'ciUpperLimit': '6.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.54'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Percent Overall Work Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0774', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-6.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-14.26', 'ciUpperLimit': '0.76', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.79'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Percent Overall Work Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0017', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-12.48', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-20.15', 'ciUpperLimit': '-4.81', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.87'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Percent Overall Work Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0135', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-9.41', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-16.83', 'ciUpperLimit': '-1.99', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.74'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Percent Overall Work Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0129', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-10.04', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-17.91', 'ciUpperLimit': '-2.17', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '3.97'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Percent Overall Work Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3869', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-3.85', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-12.66', 'ciUpperLimit': '4.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.43'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Percent Overall Work Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.6485', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-2.11', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-11.31', 'ciUpperLimit': '7.08', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '4.62'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Percent Activity Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-6.18', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-9.34', 'ciUpperLimit': '-3.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.61'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Percent Activity Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-9.13', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-12.26', 'ciUpperLimit': '-6.00', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.60'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Percent Activity Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0008', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-6.00', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-9.51', 'ciUpperLimit': '-2.50', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.79'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Percent Activity Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-6.97', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-10.44', 'ciUpperLimit': '-3.51', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.77'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Percent Activity Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1004', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-3.08', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-6.76', 'ciUpperLimit': '0.60', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.87'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Percent Activity Impairment: WPAI parameters were analyzed using ANCOVA model which included covariates of the corresponding baseline score, baseline diary average pain, index joint, highest Kellgren-Lawrence grade (2, 3 or 4), and treatment, with study site as a random effect', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0079', 'statisticalMethod': 'ANCOVA', 'paramType': 'Least Square Mean Difference', 'paramValue': '-4.94', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '-8.59', 'ciUpperLimit': '-1.30', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '1.86'}]}, {'type': 'SECONDARY', 'title': 'European Quality of Life- 5 Dimension-5 Levels (EQ-5D-5L) Dimensions Score', 'description': 'EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. The health utility score for a participant with no problems in all 5 items is 1 for all countries (except for Zimbabwe where it is 0.9), and is reduced where a participant reports greater levels of problems across the five dimensions.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 8, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline: Mobility', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.1', 'spread': '0.63'}, {'groupId': 'OG001', 'value': '3.1', 'spread': '0.62'}, {'groupId': 'OG002', 'value': '3.2', 'spread': '0.65'}]}]}, {'title': 'Baseline: Self-care', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.4', 'spread': '0.92'}, {'groupId': 'OG001', 'value': '2.3', 'spread': '0.92'}, {'groupId': 'OG002', 'value': '2.3', 'spread': '0.90'}]}]}, {'title': 'Baseline: Usual activities', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.0', 'spread': '0.65'}, {'groupId': 'OG001', 'value': '3.0', 'spread': '0.68'}, {'groupId': 'OG002', 'value': '3.0', 'spread': '0.68'}]}]}, {'title': 'Baseline: Pain/Discomfort', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.3', 'spread': '0.72'}, {'groupId': 'OG001', 'value': '3.2', 'spread': '0.73'}, {'groupId': 'OG002', 'value': '3.3', 'spread': '0.69'}]}]}, {'title': 'Baseline: Anxiety/Depression', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.7', 'spread': '0.87'}, {'groupId': 'OG001', 'value': '1.7', 'spread': '0.88'}, {'groupId': 'OG002', 'value': '1.7', 'spread': '0.87'}]}]}, {'title': 'Week 8: Mobility', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '273'}, {'groupId': 'OG001', 'value': '276'}, {'groupId': 'OG002', 'value': '282'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.6', 'spread': '0.82'}, {'groupId': 'OG001', 'value': '2.3', 'spread': '0.83'}, {'groupId': 'OG002', 'value': '2.3', 'spread': '0.80'}]}]}, {'title': 'Week 8: Self-care', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '273'}, {'groupId': 'OG001', 'value': '276'}, {'groupId': 'OG002', 'value': '282'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'spread': '0.90'}, {'groupId': 'OG001', 'value': '1.8', 'spread': '0.80'}, {'groupId': 'OG002', 'value': '1.6', 'spread': '0.78'}]}]}, {'title': 'Week 8: Usual activities', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '273'}, {'groupId': 'OG001', 'value': '276'}, {'groupId': 'OG002', 'value': '282'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.5', 'spread': '0.78'}, {'groupId': 'OG001', 'value': '2.3', 'spread': '0.82'}, {'groupId': 'OG002', 'value': '2.2', 'spread': '0.78'}]}]}, {'title': 'Week 8: Pain/Discomfort', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '273'}, {'groupId': 'OG001', 'value': '276'}, {'groupId': 'OG002', 'value': '282'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.7', 'spread': '0.85'}, {'groupId': 'OG001', 'value': '2.5', 'spread': '0.80'}, {'groupId': 'OG002', 'value': '2.4', 'spread': '0.79'}]}]}, {'title': 'Week 8: Anxiety/Depression', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '273'}, {'groupId': 'OG001', 'value': '276'}, {'groupId': 'OG002', 'value': '282'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.5', 'spread': '0.80'}, {'groupId': 'OG001', 'value': '1.4', 'spread': '0.64'}, {'groupId': 'OG002', 'value': '1.4', 'spread': '0.71'}]}]}, {'title': 'Week 16: Mobility', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '259'}, {'groupId': 'OG001', 'value': '266'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.4', 'spread': '0.88'}, {'groupId': 'OG001', 'value': '2.2', 'spread': '0.84'}, {'groupId': 'OG002', 'value': '2.2', 'spread': '0.84'}]}]}, {'title': 'Week 16: Self-care', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '259'}, {'groupId': 'OG001', 'value': '266'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.8', 'spread': '0.88'}, {'groupId': 'OG001', 'value': '1.7', 'spread': '0.78'}, {'groupId': 'OG002', 'value': '1.6', 'spread': '0.80'}]}]}, {'title': 'Week 16: Usual activities', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '259'}, {'groupId': 'OG001', 'value': '266'}, {'groupId': 'OG002', 'value': '272'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.3', 'spread': '0.81'}, {'groupId': 'OG001', 'value': '2.2', 'spread': '0.78'}, {'groupId': 'OG002', 'value': '2.1', 'spread': '0.84'}]}]}, {'title': 'Week 16: Pain/Discomfort', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '259'}, {'groupId': 'OG001', 'value': '266'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.5', 'spread': '0.82'}, {'groupId': 'OG001', 'value': '2.3', 'spread': '0.80'}, {'groupId': 'OG002', 'value': '2.3', 'spread': '0.80'}]}]}, {'title': 'Week 16: Anxiety/Depression', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '259'}, {'groupId': 'OG001', 'value': '266'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.4', 'spread': '0.78'}, {'groupId': 'OG001', 'value': '1.3', 'spread': '0.61'}, {'groupId': 'OG002', 'value': '1.4', 'spread': '0.68'}]}]}, {'title': 'Week 24: Mobility', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.4', 'spread': '0.78'}, {'groupId': 'OG001', 'value': '2.3', 'spread': '0.84'}, {'groupId': 'OG002', 'value': '2.3', 'spread': '0.84'}]}]}, {'title': 'Week 24: Self-care', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.7', 'spread': '0.83'}, {'groupId': 'OG001', 'value': '1.7', 'spread': '0.77'}, {'groupId': 'OG002', 'value': '1.6', 'spread': '0.76'}]}]}, {'title': 'Week 24: Usual activities', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.3', 'spread': '0.78'}, {'groupId': 'OG001', 'value': '2.2', 'spread': '0.82'}, {'groupId': 'OG002', 'value': '2.2', 'spread': '0.82'}]}]}, {'title': 'Week 24: Pain/Discomfort', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.5', 'spread': '0.81'}, {'groupId': 'OG001', 'value': '2.4', 'spread': '0.78'}, {'groupId': 'OG002', 'value': '2.4', 'spread': '0.77'}]}]}, {'title': 'Week 24: Anxiety/Depression', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.4', 'spread': '0.67'}, {'groupId': 'OG001', 'value': '1.4', 'spread': '0.71'}, {'groupId': 'OG002', 'value': '1.4', 'spread': '0.68'}]}]}]}, {'type': 'SECONDARY', 'title': 'European Quality of Life- 5 Dimension-5 Levels (EQ-5D-5L) Overall Health Utility Score/ Index Value', 'description': 'EQ-5D-5L: standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional VAS. EQ-5D health state profile comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems, and 5=extreme problems. Responses from the five domains were used to calculate a single utility index (the Overall health utility score) where values are less than equal to (\\<=) 1. The Overall health utility score for a participant with no problems in all 5 items is 1 for all countries (except for Zimbabwe where it is 0.9), and is reduced where a participant reports greater levels of problems across the five dimensions.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 8, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '277'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.57', 'spread': '0.18'}, {'groupId': 'OG001', 'value': '0.56', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '0.56', 'spread': '0.18'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '273'}, {'groupId': 'OG001', 'value': '276'}, {'groupId': 'OG002', 'value': '282'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.67', 'spread': '0.17'}, {'groupId': 'OG001', 'value': '0.71', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '0.73', 'spread': '0.17'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '259'}, {'groupId': 'OG001', 'value': '266'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.70', 'spread': '0.19'}, {'groupId': 'OG001', 'value': '0.73', 'spread': '0.15'}, {'groupId': 'OG002', 'value': '0.73', 'spread': '0.17'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.70', 'spread': '0.16'}, {'groupId': 'OG001', 'value': '0.72', 'spread': '0.16'}, {'groupId': 'OG002', 'value': '0.73', 'spread': '0.15'}]}]}]}, {'type': 'SECONDARY', 'title': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Reported Treatment Impact Assessment-Overall, How Satisfied Are You With The Drug That You Received in This Study?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. For participant satisfaction, participants responded using interactive response technology (IRT) on a 5 point likert scale from 1-5, where 1=extremely dissatisfied, 2=dissatisfied, 3=neither satisfied nor dissatisfied, 4=satisfied and 5=extremely satisfied. Higher scores indicated greater satisfaction.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Weeks 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '268'}, {'groupId': 'OG001', 'value': '270'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'title': 'Extremely Satisfied', 'measurements': [{'groupId': 'OG000', 'value': '41'}, {'groupId': 'OG001', 'value': '65'}, {'groupId': 'OG002', 'value': '65'}]}, {'title': 'Satisfied', 'measurements': [{'groupId': 'OG000', 'value': '109'}, {'groupId': 'OG001', 'value': '141'}, {'groupId': 'OG002', 'value': '137'}]}, {'title': 'Neither satisfied nor dissatisfied', 'measurements': [{'groupId': 'OG000', 'value': '78'}, {'groupId': 'OG001', 'value': '50'}, {'groupId': 'OG002', 'value': '63'}]}, {'title': 'Dissatisfied', 'measurements': [{'groupId': 'OG000', 'value': '31'}, {'groupId': 'OG001', 'value': '13'}, {'groupId': 'OG002', 'value': '11'}]}, {'title': 'Extremely dissatisfied', 'measurements': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '2'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '238'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'title': 'Extremely Satisfied', 'measurements': [{'groupId': 'OG000', 'value': '46'}, {'groupId': 'OG001', 'value': '72'}, {'groupId': 'OG002', 'value': '66'}]}, {'title': 'Satisfied', 'measurements': [{'groupId': 'OG000', 'value': '97'}, {'groupId': 'OG001', 'value': '119'}, {'groupId': 'OG002', 'value': '128'}]}, {'title': 'Neither satisfied nor dissatisfied', 'measurements': [{'groupId': 'OG000', 'value': '64'}, {'groupId': 'OG001', 'value': '54'}, {'groupId': 'OG002', 'value': '48'}]}, {'title': 'Dissatisfied', 'measurements': [{'groupId': 'OG000', 'value': '28'}, {'groupId': 'OG001', 'value': '10'}, {'groupId': 'OG002', 'value': '9'}]}, {'title': 'Extremely dissatisfied', 'measurements': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '4'}]}]}]}, {'type': 'SECONDARY', 'title': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Global Preference Assessment- What is The Current or Most Recent Treatment You Were Receiving For Osteoarthritis Pain Before Enrolling?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. To assess previous treatment, participants responded for, 1=injectable prescription medicines, 2=prescription medicines taken by mouth, 3=surgery, 4=prescription medicines and surgery and 5=no treatment.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Weeks 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '268'}, {'groupId': 'OG001', 'value': '270'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'title': 'Injectable prescription medicines', 'measurements': [{'groupId': 'OG000', 'value': '23'}, {'groupId': 'OG001', 'value': '34'}, {'groupId': 'OG002', 'value': '28'}]}, {'title': 'Prescription medicines taken by mouth', 'measurements': [{'groupId': 'OG000', 'value': '214'}, {'groupId': 'OG001', 'value': '212'}, {'groupId': 'OG002', 'value': '224'}]}, {'title': 'Surgery', 'measurements': [{'groupId': 'OG000', 'value': '5'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Prescription medicines and surgery', 'measurements': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '5'}]}, {'title': 'No treatment', 'measurements': [{'groupId': 'OG000', 'value': '18'}, {'groupId': 'OG001', 'value': '19'}, {'groupId': 'OG002', 'value': '20'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '238'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'title': 'Injectable prescription medicines', 'measurements': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '21'}, {'groupId': 'OG002', 'value': '35'}]}, {'title': 'Prescription medicines taken by mouth', 'measurements': [{'groupId': 'OG000', 'value': '196'}, {'groupId': 'OG001', 'value': '211'}, {'groupId': 'OG002', 'value': '196'}]}, {'title': 'Surgery', 'measurements': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '3'}]}, {'title': 'Prescription medicines and surgery', 'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '4'}]}, {'title': 'No treatment', 'measurements': [{'groupId': 'OG000', 'value': '19'}, {'groupId': 'OG001', 'value': '22'}, {'groupId': 'OG002', 'value': '17'}]}]}]}, {'type': 'SECONDARY', 'title': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Global Preference Assessment- Overall, do You Prefer The Drug That You Received in This Study to Previous Treatment?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. To assess preference to continue using the investigational product, participants responded using interactive response technology (IRT) on a 5 point likert scale from 1-5, where, 1= yes, I definitely prefer the drug that I am receiving now, 2= I have a slight preference for the drug that I am receiving now, 3= I have no preference either way, 4= I have a slight preference for my previous treatment, 5= No, I definitely prefer my previous treatment. Higher scores indicate lesser preference to use the investigational product.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Weeks 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '268'}, {'groupId': 'OG001', 'value': '270'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'title': 'Yes, definitely prefer the study drug', 'measurements': [{'groupId': 'OG000', 'value': '106'}, {'groupId': 'OG001', 'value': '129'}, {'groupId': 'OG002', 'value': '138'}]}, {'title': 'Slight preference for the study drug', 'measurements': [{'groupId': 'OG000', 'value': '66'}, {'groupId': 'OG001', 'value': '86'}, {'groupId': 'OG002', 'value': '83'}]}, {'title': 'No preference either way', 'measurements': [{'groupId': 'OG000', 'value': '65'}, {'groupId': 'OG001', 'value': '41'}, {'groupId': 'OG002', 'value': '48'}]}, {'title': 'Slight preference for my previous treatment', 'measurements': [{'groupId': 'OG000', 'value': '14'}, {'groupId': 'OG001', 'value': '11'}, {'groupId': 'OG002', 'value': '4'}]}, {'title': 'No, definitely prefer my previous treatment', 'measurements': [{'groupId': 'OG000', 'value': '17'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '5'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '238'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'title': 'Yes, definitely prefer the study drug', 'measurements': [{'groupId': 'OG000', 'value': '87'}, {'groupId': 'OG001', 'value': '129'}, {'groupId': 'OG002', 'value': '127'}]}, {'title': 'Slight preference for the study drug', 'measurements': [{'groupId': 'OG000', 'value': '73'}, {'groupId': 'OG001', 'value': '79'}, {'groupId': 'OG002', 'value': '78'}]}, {'title': 'No preference either way', 'measurements': [{'groupId': 'OG000', 'value': '58'}, {'groupId': 'OG001', 'value': '43'}, {'groupId': 'OG002', 'value': '36'}]}, {'title': 'Slight preference for my previous treatment', 'measurements': [{'groupId': 'OG000', 'value': '14'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '8'}]}, {'title': 'No, definitely prefer my previous treatment', 'measurements': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '6'}]}]}]}, {'type': 'SECONDARY', 'title': 'Patient Reported Treatment Impact Assessment-Modified (mPRTI) Score at Weeks 16 and 24: Participant Willingness to Use Drug Again Assessment- Willing to Use The Same Drug That You Have Received in This Study For Your Osteoarthritis Pain?', 'description': 'The mPRTI is a self-administered questionnaire containing participant reported treatment impact assessment (to assess participant satisfaction), participant global preference assessment (to assess previous treatment and preference to continue using the investigational product) and participant willingness to use drug again assessment. To assess Patient willingness to use drug again, participants responded using interactive response technology (IRT) on a 5 point likert scale from 1-5, where, 1= yes, I would definitely want to use the same drug again, 2= I might want to use the same drug again, 3= I am not sure, 4= I might not want to use the same drug again, 5= no, I definitely would not want to use the same drug again. Higher scores indicate lesser willingness to use the investigational product.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time point."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Weeks 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '268'}, {'groupId': 'OG001', 'value': '270'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'title': 'Yes, definitely want to use the same drug again', 'measurements': [{'groupId': 'OG000', 'value': '111'}, {'groupId': 'OG001', 'value': '144'}, {'groupId': 'OG002', 'value': '155'}]}, {'title': 'Might want to use the same drug again', 'measurements': [{'groupId': 'OG000', 'value': '67'}, {'groupId': 'OG001', 'value': '83'}, {'groupId': 'OG002', 'value': '74'}]}, {'title': 'I am not sure', 'measurements': [{'groupId': 'OG000', 'value': '59'}, {'groupId': 'OG001', 'value': '29'}, {'groupId': 'OG002', 'value': '41'}]}, {'title': 'Might not want to use the same drug again', 'measurements': [{'groupId': 'OG000', 'value': '10'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '5'}]}, {'title': ""No:definitely wouldn't want to use same drug again"", 'measurements': [{'groupId': 'OG000', 'value': '21'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '3'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '238'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '255'}]}], 'categories': [{'title': 'Yes, definitely want to use the same drug again', 'measurements': [{'groupId': 'OG000', 'value': '101'}, {'groupId': 'OG001', 'value': '131'}, {'groupId': 'OG002', 'value': '139'}]}, {'title': 'Might want to use the same drug again', 'measurements': [{'groupId': 'OG000', 'value': '62'}, {'groupId': 'OG001', 'value': '73'}, {'groupId': 'OG002', 'value': '63'}]}, {'title': 'I am not sure', 'measurements': [{'groupId': 'OG000', 'value': '53'}, {'groupId': 'OG001', 'value': '43'}, {'groupId': 'OG002', 'value': '38'}]}, {'title': 'Might not want to use the same drug again', 'measurements': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '9'}]}, {'title': ""No:definitely wouldn't want to use same drug again"", 'measurements': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '6'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Visits of Services Directly Related to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Visits of services directly related to osteoarthritis evaluated were: visits to primary care physician, neurologist, rheumatologist, physician assistant or nurse practitioner, pain specialist, orthopedist, physical therapist, chiropractor, alternative medicine or therapy, podiatrist, nutritionist/dietitian, radiologist, home healthcare services and other practitioner.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': 'Full Range', 'unitOfMeasure': 'visits', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline: Primary Care Physician', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '116'}, {'groupId': 'OG001', 'value': '115'}, {'groupId': 'OG002', 'value': '112'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '14.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '10.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '7.0'}]}]}, {'title': 'Baseline: Neurologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '5'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '100.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}]}]}, {'title': 'Baseline: Rheumatologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '82'}, {'groupId': 'OG001', 'value': '99'}, {'groupId': 'OG002', 'value': '89'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '102.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '11.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '5.0'}]}]}, {'title': 'Baseline:Physician assistant or nurse Practitioner', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '6'}, {'groupId': 'OG002', 'value': '5'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.0', 'lowerLimit': '1.0', 'upperLimit': '7.0'}, {'groupId': 'OG001', 'value': '2.5', 'lowerLimit': '1.0', 'upperLimit': '5.0'}, {'groupId': 'OG002', 'value': '3.0', 'lowerLimit': '3.0', 'upperLimit': '8.0'}]}]}, {'title': 'Baseline: Pain specialist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '12'}, {'groupId': 'OG001', 'value': '21'}, {'groupId': 'OG002', 'value': '24'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '5.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '6.0'}]}]}, {'title': 'Baseline: Orthopedist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '84'}, {'groupId': 'OG001', 'value': '83'}, {'groupId': 'OG002', 'value': '85'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '12.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '12.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '7.0'}]}]}, {'title': 'Baseline: Physical therapist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '20'}, {'groupId': 'OG002', 'value': '30'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.0', 'lowerLimit': '1.0', 'upperLimit': '24.0'}, {'groupId': 'OG001', 'value': '3.5', 'lowerLimit': '1.0', 'upperLimit': '100.0'}, {'groupId': 'OG002', 'value': '2.5', 'lowerLimit': '1.0', 'upperLimit': '60.0'}]}]}, {'title': 'Baseline: Chiropractor', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}]}]}, {'title': 'Baseline: Alternative medicine or therapy', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '4'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '2.5', 'lowerLimit': '1.0', 'upperLimit': '4.0'}]}]}, {'title': 'Baseline: Podiatrist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '3'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '3.0', 'lowerLimit': '2.0', 'upperLimit': '3.0'}]}]}, {'title': 'Baseline: Nutritionist/dietitian', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '7'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.0', 'lowerLimit': '2.0', 'upperLimit': '5.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG002', 'value': '3.0', 'lowerLimit': '1.0', 'upperLimit': '8.0'}]}]}, {'title': 'Baseline: Radiologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '44'}, {'groupId': 'OG001', 'value': '34'}, {'groupId': 'OG002', 'value': '46'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '4.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '4.0'}]}]}, {'title': 'Baseline: Home healthcare services', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '24.0', 'lowerLimit': '24.0', 'upperLimit': '24.0'}]}]}, {'title': 'Baseline: Other practitioner', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '15'}, {'groupId': 'OG002', 'value': '21'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '6.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '12.0'}]}]}, {'title': 'Week 32: Primary Care Physician', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '62'}, {'groupId': 'OG001', 'value': '61'}, {'groupId': 'OG002', 'value': '57'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '101.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '100.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '190.0'}]}]}, {'title': 'Week 32: Neurologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '2'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '51.0', 'lowerLimit': '1.0', 'upperLimit': '101.0'}]}]}, {'title': 'Week 32: Rheumatologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '23'}, {'groupId': 'OG001', 'value': '34'}, {'groupId': 'OG002', 'value': '33'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '10.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '20.0'}]}]}, {'title': 'Week 32: Physician assistant or nurse Practitioner', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '3'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '111.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG002', 'value': '4.0', 'lowerLimit': '1.0', 'upperLimit': '101.0'}]}]}, {'title': 'Week 32: Pain specialist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '16.0'}]}]}, {'title': 'Week 32: Orthopedist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '34'}, {'groupId': 'OG001', 'value': '36'}, {'groupId': 'OG002', 'value': '35'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '111.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '6.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 32: Physical therapist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '11'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '12'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '8.0', 'lowerLimit': '1.0', 'upperLimit': '111.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '12.0'}, {'groupId': 'OG002', 'value': '5.5', 'lowerLimit': '1.0', 'upperLimit': '16.0'}]}]}, {'title': 'Week 32: Chiropractor', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG001', 'value': '8.0', 'lowerLimit': '8.0', 'upperLimit': '8.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 32: Alternative medicine or therapy', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '5'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '6'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.0', 'lowerLimit': '1.0', 'upperLimit': '10.0'}, {'groupId': 'OG001', 'value': '2.5', 'lowerLimit': '1.0', 'upperLimit': '4.0'}, {'groupId': 'OG002', 'value': '1.5', 'lowerLimit': '1.0', 'upperLimit': '10.0'}]}]}, {'title': 'Week 32: Podiatrist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '1.5', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}]}]}, {'title': 'Week 32: Nutritionist/dietitian', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 32: Radiologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '10'}, {'groupId': 'OG001', 'value': '10'}, {'groupId': 'OG002', 'value': '14'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 32: Home healthcare services', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '10.0', 'lowerLimit': '10.0', 'upperLimit': '10.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '10.0', 'lowerLimit': '10.0', 'upperLimit': '10.0'}]}]}, {'title': 'Week 32: Other practitioner', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '14'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '8.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '8.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '16.0'}]}]}, {'title': 'Week 48: Primary Care Physician', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '53'}, {'groupId': 'OG001', 'value': '63'}, {'groupId': 'OG002', 'value': '64'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '7.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '100.0'}]}]}, {'title': 'Week 48: Neurologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '4.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 48: Rheumatologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '16'}, {'groupId': 'OG001', 'value': '34'}, {'groupId': 'OG002', 'value': '27'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 48: Physician assistant or nurse Practitioner', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '4'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.5', 'lowerLimit': '2.0', 'upperLimit': '55.0'}, {'groupId': 'OG001', 'value': '2.5', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '4.0'}]}]}, {'title': 'Week 48: Pain specialist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '2'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '3.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}]}]}, {'title': 'Week 48: Orthopedist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '31'}, {'groupId': 'OG001', 'value': '44'}, {'groupId': 'OG002', 'value': '55'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '6.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '8.0'}]}]}, {'title': 'Week 48: Physical therapist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '19'}, {'groupId': 'OG002', 'value': '20'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.0', 'lowerLimit': '1.0', 'upperLimit': '16.0'}, {'groupId': 'OG001', 'value': '6.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '10.0', 'lowerLimit': '1.0', 'upperLimit': '36.0'}]}]}, {'title': 'Week 48: Chiropractor', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '46.5', 'lowerLimit': '3.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '3.0', 'lowerLimit': '3.0', 'upperLimit': '3.0'}]}]}, {'title': 'Week 48: Alternative medicine or therapy', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '6'}, {'groupId': 'OG002', 'value': '3'}]}], 'categories': [{'measurements': [{'groupId': 'OG001', 'value': '11.0', 'lowerLimit': '3.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '3.0', 'lowerLimit': '2.0', 'upperLimit': '5.0'}]}]}, {'title': 'Week 48: Podiatrist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '5'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '3'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '190.0'}, {'groupId': 'OG002', 'value': '3.0', 'lowerLimit': '1.0', 'upperLimit': '110.0'}]}]}, {'title': 'Week 48: Nutritionist/dietitian', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '3'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG001', 'value': '130.0', 'lowerLimit': '130.0', 'upperLimit': '130.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 48: Radiologist', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '5'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '11'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '1.5', 'lowerLimit': '1.0', 'upperLimit': '190.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '91.0'}]}]}, {'title': 'Week 48: Home healthcare services', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG001', 'value': '5.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}]}]}, {'title': 'Week 48: Other practitioner', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '13'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '90.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '4.0'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Participants Who Visited the Emergency Room Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of participants who visited the emergency room due to osteoarthritis.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '2'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '2'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Visits to the Emergency Room Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of visits to the emergency room due to OA.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': 'Full Range', 'unitOfMeasure': 'visits', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '2'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '1.5', 'lowerLimit': '1.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '0'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.5', 'lowerLimit': '1.0', 'upperLimit': '2.0'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '2'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '1.0', 'upperLimit': '3.0'}, {'groupId': 'OG001', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Participants Hospitalized Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of participants who were hospitalized due to OA.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '5'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Nights Stayed in the Hospital Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of nights stayed in the hospital due to OA.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': 'Full Range', 'unitOfMeasure': 'nights', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG001', 'value': '11.0', 'lowerLimit': '1.0', 'upperLimit': '21.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '5.0', 'lowerLimit': '5.0', 'upperLimit': '5.0'}, {'groupId': 'OG001', 'value': '21.0', 'lowerLimit': '21.0', 'upperLimit': '21.0'}, {'groupId': 'OG002', 'value': '2.0', 'lowerLimit': '2.0', 'upperLimit': '2.0'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '5'}]}], 'categories': [{'measurements': [{'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '1.0'}, {'groupId': 'OG002', 'value': '1.0', 'lowerLimit': '1.0', 'upperLimit': '9.0'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Participants Who Used Any Aids/Devices for Doing Things', 'description': 'Osteoarthritis HCRU assessed healthcare usage during last 3 months (for Baseline and Week 48) and past 8 weeks (for Week 32). Domain evaluated was number of participants who used any aids/devices for doing things. Aids such as walking aid, wheelchair, device or utensil for dress/bathe/eat and any other aids/devices.', 'populationDescription': ""The intent to treat (ITT) population included all randomized participants who received at least one dose of subcutaneous (SC) study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline:Walking aid use', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '242'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '5'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '11'}, {'groupId': 'OG001', 'value': '13'}, {'groupId': 'OG002', 'value': '15'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '7'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '15'}]}]}, {'title': 'Baseline: Wheelchair use', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Baseline:Device/Utensil to dress bathe eat', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '271'}, {'groupId': 'OG001', 'value': '274'}, {'groupId': 'OG002', 'value': '279'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '2'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '3'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Baseline:Other aids or devices', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '275'}, {'groupId': 'OG001', 'value': '265'}, {'groupId': 'OG002', 'value': '270'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '5'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '4'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '3'}, {'groupId': 'OG001', 'value': '5'}, {'groupId': 'OG002', 'value': '3'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '2'}]}]}, {'title': 'Week 32: Walking aid use', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '225'}, {'groupId': 'OG001', 'value': '232'}, {'groupId': 'OG002', 'value': '214'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '6'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '8'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '10'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '12'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '9'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '9'}]}]}, {'title': 'Week 32: Wheelchair use', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '248'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '250'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 32: Device/Utensil to dress bathe eat', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '248'}, {'groupId': 'OG001', 'value': '257'}, {'groupId': 'OG002', 'value': '246'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '2'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 32: Other aids or devices', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '246'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '245'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '3'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '4'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 48: Walking aid use', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '200'}, {'groupId': 'OG001', 'value': '211'}, {'groupId': 'OG002', 'value': '191'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '3'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '6'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '13'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '4'}, {'groupId': 'OG001', 'value': '8'}, {'groupId': 'OG002', 'value': '10'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '14'}]}]}, {'title': 'Week 48: Wheelchair use', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '217'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '230'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 48: Device/Utensil to dress bathe eat', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '217'}, {'groupId': 'OG001', 'value': '238'}, {'groupId': 'OG002', 'value': '228'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '2'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 48: Other aids or devices', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'title': 'Never', 'measurements': [{'groupId': 'OG000', 'value': '215'}, {'groupId': 'OG001', 'value': '234'}, {'groupId': 'OG002', 'value': '225'}]}, {'title': 'Rarely', 'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Sometimes', 'measurements': [{'groupId': 'OG000', 'value': '2'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '1'}]}, {'title': 'Often', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '3'}, {'groupId': 'OG002', 'value': '3'}]}, {'title': 'Always', 'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Number of Participants Who Quit Job Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage (during 3 months prior to baseline) at baseline, Week 32 and Week 48. Domain evaluated was number of participants who quit job due to OA.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '9'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '250'}, {'groupId': 'OG001', 'value': '260'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '9'}, {'groupId': 'OG002', 'value': '4'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '218'}, {'groupId': 'OG001', 'value': '240'}, {'groupId': 'OG002', 'value': '231'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '4'}]}]}]}, {'type': 'SECONDARY', 'title': 'Health Care Resource Utilization (HCRU): Duration Since Quitting Job Due to Osteoarthritis', 'description': 'Osteoarthritis HCRU assessed healthcare usage (during 3 months prior to baseline) at baseline, Week 32 and Week 48. Domain evaluated was duration since quitting job due to OA.', 'populationDescription': ""ITT population: all randomized participants who received at least one dose of SC study medication (either Tanezumab or placebo). One additional participant apart from the ones who had responded for quitting job responded to duration since quitting job. 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': 'Full Range', 'unitOfMeasure': 'years', 'timeFrame': 'Baseline, Weeks 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '13'}, {'groupId': 'OG001', 'value': '12'}, {'groupId': 'OG002', 'value': '9'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.0', 'lowerLimit': '0.1', 'upperLimit': '20.9'}, {'groupId': 'OG001', 'value': '1.0', 'lowerLimit': '0.2', 'upperLimit': '7.0'}, {'groupId': 'OG002', 'value': '5.3', 'lowerLimit': '0.1', 'upperLimit': '30.0'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '10'}, {'groupId': 'OG002', 'value': '4'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.5', 'lowerLimit': '0.3', 'upperLimit': '2.9'}, {'groupId': 'OG001', 'value': '2.4', 'lowerLimit': '0.2', 'upperLimit': '17.8'}, {'groupId': 'OG002', 'value': '1.1', 'lowerLimit': '0.1', 'upperLimit': '10.2'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '7'}, {'groupId': 'OG001', 'value': '7'}, {'groupId': 'OG002', 'value': '4'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.8', 'lowerLimit': '0.3', 'upperLimit': '2.8'}, {'groupId': 'OG001', 'value': '2.5', 'lowerLimit': '0.6', 'upperLimit': '10.0'}, {'groupId': 'OG002', 'value': '0.7', 'lowerLimit': '0.1', 'upperLimit': '1.5'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Withdrew Due to Lack of Efficacy', 'description': 'Number of participants who withdrew from treatment due to lack of efficacy have been reported here.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline up to Week 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '18'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '3'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Logistic regression model included baseline diary average pain, baseline WOMAC pain score, classification variables index joint, highest Kellgren-Lawrence grade and treatment. Odds ratio and 95% CI estimated from logistic regression model.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0027', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.10', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.02', 'ciUpperLimit': '0.46'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Logistic regression model included baseline diary average pain, baseline WOMAC pain score, classification variables index joint, highest Kellgren-Lawrence grade and treatment. Odds ratio and 95% CI estimated from logistic regression model.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0033', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.16', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.05', 'ciUpperLimit': '0.54'}]}, {'type': 'SECONDARY', 'title': 'Time to Discontinuation Due to Lack of Efficacy', 'description': 'Time to discontinuation due to lack of efficacy was defined as the time interval from the date of first study drug administration up to the date of discontinuation of participant from treatment due to lack of efficacy.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Overall number of participants analyzed' signifies participants who discontinued from the study due to lack of efficacy."", 'reportingStatus': 'POSTED', 'paramType': 'MEDIAN', 'dispersionType': 'Full Range', 'unitOfMeasure': 'days', 'timeFrame': 'Baseline up to Week 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '18'}, {'groupId': 'OG001', 'value': '2'}, {'groupId': 'OG002', 'value': '3'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': 'NA', 'lowerLimit': '10', 'upperLimit': 'NA', 'comment': 'Due to the Kaplan-Meier estimate not reaching the level for discontinuation due to lack of efficacy, median and upper limit could not be calculated.'}, {'groupId': 'OG001', 'value': 'NA', 'lowerLimit': '27', 'upperLimit': 'NA', 'comment': 'Due to the Kaplan-Meier estimate not reaching the level for discontinuation due to lack of efficacy, median and upper limit could not be calculated.'}, {'groupId': 'OG002', 'value': 'NA', 'lowerLimit': '12', 'upperLimit': 'NA', 'comment': 'Due to the Kaplan-Meier estimate not reaching the level for discontinuation due to lack of efficacy, median and upper limit could not be calculated.'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Missing data for the selected percentile(s) was due to the Kaplan-Meier estimate not reaching the level for discontinuation due to lack of efficacy.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0002', 'pValueComment': 'P-value based on the log-rank test.', 'statisticalMethod': 'Log Rank'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Missing data for the selected percentile(s) was due to the Kaplan-Meier estimate not reaching the level for discontinuation due to lack of efficacy.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0007', 'pValueComment': 'P-value based on the log-rank test.', 'statisticalMethod': 'Log Rank'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Took Rescue Medication During Weeks 2, 4, 8, 12, 16 and 24', 'description': 'In case of inadequate pain relief, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week could be taken as rescue medication between day 1 and week 24. Number of participants with any use of rescue medication during the particular study week were summarized.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '205'}, {'groupId': 'OG001', 'value': '150'}, {'groupId': 'OG002', 'value': '169'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '181'}, {'groupId': 'OG001', 'value': '134'}, {'groupId': 'OG002', 'value': '150'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '166'}, {'groupId': 'OG001', 'value': '135'}, {'groupId': 'OG002', 'value': '146'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '151'}, {'groupId': 'OG001', 'value': '122'}, {'groupId': 'OG002', 'value': '122'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '154'}, {'groupId': 'OG001', 'value': '130'}, {'groupId': 'OG002', 'value': '122'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '126'}, {'groupId': 'OG001', 'value': '127'}, {'groupId': 'OG002', 'value': '115'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.42', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.29', 'ciUpperLimit': '0.59'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0010', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.55', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.38', 'ciUpperLimit': '0.78'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '<.0001', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.50', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.36', 'ciUpperLimit': '0.70'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0067', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.44', 'ciUpperLimit': '0.88'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0087', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.64', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.45', 'ciUpperLimit': '0.89'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0787', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.53', 'ciUpperLimit': '1.04'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0129', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.47', 'ciUpperLimit': '0.91'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0124', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.47', 'ciUpperLimit': '0.91'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0399', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.70', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.50', 'ciUpperLimit': '0.98'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0060', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.45', 'ciUpperLimit': '0.87'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.9449', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '1.01', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.72', 'ciUpperLimit': '1.42'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: Odds ratio and 95%CI estimated from logistic regression model. Logistic regression model included baseline WOMAC pain subscale, baseline diary average pain, and classification variables index joint, highest Kellgren-Lawrence grade and treatment.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3238', 'statisticalMethod': 'Regression, Logistic', 'paramType': 'Odds Ratio (OR)', 'paramValue': '0.84', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.60', 'ciUpperLimit': '1.18'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants Who Took Rescue Medication During Week 32', 'description': 'In case of inadequate pain relief, after Week 24, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week could be taken as rescue medication and use was reported weekly via diary. Number of participants with any use of rescue medication during the 4 weeks up to and including the particular study week were summarized.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Overall number of participants analyzed' signifies participants who were evaluable for this outcome measure."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '251'}, {'groupId': 'OG002', 'value': '249'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '130'}, {'groupId': 'OG001', 'value': '158'}, {'groupId': 'OG002', 'value': '149'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Days of Rescue Medication Used at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'In case of inadequate pain relief during the treatment period, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week a could be taken as rescue medication. Number of days the participants used the rescue medication during the particular study weeks were summarized.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'days', 'timeFrame': 'Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3.17', 'spread': '0.27'}, {'groupId': 'OG001', 'value': '2.12', 'spread': '0.19'}, {'groupId': 'OG002', 'value': '2.39', 'spread': '0.21'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.82', 'spread': '0.28'}, {'groupId': 'OG001', 'value': '1.81', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '2.07', 'spread': '0.21'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.54', 'spread': '0.26'}, {'groupId': 'OG001', 'value': '1.83', 'spread': '0.19'}, {'groupId': 'OG002', 'value': '1.92', 'spread': '0.20'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.29', 'spread': '0.27'}, {'groupId': 'OG001', 'value': '1.70', 'spread': '0.20'}, {'groupId': 'OG002', 'value': '1.72', 'spread': '0.20'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2.11', 'spread': '0.24'}, {'groupId': 'OG001', 'value': '1.64', 'spread': '0.19'}, {'groupId': 'OG002', 'value': '1.70', 'spread': '0.19'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.74', 'spread': '0.22'}, {'groupId': 'OG001', 'value': '1.49', 'spread': '0.18'}, {'groupId': 'OG002', 'value': '1.43', 'spread': '0.18'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: Least square (LS) Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0001', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.54', 'ciUpperLimit': '0.82', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.07'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0067', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.61', 'ciUpperLimit': '0.92', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.08'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0003', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.64', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.51', 'ciUpperLimit': '0.82', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.08'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0112', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.58', 'ciUpperLimit': '0.93', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.09'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0093', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.56', 'ciUpperLimit': '0.92', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.09'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0237', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.59', 'ciUpperLimit': '0.96', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.09'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0374', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.74', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.56', 'ciUpperLimit': '0.98', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0468', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.57', 'ciUpperLimit': '1.00', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0751', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.78', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.59', 'ciUpperLimit': '1.03', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1305', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.81', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.61', 'ciUpperLimit': '1.06', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.11'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3057', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.85', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.63', 'ciUpperLimit': '1.16', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.13'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2056', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.82', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.61', 'ciUpperLimit': '1.11', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.13'}]}, {'type': 'SECONDARY', 'title': 'Number of Days of Rescue Medication Used at Week 32', 'description': 'In case of inadequate pain relief, after Week 24, acetaminophen/paracetamol up to 4000 mg per day up to 7 days in a week could be taken as rescue medication and use was reported weekly via diary. Number of days per week the participants used the rescue medication during the 4 weeks up to and including the particular study week were summarized.', 'populationDescription': ""The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo). Here, 'Overall number of participants analyzed' signifies participants who took rescue medication."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'days', 'timeFrame': 'Week 32', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '231'}, {'groupId': 'OG001', 'value': '251'}, {'groupId': 'OG002', 'value': '249'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.8', 'spread': '2.24'}, {'groupId': 'OG001', 'value': '2.2', 'spread': '2.34'}, {'groupId': 'OG002', 'value': '2.0', 'spread': '2.28'}]}]}]}, {'type': 'SECONDARY', 'title': 'Amount of Rescue Medication Used at Weeks 2, 4, 8, 12, 16 and 24', 'description': 'In case of inadequate pain relief, acetaminophen/paracetamol up to 4000 mg per day up to 5 days in a week could be taken as rescue medication. The total dosage of acetaminophen in milligrams used during the specified week were summarized.', 'populationDescription': 'The intent to treat population included all randomized participants who received at least one dose of subcutaneous study medication (either tanezumab or placebo).', 'reportingStatus': 'POSTED', 'paramType': 'LEAST_SQUARES_MEAN', 'dispersionType': 'Standard Error', 'unitOfMeasure': 'milligrams', 'timeFrame': 'Weeks 2, 4, 8, 12, 16 and 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3690.6', 'spread': '714.30'}, {'groupId': 'OG001', 'value': '2283.4', 'spread': '444.56'}, {'groupId': 'OG002', 'value': '2703.4', 'spread': '516.83'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '3139.0', 'spread': '707.35'}, {'groupId': 'OG001', 'value': '1868.9', 'spread': '396.26'}, {'groupId': 'OG002', 'value': '2366.6', 'spread': '529.63'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2940.9', 'spread': '678.61'}, {'groupId': 'OG001', 'value': '1902.4', 'spread': '425.30'}, {'groupId': 'OG002', 'value': '2269.4', 'spread': '523.10'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2893.1', 'spread': '749.38'}, {'groupId': 'OG001', 'value': '1950.1', 'spread': '495.07'}, {'groupId': 'OG002', 'value': '1992.3', 'spread': '509.28'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2627.1', 'spread': '658.47'}, {'groupId': 'OG001', 'value': '1864.2', 'spread': '458.32'}, {'groupId': 'OG002', 'value': '1897.6', 'spread': '466.14'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '2273.8', 'spread': '625.84'}, {'groupId': 'OG001', 'value': '1868.1', 'spread': '482.13'}, {'groupId': 'OG002', 'value': '1828.8', 'spread': '491.51'}]}]}], 'analyses': [{'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 2: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0441', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.62', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.39', 'ciUpperLimit': '0.99', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.15'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 2: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1895', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.73', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.46', 'ciUpperLimit': '1.17', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.17'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 4: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.0567', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.60', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.35', 'ciUpperLimit': '1.01', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.16'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 4: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2960', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.75', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.44', 'ciUpperLimit': '1.28', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.20'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 8: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.1215', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.65', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.37', 'ciUpperLimit': '1.12', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.18'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 8: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.3569', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.77', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.44', 'ciUpperLimit': '1.34', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.22'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 12: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2096', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.67', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.36', 'ciUpperLimit': '1.25', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.21'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 12: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2387', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.69', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.37', 'ciUpperLimit': '1.28', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.22'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 16: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2627', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.71', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.39', 'ciUpperLimit': '1.29', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.22'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 16: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.2863', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.72', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.40', 'ciUpperLimit': '1.31', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.22'}, {'groupIds': ['OG000', 'OG001'], 'groupDescription': 'Week 24: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.5560', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.82', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.43', 'ciUpperLimit': '1.58', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.27'}, {'groupIds': ['OG000', 'OG002'], 'groupDescription': 'Week 24: LS Mean was ratio of treatments. Analysis was performed using negative binomial model with model terms of baseline WOMAC Pain subscale score, baseline diary average pain score, index joint, Kellgren Lawrence grade, and treatment group.', 'nonInferiorityType': 'SUPERIORITY', 'pValue': '0.5076', 'statisticalMethod': 'Negative binomial model', 'paramType': 'LS Mean Ratio', 'paramValue': '0.80', 'ciPctValue': '95', 'ciNumSides': 'TWO_SIDED', 'ciLowerLimit': '0.42', 'ciUpperLimit': '1.53', 'dispersionType': 'STANDARD_ERROR_OF_MEAN', 'dispersionValue': '0.26'}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) up to End of Study', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to week 48 that were absent before treatment or that worsened relative to pretreatment state. AEs included both serious and non-serious AEs.', 'populationDescription': 'The safety population was defined as all participants treated with tanezumab or placebo subcutaneously.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline up to Week 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'AEs', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '178'}, {'groupId': 'OG001', 'value': '184'}, {'groupId': 'OG002', 'value': '198'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '11'}, {'groupId': 'OG001', 'value': '24'}, {'groupId': 'OG002', 'value': '27'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Treatment-Emergent Treatment-Related Adverse Events (AEs) and Serious Adverse Events (SAEs) up to End of Study', 'description': 'Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study drug and up to week 48 that were absent before treatment or that worsened relative to pre-treatment state. Relatedness to study drug was assessed by the investigator.', 'populationDescription': 'The safety population was defined as all participants treated with tanezumab or placebo subcutaneously.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline up to Week 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'AEs', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '46'}, {'groupId': 'OG001', 'value': '52'}, {'groupId': 'OG002', 'value': '59'}]}]}, {'title': 'SAEs', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '3'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Laboratory Test Abnormalities With Regard to Normal Baseline', 'description': 'Primary Abnormality criteria: HGB, hematocrit, RBC count \\<0.8\\* lower limit of normal(LLN); Ery. mean corpuscular volume/hemoglobin/ HGB concentration, RBCs distribution width \\<0.9\\*LLN, \\>1.1\\*upper limit of normal(ULN); platelets \\<0.5\\*LLN,\\>1.75\\*ULN; WBC count\\<0.6\\*LLN, \\>1.5\\*ULN; Lymphocytes,Leukocytes,Neutrophils \\<0.8\\*LLN, \\>1.2\\*ULN; Basophils,Eosinophils,Monocytes\\>1.2\\*ULN; Prothrombin time/Intl. normalized ratio\\>1.1\\*ULN; total bilirubin\\>1.5\\*ULN; aspartate aminotransferase,alanine aminotransferase,gamma GT,LDH,alkaline phosphatase \\>3.0\\*ULN; total protein; albumin\\<0.8\\*LLN, \\>1.2\\*ULN; blood urea nitrogen,creatinine,Cholesterol,triglycerides \\>1.3\\*ULN; Urate\\>1.2\\*ULN; sodium\\<0.95\\*LLN,\\>1.05\\*ULN; potassium,chloride,calcium,magnesium,bicarbonate \\<0.9\\*LLN, \\>1.1\\*ULN; phosphate\\<0.8\\*LLN, \\>1.2\\*ULN; glucose\\<0.6\\*LLN, \\>1.5\\*ULN; HGB A1C \\>1.3\\*ULN; creatine kinase\\>2.0\\*ULN, specific gravity\\<1.003, \\>1.030; pH\\<4.5, \\>8; Urine Glucose, protein,HGB,bilirubin \\>=1; Ketones\\>=1;Urine erythrocytes,Leukocytes\\>=20.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here 'Overall number of participants analyzed' signifies participants who were evaluable for this outcome measure."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline up to Week 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '265'}, {'groupId': 'OG001', 'value': '271'}, {'groupId': 'OG002', 'value': '274'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '32'}, {'groupId': 'OG001', 'value': '34'}, {'groupId': 'OG002', 'value': '34'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Laboratory Test Abnormalities With Regard to Abnormal Baseline', 'description': 'Primary Abnormality criteria: hemoglobin; hematocrit; RBC count \\< 0.8\\*LLN; Ery. mean corpuscular volume/ hemoglobin/ HGB concentration, erythrocytes distribution width \\<0.9\\*LLN, \\>1.1\\*ULN; platelets \\<0.5\\*LLN,\\>1.75\\*upper limit of normal (ULN); white blood cell count\\<0.6\\*LLN, \\>1.5\\*ULN; Lymphocytes, Leukocytes, Neutrophils \\<0.8\\*LLN, \\>1.2\\*ULN; Basophils, Eosinophils, Monocytes \\>1.2\\*ULN; total bilirubin\\>1.5\\*ULN; aspartate aminotransferase, alanine aminotransferase, gamma GT,LDH, alkaline phosphatase \\>3.0\\*ULN; total protein; albumin\\<0.8\\*LLN, \\>1.2\\*ULN; blood urea nitrogen, creatinine, Cholesterol, triglycerides \\>1.3\\*ULN; Urate \\>1.2\\*ULN; sodium \\<0.95\\*LLN,\\>1.05\\*ULN; potassium, chloride, calcium, magnesium, bicarbonate \\<0.9\\*LLN, \\>1.1\\*ULN; phosphate \\<0.8\\*LLN, \\>1.2\\*ULN; glucose \\<0.6\\*LLN, \\>1.5\\*ULN; Hemoglobin A1C \\>1.3\\*ULN; creatine kinase \\>2.0\\*ULN; Nitrite \\>=1.', 'populationDescription': 'The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here ""Overall number of participants analysed"" signifies participants who were evaluable for this outcome measure.', 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline up to Week 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '205'}, {'groupId': 'OG001', 'value': '215'}, {'groupId': 'OG002', 'value': '207'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '19'}, {'groupId': 'OG001', 'value': '26'}, {'groupId': 'OG002', 'value': '22'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Blood Pressure (BP) at Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'description': 'Measurement of BP included sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP).', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'millimeters of mercury (mmHg)', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'SBP: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '132.0', 'spread': '13.54'}, {'groupId': 'OG001', 'value': '132.7', 'spread': '12.59'}, {'groupId': 'OG002', 'value': '132.0', 'spread': '12.12'}]}]}, {'title': 'SBP:Change at Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.0', 'spread': '10.26'}, {'groupId': 'OG001', 'value': '-2.0', 'spread': '11.24'}, {'groupId': 'OG002', 'value': '-2.4', 'spread': '11.24'}]}]}, {'title': 'SBP:Change at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '272'}, {'groupId': 'OG001', 'value': '280'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.3', 'spread': '11.09'}, {'groupId': 'OG001', 'value': '-2.0', 'spread': '10.94'}, {'groupId': 'OG002', 'value': '-2.4', 'spread': '11.52'}]}]}, {'title': 'SBP:Change at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '265'}, {'groupId': 'OG001', 'value': '275'}, {'groupId': 'OG002', 'value': '275'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.8', 'spread': '10.89'}, {'groupId': 'OG001', 'value': '-2.1', 'spread': '10.63'}, {'groupId': 'OG002', 'value': '-2.5', 'spread': '12.07'}]}]}, {'title': 'SBP:Change at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '255'}, {'groupId': 'OG001', 'value': '274'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.2', 'spread': '11.38'}, {'groupId': 'OG001', 'value': '-1.8', 'spread': '11.53'}, {'groupId': 'OG002', 'value': '-2.8', 'spread': '11.64'}]}]}, {'title': 'SBP:Change at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '242'}, {'groupId': 'OG001', 'value': '265'}, {'groupId': 'OG002', 'value': '265'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.4', 'spread': '12.18'}, {'groupId': 'OG001', 'value': '-1.6', 'spread': '12.92'}, {'groupId': 'OG002', 'value': '-2.3', 'spread': '11.63'}]}]}, {'title': 'SBP:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '255'}, {'groupId': 'OG002', 'value': '254'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.5', 'spread': '11.47'}, {'groupId': 'OG001', 'value': '-2.0', 'spread': '12.55'}, {'groupId': 'OG002', 'value': '-2.5', 'spread': '12.11'}]}]}, {'title': 'SBP:Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '228'}, {'groupId': 'OG001', 'value': '251'}, {'groupId': 'OG002', 'value': '139'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.1', 'spread': '12.61'}, {'groupId': 'OG001', 'value': '-1.8', 'spread': '12.40'}, {'groupId': 'OG002', 'value': '-1.0', 'spread': '12.55'}]}]}, {'title': 'SBP:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '220'}, {'groupId': 'OG001', 'value': '242'}, {'groupId': 'OG002', 'value': '229'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.7', 'spread': '10.38'}, {'groupId': 'OG001', 'value': '-1.7', 'spread': '11.60'}, {'groupId': 'OG002', 'value': '-1.8', 'spread': '11.34'}]}]}, {'title': 'DBP: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '79.7', 'spread': '8.28'}, {'groupId': 'OG001', 'value': '79.3', 'spread': '8.45'}, {'groupId': 'OG002', 'value': '79.5', 'spread': '8.10'}]}]}, {'title': 'DBP:Change at Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.4', 'spread': '6.81'}, {'groupId': 'OG001', 'value': '-1.7', 'spread': '7.18'}, {'groupId': 'OG002', 'value': '-1.7', 'spread': '7.33'}]}]}, {'title': 'DBP:Change at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '272'}, {'groupId': 'OG001', 'value': '280'}, {'groupId': 'OG002', 'value': '278'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.6', 'spread': '7.06'}, {'groupId': 'OG001', 'value': '-1.7', 'spread': '7.35'}, {'groupId': 'OG002', 'value': '-1.8', 'spread': '7.85'}]}]}, {'title': 'DBP:Change at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '265'}, {'groupId': 'OG001', 'value': '275'}, {'groupId': 'OG002', 'value': '275'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.1', 'spread': '7.59'}, {'groupId': 'OG001', 'value': '-1.0', 'spread': '7.11'}, {'groupId': 'OG002', 'value': '-1.7', 'spread': '7.65'}]}]}, {'title': 'DBP:Change at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '255'}, {'groupId': 'OG001', 'value': '274'}, {'groupId': 'OG002', 'value': '271'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.0', 'spread': '7.44'}, {'groupId': 'OG001', 'value': '-1.3', 'spread': '7.79'}, {'groupId': 'OG002', 'value': '-2.8', 'spread': '7.94'}]}]}, {'title': 'DBP:Change at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '242'}, {'groupId': 'OG001', 'value': '265'}, {'groupId': 'OG002', 'value': '265'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.7', 'spread': '7.85'}, {'groupId': 'OG001', 'value': '-0.6', 'spread': '8.26'}, {'groupId': 'OG002', 'value': '-1.8', 'spread': '7.90'}]}]}, {'title': 'DBP:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '255'}, {'groupId': 'OG002', 'value': '254'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.1', 'spread': '7.81'}, {'groupId': 'OG001', 'value': '-0.2', 'spread': '8.42'}, {'groupId': 'OG002', 'value': '-2.0', 'spread': '7.90'}]}]}, {'title': 'DBP:Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '228'}, {'groupId': 'OG001', 'value': '251'}, {'groupId': 'OG002', 'value': '239'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.2', 'spread': '8.52'}, {'groupId': 'OG001', 'value': '-0.7', 'spread': '8.06'}, {'groupId': 'OG002', 'value': '-1.5', 'spread': '8.64'}]}]}, {'title': 'DBP:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.6', 'spread': '7.22'}, {'groupId': 'OG001', 'value': '-0.7', 'spread': '8.32'}, {'groupId': 'OG002', 'value': '-0.9', 'spread': '8.17'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Heart Rate at Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'description': 'Heart rate was measured at sitting position.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'beats per minute', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12,16, 24, 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '71.1', 'spread': '8.45'}, {'groupId': 'OG001', 'value': '70.4', 'spread': '8.62'}, {'groupId': 'OG002', 'value': '70.8', 'spread': '8.33'}]}]}, {'title': 'Change at Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '275'}, {'groupId': 'OG001', 'value': '277'}, {'groupId': 'OG002', 'value': '277'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.2', 'spread': '7.26'}, {'groupId': 'OG001', 'value': '1.2', 'spread': '7.25'}, {'groupId': 'OG002', 'value': '0.2', 'spread': '8.45'}]}]}, {'title': 'Change at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '272'}, {'groupId': 'OG001', 'value': '280'}, {'groupId': 'OG002', 'value': '277'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.8', 'spread': '7.92'}, {'groupId': 'OG001', 'value': '0.9', 'spread': '7.91'}, {'groupId': 'OG002', 'value': '-0.1', 'spread': '7.99'}]}]}, {'title': 'Change at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '265'}, {'groupId': 'OG001', 'value': '275'}, {'groupId': 'OG002', 'value': '274'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.5', 'spread': '7.61'}, {'groupId': 'OG001', 'value': '-0.3', 'spread': '8.08'}, {'groupId': 'OG002', 'value': '-0.9', 'spread': '7.54'}]}]}, {'title': 'Change at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '255'}, {'groupId': 'OG001', 'value': '274'}, {'groupId': 'OG002', 'value': '270'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.9', 'spread': '8.14'}, {'groupId': 'OG001', 'value': '1.6', 'spread': '8.28'}, {'groupId': 'OG002', 'value': '0.5', 'spread': '8.39'}]}]}, {'title': 'Change at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '242'}, {'groupId': 'OG001', 'value': '265'}, {'groupId': 'OG002', 'value': '264'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.3', 'spread': '8.13'}, {'groupId': 'OG001', 'value': '-0.4', 'spread': '8.01'}, {'groupId': 'OG002', 'value': '-0.0', 'spread': '8.12'}]}]}, {'title': 'Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '255'}, {'groupId': 'OG002', 'value': '253'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.5', 'spread': '8.56'}, {'groupId': 'OG001', 'value': '0.5', 'spread': '8.77'}, {'groupId': 'OG002', 'value': '0.4', 'spread': '8.86'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '228'}, {'groupId': 'OG001', 'value': '251'}, {'groupId': 'OG002', 'value': '238'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.1', 'spread': '8.51'}, {'groupId': 'OG001', 'value': '0.8', 'spread': '8.19'}, {'groupId': 'OG002', 'value': '0.6', 'spread': '9.40'}]}]}, {'title': 'Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '220'}, {'groupId': 'OG001', 'value': '242'}, {'groupId': 'OG002', 'value': '228'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.2', 'spread': '8.13'}, {'groupId': 'OG001', 'value': '1.4', 'spread': '9.87'}, {'groupId': 'OG002', 'value': '0.6', 'spread': '10.01'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Electrocardiogram (ECG) Parameters at Weeks 24 and 48', 'description': 'A 12-lead ECG was recorded after participants had rested for at least 5 minutes in the supine position in a quiet environment. All standard intervals (PR, QRS, QT, QTcF, QTcB, QTcF, RR intervals) were collected.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure for specified categories."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'millisecond', 'timeFrame': 'Baseline, Weeks 24 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'RR Interval: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '923.9', 'spread': '124.86'}, {'groupId': 'OG001', 'value': '923.6', 'spread': '139.69'}, {'groupId': 'OG002', 'value': '928.3', 'spread': '126.14'}]}]}, {'title': 'RR Interval:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '254'}, {'groupId': 'OG002', 'value': '252'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-3.2', 'spread': '108.30'}, {'groupId': 'OG001', 'value': '-14.6', 'spread': '119.62'}, {'groupId': 'OG002', 'value': '-16.1', 'spread': '124.65'}]}]}, {'title': 'RR Interval:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '216'}, {'groupId': 'OG001', 'value': '238'}, {'groupId': 'OG002', 'value': '224'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-19.0', 'spread': '118.49'}, {'groupId': 'OG001', 'value': '-16.0', 'spread': '112.48'}, {'groupId': 'OG002', 'value': '-26.7', 'spread': '125.81'}]}]}, {'title': 'PR Interval: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '276'}, {'groupId': 'OG001', 'value': '278'}, {'groupId': 'OG002', 'value': '277'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '168.7', 'spread': '23.95'}, {'groupId': 'OG001', 'value': '165.6', 'spread': '21.92'}, {'groupId': 'OG002', 'value': '168.0', 'spread': '24.54'}]}]}, {'title': 'PR Interval:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '229'}, {'groupId': 'OG001', 'value': '248'}, {'groupId': 'OG002', 'value': '240'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.1', 'spread': '14.07'}, {'groupId': 'OG001', 'value': '0.5', 'spread': '13.38'}, {'groupId': 'OG002', 'value': '2.0', 'spread': '15.43'}]}]}, {'title': 'PR Interval:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '209'}, {'groupId': 'OG001', 'value': '231'}, {'groupId': 'OG002', 'value': '213'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.3', 'spread': '13.64'}, {'groupId': 'OG001', 'value': '-1.1', 'spread': '14.38'}, {'groupId': 'OG002', 'value': '-0.4', 'spread': '14.23'}]}]}, {'title': 'QRS Interval: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '95.7', 'spread': '12.69'}, {'groupId': 'OG001', 'value': '95.6', 'spread': '14.05'}, {'groupId': 'OG002', 'value': '95.8', 'spread': '14.48'}]}]}, {'title': 'QRS Interval:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '254'}, {'groupId': 'OG002', 'value': '252'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.2', 'spread': '7.22'}, {'groupId': 'OG001', 'value': '0.2', 'spread': '7.57'}, {'groupId': 'OG002', 'value': '0.0', 'spread': '7.34'}]}]}, {'title': 'QRS Interval:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '216'}, {'groupId': 'OG001', 'value': '238'}, {'groupId': 'OG002', 'value': '224'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.2', 'spread': '8.04'}, {'groupId': 'OG001', 'value': '0.2', 'spread': '8.33'}, {'groupId': 'OG002', 'value': '0.8', 'spread': '8.73'}]}]}, {'title': 'QT Interval: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '402.0', 'spread': '28.45'}, {'groupId': 'OG001', 'value': '403.1', 'spread': '29.92'}, {'groupId': 'OG002', 'value': '405.6', 'spread': '26.84'}]}]}, {'title': 'QT Interval:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '234'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.2', 'spread': '22.65'}, {'groupId': 'OG001', 'value': '-3.1', 'spread': '21.78'}, {'groupId': 'OG002', 'value': '-3.8', 'spread': '25.84'}]}]}, {'title': 'QT Interval:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '215'}, {'groupId': 'OG001', 'value': '237'}, {'groupId': 'OG002', 'value': '222'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-2.5', 'spread': '23.27'}, {'groupId': 'OG001', 'value': '-1.6', 'spread': '24.40'}, {'groupId': 'OG002', 'value': '-4.9', 'spread': '24.06'}]}]}, {'title': 'QTCB Interval: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '419.8', 'spread': '22.32'}, {'groupId': 'OG001', 'value': '421.3', 'spread': '20.78'}, {'groupId': 'OG002', 'value': '422.5', 'spread': '20.57'}]}]}, {'title': 'QTCB Interval:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '234'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.5', 'spread': '17.56'}, {'groupId': 'OG001', 'value': '0.2', 'spread': '18.47'}, {'groupId': 'OG002', 'value': '0.0', 'spread': '16.26'}]}]}, {'title': 'QTCB Interval:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '215'}, {'groupId': 'OG001', 'value': '237'}, {'groupId': 'OG002', 'value': '222'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.5', 'spread': '16.45'}, {'groupId': 'OG001', 'value': '1.7', 'spread': '16.70'}, {'groupId': 'OG002', 'value': '1.8', 'spread': '16.80'}]}]}, {'title': 'QTCF Interval: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '413.6', 'spread': '20.70'}, {'groupId': 'OG001', 'value': '414.9', 'spread': '19.23'}, {'groupId': 'OG002', 'value': '416.6', 'spread': '18.61'}]}]}, {'title': 'QTCF Interval:Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '234'}, {'groupId': 'OG001', 'value': '252'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-1.7', 'spread': '15.72'}, {'groupId': 'OG001', 'value': '-1.0', 'spread': '14.94'}, {'groupId': 'OG002', 'value': '-1.3', 'spread': '15.05'}]}]}, {'title': 'QTCF Interval:Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '215'}, {'groupId': 'OG001', 'value': '237'}, {'groupId': 'OG002', 'value': '222'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.2', 'spread': '14.50'}, {'groupId': 'OG001', 'value': '0.5', 'spread': '15.58'}, {'groupId': 'OG002', 'value': '-0.5', 'spread': '13.96'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Heart Rate (as Assessed by ECG) at Weeks 24 and 48', 'description': 'Heart rate was measured at sitting position.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'beats per minute', 'timeFrame': 'Baseline, Weeks 24 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '66.2', 'spread': '9.28'}, {'groupId': 'OG001', 'value': '66.5', 'spread': '10.69'}, {'groupId': 'OG002', 'value': '65.9', 'spread': '9.22'}]}]}, {'title': 'change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '236'}, {'groupId': 'OG001', 'value': '254'}, {'groupId': 'OG002', 'value': '252'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.3', 'spread': '8.05'}, {'groupId': 'OG001', 'value': '0.9', 'spread': '9.15'}, {'groupId': 'OG002', 'value': '1.4', 'spread': '10.19'}]}]}, {'title': 'Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '216'}, {'groupId': 'OG001', 'value': '238'}, {'groupId': 'OG002', 'value': '224'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.4', 'spread': '8.59'}, {'groupId': 'OG001', 'value': '1.1', 'spread': '8.98'}, {'groupId': 'OG002', 'value': '2.3', 'spread': '10.44'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Adjudicated Joint Safety Outcomes', 'description': 'Incidence of participants with any of the joint safety adjudication outcomes of primary osteonecrosis, rapidly progressive OA (type 1 and type 2), subchondral insufficiency fracture (or SPONK), or pathological fracture.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Overall number of participants analyzed' signifies participants analyzed by adjudication committee."", 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Baseline up to Week 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '19'}, {'groupId': 'OG001', 'value': '27'}, {'groupId': 'OG002', 'value': '33'}]}], 'classes': [{'title': 'Composite Joint Safety Endpoint', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '1.8', 'lowerLimit': '0.6', 'upperLimit': '4.1'}, {'groupId': 'OG002', 'value': '3.2', 'lowerLimit': '1.5', 'upperLimit': '5.9'}]}]}, {'title': 'Rapidly Progressive OA', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '1.4', 'lowerLimit': '0.4', 'upperLimit': '3.6'}, {'groupId': 'OG002', 'value': '2.8', 'lowerLimit': '1.2', 'upperLimit': '5.5'}]}]}, {'title': 'Rapidly Progressive OA type 1', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '1.1', 'lowerLimit': '0.2', 'upperLimit': '3.1'}, {'groupId': 'OG002', 'value': '1.8', 'lowerLimit': '0.6', 'upperLimit': '4.1'}]}]}, {'title': 'Rapidly Progressive OA type 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '0.4', 'lowerLimit': '0.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '1.1', 'lowerLimit': '0.2', 'upperLimit': '3.1'}]}]}, {'title': 'Primary Osteonecrosis', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG002', 'value': '0.4', 'lowerLimit': '0.0', 'upperLimit': '1.9'}]}]}, {'title': 'Pathological Fracture', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG002', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}]}]}, {'title': 'Subchondral Insufficiency Fracture', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}, {'groupId': 'OG001', 'value': '0.4', 'lowerLimit': '0.0', 'upperLimit': '2.0'}, {'groupId': 'OG002', 'value': '0', 'lowerLimit': '0.0', 'upperLimit': '1.3'}]}]}]}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Total Joint Replacements', 'description': 'Percentage of participants who underwent at least one total knee, hip or shoulder joint replacement surgery.', 'populationDescription': 'The safety population was defined as all participants treated with tanezumab or placebo subcutaneously.', 'reportingStatus': 'POSTED', 'paramType': 'NUMBER', 'dispersionType': '95% Confidence Interval', 'unitOfMeasure': 'percentage of participants', 'timeFrame': 'Baseline up to Week 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'categories': [{'measurements': [{'groupId': 'OG000', 'value': '6.7', 'lowerLimit': '4.1', 'upperLimit': '10.3'}, {'groupId': 'OG001', 'value': '7.8', 'lowerLimit': '4.9', 'upperLimit': '11.5'}, {'groupId': 'OG002', 'value': '7.0', 'lowerLimit': '4.4', 'upperLimit': '10.7'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Confirmed Orthostatic Hypotension', 'description': 'Orthostatic hypotension was defined as postural change (supine to standing) that met the following criteria: For systolic BP \\<=150 mmHg (mean supine): Reduction in systolic BP\\>=20 mmHg or reduction in diastolic BP\\>=10 mmHg at the 1 and/or 3 minute standing BP measurements. For systolic BP \\>150 mmHg (mean supine): Reduction in systolic BP\\>=30 mmHg or reduction in diastolic BP\\>=15 mmHg at the 1 and/or 3 minute standing BP measurements. If the 1 minute or 3 minute standing BP in a sequence met the orthostatic hypotension criteria, then that sequence was considered positive. If 2 of 2 or 2 of 3 sequences were positive, then orthostatic hypotension was considered confirmed.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Overall number of participants analyzed' signifies participants analyzed for this outcome measure."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '221'}, {'groupId': 'OG001', 'value': '242'}, {'groupId': 'OG002', 'value': '228'}]}], 'classes': [{'title': 'Baseline', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 2', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 4', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 8', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 12', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 16', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '1'}]}]}, {'title': 'Week 24', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 32', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '0'}, {'groupId': 'OG002', 'value': '0'}]}]}, {'title': 'Week 48', 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0'}, {'groupId': 'OG001', 'value': '1'}, {'groupId': 'OG002', 'value': '1'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Survey of Autonomic Symptom (SAS) Scores at Week 24', 'description': 'The SAS is a 12 item (11 for females) questionnaire, from which the total number of symptoms (0-12 for males and 0-11 for females) is calculated. Each positive symptom is rated from 1 (not at all) to 5 (a lot). The total impact score was the sum of all symptom rating scores, with 0 assigned where the participant did not have the particular symptom. The range for the total impact score is 0-60 for males and 0-55 for females, higher scores indicating higher impact.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Week 24', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Number of symptoms reported: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '280'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.55', 'spread': '0.85'}, {'groupId': 'OG001', 'value': '0.53', 'spread': '0.85'}, {'groupId': 'OG002', 'value': '0.55', 'spread': '0.83'}]}]}, {'title': 'Number of symptoms reported: Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '232'}, {'groupId': 'OG001', 'value': '255'}, {'groupId': 'OG002', 'value': '254'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.03', 'spread': '1.07'}, {'groupId': 'OG001', 'value': '0.15', 'spread': '1.18'}, {'groupId': 'OG002', 'value': '0.18', 'spread': '1.22'}]}]}, {'title': 'Total Symptom Impact Score: Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '280'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.14', 'spread': '1.94'}, {'groupId': 'OG001', 'value': '1.11', 'spread': '1.79'}, {'groupId': 'OG002', 'value': '1.20', 'spread': '1.99'}]}]}, {'title': 'Total Symptom Impact Score: Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '232'}, {'groupId': 'OG001', 'value': '255'}, {'groupId': 'OG002', 'value': '254'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.32', 'spread': '2.92'}, {'groupId': 'OG001', 'value': '0.53', 'spread': '3.23'}, {'groupId': 'OG002', 'value': '0.56', 'spread': '3.11'}]}]}]}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Neuropathy Impairment Score (NIS) at Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'description': 'NIS is a standardized instrument used to evaluate participant for signs of peripheral neuropathy. NIS is the sum of scores of 37 items, from both the left and right side, where 24 items scored from 0 (normal) to 4 (paralysis), higher score indicated higher abnormality/impairment and 13 items scored from 0 (normal), 1 (decreased) and 2 (absent), higher score indicated higher impairment. NIS possible overall score ranged from 0 (no impairment) to 244 (maximum impairment), higher scores indicated increased impairment.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'MEAN', 'dispersionType': 'Standard Deviation', 'unitOfMeasure': 'units on a scale', 'timeFrame': 'Baseline, Weeks 2, 4, 8, 12, 16, 24, 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '1.35', 'spread': '2.85'}, {'groupId': 'OG001', 'value': '1.35', 'spread': '3.72'}, {'groupId': 'OG002', 'value': '1.48', 'spread': '3.11'}]}]}, {'title': 'Change at Week 2', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '280'}, {'groupId': 'OG001', 'value': '280'}, {'groupId': 'OG002', 'value': '276'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.03', 'spread': '0.92'}, {'groupId': 'OG001', 'value': '-0.09', 'spread': '0.68'}, {'groupId': 'OG002', 'value': '-0.21', 'spread': '1.14'}]}]}, {'title': 'Change at Week 4', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '281'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '0.01', 'spread': '1.16'}, {'groupId': 'OG001', 'value': '0.00', 'spread': '1.31'}, {'groupId': 'OG002', 'value': '-0.32', 'spread': '1.24'}]}]}, {'title': 'Change at Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.11', 'spread': '1.42'}, {'groupId': 'OG001', 'value': '-0.13', 'spread': '1.20'}, {'groupId': 'OG002', 'value': '-0.41', 'spread': '1.56'}]}]}, {'title': 'Change at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.12', 'spread': '1.38'}, {'groupId': 'OG001', 'value': '-0.03', 'spread': '1.50'}, {'groupId': 'OG002', 'value': '-0.39', 'spread': '1.59'}]}]}, {'title': 'Change at Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.17', 'spread': '1.59'}, {'groupId': 'OG001', 'value': '-0.03', 'spread': '1.72'}, {'groupId': 'OG002', 'value': '-0.46', 'spread': '1.53'}]}]}, {'title': 'Change at Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.20', 'spread': '1.51'}, {'groupId': 'OG001', 'value': '-0.01', 'spread': '1.85'}, {'groupId': 'OG002', 'value': '-0.47', 'spread': '1.58'}]}]}, {'title': 'Change at Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.23', 'spread': '1.69'}, {'groupId': 'OG001', 'value': '0.00', 'spread': '1.75'}, {'groupId': 'OG002', 'value': '-0.41', 'spread': '1.57'}]}]}, {'title': 'Change at Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '283'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '-0.22', 'spread': '1.67'}, {'groupId': 'OG001', 'value': '0.01', 'spread': '1.91'}, {'groupId': 'OG002', 'value': '-0.43', 'spread': '1.57'}]}]}]}, {'type': 'SECONDARY', 'title': 'Number of Participants With Anti Tanezumab Antibodies', 'description': 'Human serum ADA samples were analyzed for the presence or absence of anti-tanezumab antibodies by using a semi quantitative enzyme linked immunosorbent assay (ELISA). Participants listed as having anti-tanezumab antibodies had ADA titer level \\>=3.32. Less than 3.32 was considered below the limit of quantitation.', 'populationDescription': ""The safety population was defined as all participants treated with tanezumab or placebo subcutaneously. Here, 'Number analyzed' = Participants evaluable for this outcome measure at specified time points."", 'reportingStatus': 'POSTED', 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants', 'timeFrame': 'Baseline, Weeks 8,16, 24, 32 and 48', 'groups': [{'id': 'OG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}, {'id': 'OG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.'}], 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '282'}, {'groupId': 'OG001', 'value': '283'}, {'groupId': 'OG002', 'value': '284'}]}], 'classes': [{'title': 'Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '281'}, {'groupId': 'OG001', 'value': '282'}, {'groupId': 'OG002', 'value': '281'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '24'}, {'groupId': 'OG001', 'value': '26'}, {'groupId': 'OG002', 'value': '36'}]}]}, {'title': 'Week 8', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '261'}, {'groupId': 'OG001', 'value': '275'}, {'groupId': 'OG002', 'value': '275'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '24'}, {'groupId': 'OG001', 'value': '27'}, {'groupId': 'OG002', 'value': '41'}]}]}, {'title': 'Week 16', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '242'}, {'groupId': 'OG001', 'value': '263'}, {'groupId': 'OG002', 'value': '265'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '25'}, {'groupId': 'OG001', 'value': '34'}, {'groupId': 'OG002', 'value': '48'}]}]}, {'title': 'Week 24', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '233'}, {'groupId': 'OG001', 'value': '253'}, {'groupId': 'OG002', 'value': '251'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '19'}, {'groupId': 'OG001', 'value': '39'}, {'groupId': 'OG002', 'value': '49'}]}]}, {'title': 'Week 32', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '224'}, {'groupId': 'OG001', 'value': '247'}, {'groupId': 'OG002', 'value': '236'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '19'}, {'groupId': 'OG001', 'value': '38'}, {'groupId': 'OG002', 'value': '42'}]}]}, {'title': 'Week 48', 'denoms': [{'units': 'Participants', 'counts': [{'groupId': 'OG000', 'value': '216'}, {'groupId': 'OG001', 'value': '242'}, {'groupId': 'OG002', 'value': '227'}]}], 'categories': [{'measurements': [{'groupId': 'OG000', 'value': '18'}, {'groupId': 'OG001', 'value': '32'}, {'groupId': 'OG002', 'value': '31'}]}]}]}]",5,Baseline up to Week 24,"Same event may appear as AE and serious AE, what is presented are distinct events. Event may be categorized as serious in 1 participant and as nonserious in another participant or 1 participant may have experienced both serious and nonserious event during study. One death was accounted as lost to follow-up in participant flow as the death was not confirmed by family nor a doctor, but a follow-up letter to the participant was returned with a note on the envelope that the addressee died.","[{'id': 'EG000', 'title': 'Placebo', 'description': 'Placebo matched to tanezumab (RN624 or PF-04383119) injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.', 'deathsNumAffected': 0, 'deathsNumAtRisk': 282, 'seriousNumAffected': 3, 'seriousNumAtRisk': 282, 'otherNumAffected': 77, 'otherNumAtRisk': 282}, {'id': 'EG001', 'title': 'Tanezumab 2.5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 2.5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.', 'deathsNumAffected': 1, 'deathsNumAtRisk': 283, 'seriousNumAffected': 8, 'seriousNumAtRisk': 283, 'otherNumAffected': 73, 'otherNumAtRisk': 283}, {'id': 'EG002', 'title': 'Tanezumab 5 mg', 'description': 'Tanezumab (RN624 or PF-04383119) 5 mg injection administered subcutaneously on Day 1 (Baseline), Week 8 and Week 16.', 'deathsNumAffected': 2, 'deathsNumAtRisk': 284, 'seriousNumAffected': 9, 'seriousNumAtRisk': 284, 'otherNumAffected': 60, 'otherNumAtRisk': 284}]","[{'term': 'Acute myocardial infarction', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Arrhythmia', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Cardio-respiratory arrest', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Coronary artery stenosis', 'organSystem': 'Cardiac disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Cataract', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Ocular vascular disorder', 'organSystem': 'Eye disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Pancreatitis', 'organSystem': 'Gastrointestinal disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Cholecystitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Cholelithiasis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Hepatitis', 'organSystem': 'Hepatobiliary disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Pneumonia', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Nerve injury', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Nerve root injury lumbar', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Pelvic fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Radius fracture', 'organSystem': 'Injury, poisoning and procedural complications', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Arthralgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 1, 'numAtRisk': 284}]}, {'term': 'Osteoarthritis', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 2, 'numAtRisk': 284}]}, {'term': 'Rotator cuff syndrome', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Cerebrovascular accident', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 0, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 1, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}, {'term': 'Lymphatic fistula', 'organSystem': 'Vascular disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 1, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 0, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 0, 'numAtRisk': 284}]}]","[{'term': 'Nasopharyngitis', 'organSystem': 'Infections and infestations', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 25, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 31, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 21, 'numAtRisk': 284}]}, {'term': 'Arthralgia', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 34, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 27, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 22, 'numAtRisk': 284}]}, {'term': 'Back pain', 'organSystem': 'Musculoskeletal and connective tissue disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 15, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 16, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 17, 'numAtRisk': 284}]}, {'term': 'Headache', 'organSystem': 'Nervous system disorders', 'sourceVocabulary': 'MedDRA v21.1', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'stats': [{'groupId': 'EG000', 'numAffected': 18, 'numAtRisk': 282}, {'groupId': 'EG001', 'numAffected': 15, 'numAtRisk': 283}, {'groupId': 'EG002', 'numAffected': 14, 'numAtRisk': 284}]}]",False,OTHER,True,"Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.",Pfizer ClinicalTrials.gov Call Center,"Pfizer, Inc.",ClinicalTrials.gov_Inquiries@pfizer.com,1-800-718-1021,"[{'typeAbbrev': 'Prot', 'hasProtocol': True, 'hasSap': False, 'hasIcf': False, 'label': 'Study Protocol', 'date': '2016-02-10', 'uploadDate': '2019-06-06T09:25', 'filename': 'Prot_000.pdf', 'size': 3702714}, {'typeAbbrev': 'SAP', 'hasProtocol': False, 'hasSap': True, 'hasIcf': False, 'label': 'Statistical Analysis Plan', 'date': '2018-12-21', 'uploadDate': '2019-06-06T09:25', 'filename': 'SAP_001.pdf', 'size': 1464379}]",2025-05-02,"[{'id': 'D010003', 'term': 'Osteoarthritis'}, {'id': 'D020370', 'term': 'Osteoarthritis, Knee'}, {'id': 'D015207', 'term': 'Osteoarthritis, Hip'}]","[{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}]","[{'id': 'M22168', 'name': 'Osteoarthritis, Knee', 'asFound': 'Osteoarthritis, Knee', 'relevance': 'HIGH'}, {'id': 'M12926', 'name': 'Osteoarthritis', 'asFound': 'Osteoarthritis', 'relevance': 'HIGH'}, {'id': 'M17912', 'name': 'Osteoarthritis, Hip', 'asFound': 'Osteoarthritis, Hip', 'relevance': 'HIGH'}, {'id': 'M13066', 'name': 'Pain', 'relevance': 'LOW'}, {'id': 'M4476', 'name': 'Arthritis', 'relevance': 'LOW'}, {'id': 'M10621', 'name': 'Joint Diseases', 'relevance': 'LOW'}, {'id': 'M12097', 'name': 'Musculoskeletal Diseases', 'relevance': 'LOW'}, {'id': 'M15045', 'name': 'Rheumatic Diseases', 'relevance': 'LOW'}, {'id': 'M6323', 'name': 'Collagen Diseases', 'relevance': 'LOW'}]","[{'abbrev': 'BC05', 'name': 'Musculoskeletal Diseases'}, {'abbrev': 'All', 'name': 'All Conditions'}, {'abbrev': 'BC23', 'name': 'Symptoms and General Pathology'}, {'abbrev': 'BC17', 'name': 'Skin and Connective Tissue Diseases'}]","[{'id': 'C549319', 'term': 'Tanezumab'}]","[{'id': 'D000700', 'term': 'Analgesics'}, {'id': 'D018689', 'term': 'Sensory System Agents'}, {'id': 'D018373', 'term': 'Peripheral Nervous System Agents'}, {'id': 'D045505', 'term': 'Physiological Effects of Drugs'}]","[{'id': 'M4032', 'name': 'Analgesics', 'relevance': 'LOW'}, {'id': 'M287982', 'name': 'Tanezumab', 'asFound': 'Scapula', 'relevance': 'HIGH'}]","[{'abbrev': 'Analg', 'name': 'Analgesics'}, {'abbrev': 'All', 'name': 'All Drugs and Chemicals'}]"
